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Abstract 
Host defence peptides (HDPs) are short antimicrobial peptides that 
form a crucial component of the innate immune system. Deficiencies in 
HDP activity contribute to enhanced susceptibility to infections; this is 
the case in cystic fibrosis (CF). Exogenously-applied HDPs can 
compensate for these deficiencies and are attractive as new anti-
infectives, but their development as antimicrobials is limited by 
cytotoxicity. This thesis describes the development of a series of HDP 
prodrugs whose cytotoxicity is reduced by net-charge decrease. As 
high levels of the host protease neutrophil elastase (NE) are co-
localised in the lung with Pseudomonas aeruginosa infection, the 
enzyme is the target for prodrug activation. This system limits 
antimicrobial activity and cytotoxicity to areas infected with the 
bacterium. 
It is demonstrated here using in vitro assays that the prodrug 
modification reduces the antimicrobial activity against CF P. 
aeruginosa clinical isolates and reference strains. This activity is 
specifically restored with NE, both purified and in CF bronchoalveolar 
lavage (BAL) fluid. In vitro assays against epithelial cells, erythrocytes, 
and neutrophils demonstrate how the modification reduces 
cytotoxicity. Refinement of the model has produced pro-HDPs, with 
very low cytotoxicity, which are active in BAL fluid, can kill bacterial 
biofilms, and display low immunogenicity. The requirements for CF 
lung activity, such as the need for D-amino acids are also 
demonstrated. We show that the pro-HDPs are deliverable by 
nebulisation in a model of the human lung using a vibrating mesh 
nebuliser. In vivo results in mice show the toxicity and inflammatory 
effects of the pro-HDPs are reduced compared to the active peptides, 
in agreement with in vitro results. 
This thesis describes the design, synthesis, in vitro/in vivo evaluation, 
and drug delivery of pro-HDPs. It describes how the large and growing 
library of active HDPs may be harnessed for use in CF. The final 
 21 
 
candidate pro-WMR has the potential to be used in CF to treat 
infection and warrants further investigation. 
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1. Introduction 
 
1.1 Cystic fibrosis  
Mutations in the gene coding for the ion channel cystic fibrosis 
transmembrane conductance regulator (CFTR) cause the autosomal 
recessive disorder cystic fibrosis (CF) (1). CFTR is a cAMP-regulated 
chloride (Cl-) channel found in epithelial cell membranes, the 
dysfunction of which leads to a multisystem disorder that is the most 
common lethal genetic disease in Caucasians (2). Over 1000 genetic 
mutations can lead to CFTR dysfunction and CF, including those that 
cause defects in function (i.e. a channel gating defect), prevent the 
channel reaching its membrane target (i.e. a trafficking dysfunction), or 
stop its initial production. Some mutations, such as ∆F508, cause both 
a trafficking and gating defect (3). This is the most common mutation, 
accounting for 70% of cases, and involves the deletion of a 
phenylalanine residue at position 508. The faulty CFTR will not pass 
the cell’s quality control mechanisms, which will prevent the proper 
trafficking of the CFTR from the endoplasmic reticulum and leads to an 
absence of activity (2). As CFTR is expressed in many organs, 
multiple systems are affected, although most common manifestations 
of the disease are found in the respiratory, gastrointestinal and 
reproductive tracts (4-6). 
The result of CFTR mutation is the dysregulation of ion and water 
transport across epithelial membranes. This has a profound effect on 
numerous biological systems e.g. male reproduction is impaired by the 
obstruction of the vas deferens by dehydrated secretions, rendering 
patients infertile (7). Digestive issues associated with CFTR 
dysfunction meant that in the past many patients died in early life, 
owing mainly to pancreatic insufficiency (6). Mucous plugs block the 
pancreatic canaliculi, preventing the release of digestive enzymes. 
This, in conjunction with a more acidic pH in the duodenum, results in 
poor digestion and malabsorption of nutrients. With improved 
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understanding of how CF interferes with these processes, nutritional 
problems are now managed with digestive enzyme treatment. Damage 
to the pancreas in CF can also lead to glucose intolerance (8), 
diabetes being a co-morbidity in 8-15% of patients. However, since the 
improvement in nutritional regimens, life expectancy has greatly 
increased, with chronic lung disease becoming the main cause of 
death (6, 9, 10). Over 80% of CF patients die directly or indirectly from 
lung disease (11). In the respiratory tract CFTR dysfunction leads to 
hyposecretion of chloride, hyperabsorption of sodium, and a 
dehydrated and volume-depleted airway surface liquid (ASL) (12). This 
20µm fluid layer is a crucial component of the pulmonary innate 
defence and mediates mucus clearance (2). The dysfunction critically 
impairs the host defensive response and leads to severe infections 
and progressive pulmonary damage (13).  
1.1.1 Aetiology of lung infection in CF  
CFTR dysfunction leads to the chronic lung disease that characterises 
CF. It impairs the innate immune system of the host in a variety of 
ways. Amongst the most profound alterations is to the ASL which 
provides one of the first barriers to bacterial pulmonary invasion. As 
stated above, CFTR dysfunction results in ASL dehydration through 
Cl-
 
and fluid hyposecretion, which in turn leads to the impairment of 
mucociliary clearance and the promotion of mucus stasis in the lung 
(13). The result of this is increased contact time between bacteria and 
the lung epithelium, and the facilitation of bacterial adhesion that 
would otherwise not occur in healthy lungs (4, 12, 14). CF infections 
are typically caused by Staphylococcus aureus (S. aureus) and 
Haemophilus influenzae (H. influenzae) in younger children and 
Pseudomonas aeruginosa (P. aeruginosa) in adults. Other pathogens 
include Burkholderia cepacia (B. cepacia), Aspergillus fumigatus (A. 
fumigatus) and Candida albicans (C. albicans) (15). It has been 
demonstrated that the airways are not sterile in healthy patients and 
the nasal cavity may act as a reservoir for potentially harmful lung 
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pathogens. An investigation with paediatric patients demonstrated that 
the nose contains a diverse microbiome in which competition between 
bacteria is normally low or stable. In contrast, in exacerbations in CF 
patients it can become over-colonised by pathogenic bacteria like P. 
aeruginosa. The abnormal airway microbiome that characterises CF is 
established in patients well before adulthood (16). 
1.1.2 P. aeruginosa infection in CF 
P. aeruginosa is the most important pathogen in CF (4, 15, 17). It is 
generally acquired from the environment and not from other patients, 
and in a normal clinical situation would be rapidly cleared from the 
lung by mucociliary clearance and other components of the innate 
immune system. However, in CF these systems are compromised as 
an indirect result of CFTR dysfunction (4, 14). CFTR dysfunction also 
has direct innate immune effects, with CFTR normally acting as a 
receptor for lipopolysaccharide (LPS) on the bacterium, internalising it 
and eliciting an inflammatory response that ultimately aids in 
eradication (18). Other changes to the lung epithelium in CF, in 
addition to impaired clearance, aid the adherence of the bacterium. 
For example, P. aeruginosa uses highly inflammatory fimbral 
adhesins, such as with type 4 pili and flagellae, to initially adhere to 
the epithelium. The receptor for these is contained on asialylated 
glycolipids, such as asioloGM1 (14), the levels of which are relatively 
high in CF epithelial cells (4). Altered fucosyl residues on 
glycopeptides, increased heparan sulphate levels, and the 
accumulation of ceramide also contribute to adhesion (19). 
As stated above, since the introduction of CF nutritional regimens, 
chronic P. aeruginosa infection has become the primary cause of 
mortality (6). Early treatment of acute infection in CF is crucial as, 
once it becomes established the bacterium can alter its phenotype to 
greatly increase its ability to evade eradication. The resulting chronic 
infection, localised to the endobronchial space, is very difficult to 
remove (20). As infection progresses, the initially non-mucoid 
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bacterium produces the polysaccharide alginate (6). This can protect 
the bacteria from phagocytosis by host defences and from the effects 
of exogenously applied antibiotics (4, 12, 19). In addition, further 
phenotypic changes occur; flagellae and pili are lost (14), biofilms are 
established (4, 19), and the bacterium becomes non-motile (19). The 
rate of infection with multidrug-resistant P. aeruginosa has increased 
substantially in older patients in recent years, perhaps resulting from 
the exposure to multiple antibiotics over a lifetime. This imposes 
selective pressure on the infecting population where resistant 
phenotypes are favoured (21).  
1.1.3 S. aureus infections in CF 
S. aureus is the most commonly isolated CF pathogen in infants and 
young children and was the first pathogen linked to lung disease in 
CF. P. aeruginosa was not recognised as a major pathogen until the 
1950s. Previously, when average life expectancy was below ten years, 
most CF bacterial cultures were collected from the age groups where 
S. aureus is most prevalent (11). The bacterium is found in 80% of 
patients aged 6-10, being replaced by P. aeruginosa as the main 
pathogen by the age of 18 (21). CFTR dysfunction may contribute 
directly to S. aureus infection. For example, it has been shown that the 
infection of Calu-3 cells by S. aureus increases when CFTR activity is 
removed (22). Despite its prevalence in younger patients and historical 
pathogenicity, whether S. aureus contributes to decreased survival in 
modern times is controversial (11). While it has been shown that 
infection with P. aeruginosa is often preceded by S. aureus infection in 
infancy (23), it has been asserted that the latter does not have a major 
impact on the status of patients (for example, it is cultured less as lung 
function declines) (24). Of greater clinical concern is the increasing 
proportion of methicillin-resistant S. aureus (MRSA) among S. aureus, 
which is being increasingly isolated from clinical samples, currently 
found in 25% of CF patients (21). Anecdotal evidence suggests that 
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more virulent strains of MRSA may potentially cause severe lung 
damage (11). 
1.1.4 H. influenzae infection in CF 
H. influenzae is another common pathogen in CF, present in 
approximately 16% of patients (21). Like S. aureus it most regular 
infects patients in childhood, being one of the first organisms to infect 
the lung, and again like S. aureus its pathogenicity is controversial 
(11). The isolation of H. influenzae from CF lungs has been observed 
to increase during acute exacerbations (25), but the presence of H. 
influenzae (and S. aureus) have been found to not be associated with 
lower-than-predicted lung function (26). Nevertheless, the expert 
opinion is that this bacterium has the potential to cause exacerbations, 
and when these occur they should be treated (11). 
1.1.5 The B. cepacia complex 
The B. cepacia complex (Bcc) is a group of 17 related Gram-negative 
bacterial species that have become notorious for their ability to spread 
rapidly between CF patients and cause great morbidity, even beyond 
that of P. aeruginosa. The phylogenetic similarities of the species 
makes them difficult to separate, but it has been determined that 
Burkholderia cenocepacia and Burkholderia multivorans account for 
the majority of Bcc CF isolates (11). Unlike S. aureus and H. 
influenzae, it generally infects patients later in life with a relatively low 
prevalence of approximately 3% (21). The low rate of infection 
compared to other bacteria discussed here is fortunate when one 
considers that it has been shown to have a significant adverse effect 
on the survival of CF patients (27). The prognosis after B. cenocepacia 
infection is poor, with the estimated 5-year survival rate after 
acquisition of one strain being 66.6%, in comparison to 85.3% with P. 
aeruginosa. It must be noted, however, that virulence is strain-
dependent. Of great concern is the fact that it is intrinsically resistant 
to polymyxins, aminoglycosides, and most β-lactam antibiotics (28). 
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1.1.6 Fungal infections in CF 
The presence of the fungi A. fumigatus and C. albicans is also 
commonly reported in CF lung samples, with recent average 
prevalence across a series of US centres reported at 11.9% and 7.8% 
respectively (21). The lungs by their nature are continuously exposed 
to the atmosphere which is a rich source of fungal spores, and as with 
bacteria the CF lung has limited capacity to clear them (29). A large 
proportion of CF patients infected with A. fumigatus may exhibit 
allergic bronchopulmonary aspergillosis (ABPA), where the infection 
induces an allergic response to the fungus. Episodic wheezing ensues 
that is unresponsive to bronchodilators but may be treated with 
corticosteroids. However, the degree to which infection can lead to 
long-term lung function decline is controversial. There is a correlation 
between non-ABPA A. fumigatus infection and poorer lung function but 
whether the relationship is causal has yet to be satisfactorily 
determined (11). The effectiveness of treatment with antifungals such 
as itraconazole has also yet to be demonstrated beyond doubt in both 
ABPA and non-ABPA Aspergillus infection (29). C. albicans can cause 
oral and genital candidiasis in CF patients, as well as infecting the 
lung. Life-long treatment with inhaled steroids and antibiotics puts CF 
patients at increased risk of acquiring it. However, the clinical 
significance of C. albicans infection is unclear and there is no evidence 
supporting treatment (29). 
 
1.2 Cystic fibrosis and the immune response to infection  
Bacterial infections must be recognised by the lung epithelium before 
the immune system can launch an appropriate response. This is 
achieved using a broad range of Toll-like receptors (TLRs) to sense 
pathogenic molecules associated with bacteria. For example, LPS is 
detected by TLR4, and flagellin by TLR5. In CF, dysfunction in these 
systems contributes to airway pathology via the combination of TLR 
hyper-responsiveness and an abundance of TLR agonists that are not 
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competently removed by mucociliary clearance (15). The manner in 
which airway dysfunction leads to TLR overstimulation can be 
illustrated by the case of the protease neutrophil elastase (NE). This 
enzyme is released in large quantities by CF neutrophils (30), 
activates TLR4 and causes exaggerated release of the cytokine 
interleukin-8 (IL-8) (31). IL-8 itself is a potent chemoattractant for NE-
producing neutrophils, leading to an amplified immune response and 
positive feedback loop of immune system stimulation (13). Other 
components of the CF lung milieu have similar effects, for example 
haem, released into the lung from microbleeds resulting from tissue 
damage, also activates the TLR system in a similar manner (32). Sex 
also has a role in the immune response to infection, the prognoses for 
female CF patients are worse than that in males. The cause for the 
discrepancy is thought to involve the female hormone 17β-estradiol.  
Although its role in vivo is complex, this hormone may have a net pro-
inflammatory effect in CF. Exogenous application of the hormone in 
male CFTR-/-
 
mice has been shown to exacerbate inflammation in P. 
aeruginosa infection and lead to increased lung bacterial burden (33). 
The hormone also contributes to the sexual dichotomy of the disease 
by promoting the early conversion of P. aeruginosa to a mucoid 
phenotype. It has been observed that the median age of chronic 
infection with this phenotype is 1.7 years earlier in females and that 
the frequency of infective exacerbations is increased (34). 
The constant activation of innate immune receptors by pathogens (and 
host molecules) leads to a dysregulated overproduction of cytokines 
such as IL-6 and tumour necrosis factor-α (TNF-α). The resulting pro-
inflammatory cascade then recruits neutrophils from the bloodstream 
to combat the inflammatory insult. In the healthy lung these immune 
cells are vital for killing bacteria, using three mechanisms: 
phagocytosis, granule release of agents such as NE, and neutrophil 
extra-cellular trap formation (13). This component of the immune 
response is also dysregulated in CF. Numerous studies have 
demonstrated how CFTR dysfunction can lead to differences between 
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normal and CF neutrophils that significantly contribute to lung damage 
rather than ameliorate it. For example, phagocytosis by neutrophils 
has been shown to be impaired in paediatric CF patients compared to 
controls (35). CFTR is present in phagolysosomes of neutrophils, and 
its defective activity leads to lower Cl- in the compartments, which is 
required for their activity against P. aeruginosa (36). In a neutrophil of 
a healthy patient, a phagocytosed foreign particle triggers the 
formation of O2- by the enzyme NADPH oxidase, which quickly forms 
H2O2. Myeloperoxidase, another enzyme, can then catalyse 
halogenation (and death) of the foreign particle by using H2O2, Cl- and 
the correct pH conditions to form hypochlorite. This is called the 
respiratory burst and can cause oxygen consumption by neutrophils to 
increase 100-fold (37). Inappropriate O2- production by CF neutrophils 
has also been linked to tissue damage. One study observed that after 
an exacerbation, CF neutrophils release larger quantities of O2- 
compared to healthy controls. The spontaneous release of NE was 
also elevated (38). In a similar manner, and despite the fact that the 
NE content of the granules of CF neutrophils is not increased, an 
elevated elastase response to bacterial stimulus compared to normal 
neutrophils has been noted with CF neutrophils after pre-incubation 
with bronchoalveolar lavage (BAL) fluid. This indicates that CF 
neutrophils intrinsically release more NE in response to bacterial 
stimulus (30).  
Neutrophil chemotaxis (movement in response to a chemical stimulus) 
in CF infection has been demonstrated to differ in comparison to 
healthy controls, displaying a degree of hypo-responsiveness to IL-8. 
This may illustrate receptor desensitisation as a result of persistently 
high levels of IL-8 present in the lung. However, as noted in a review 
of CF neutrophil dysfunction, the high levels of IL-8 in CF ensures that 
recruitment is not reduced in vivo and in the absence of infection, CF 
neutrophils can out-migrate their non-CF counterparts (37).   
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1.2.1 Sequelae of neutrophil dysfunction in CF 
While they are essential to clearing infection, the dysfunctional action 
of neutrophils in CF leads to tissue damage and remodelling (13). The 
neutrophil-dominated response to P. aeruginosa leads to the release 
of large quantities of NE which, apart from its ability to stimulate IL-8 
release as detailed above, causes extensive tissue damage (39, 40). 
Thus, the exaggerated inflammatory response leads to long-term 
reduction in lung function and is associated with premature death (17, 
19, 20). Neutrophils represent approximately 70% of the airway 
inflammatory cell population in CF, in contrast to 1% in healthy 
patients (41). This is mostly related to elevated neutrophil chemokine 
levels in the lung as a result of the ineffective clearance of P. 
aeruginosa (39). The lungs of the majority of CF patients appear 
normal at birth, however chronic neutrophilic inflammation begins 
early, with one study finding that neutrophils represented on average 
31.5% of immune cells for a group of 1 to 5 year old children (42). 
High NE levels overwhelm epithelial antiprotease defences, which 
normally protect against proteolytic damage, and can inactivate other 
components of the immune response, such as complement and 
immunoglobulins (41). The enzyme may further contribute to impaired 
bacterial clearance by inhibiting the receptors that mediate pathogen 
recognition such as CD16 (37). It can also cleave flagellin, 
compromising the host’s ability to recognise and react to the molecule 
(43).  
Dysfunctional neutrophil death is a major contributor to the lung 
disease of CF. The necrosis of the large number of neutrophils results 
in the release of extra-cellular DNA (eDNA), further increasing mucous 
viscosity (19). When neutrophils, which normally have a short lifespan, 
are inhibited in the normal process of controlled apoptosis, tissue 
damage can be increased by the uncontrolled release of pro-
inflammatory substances. Host and bacterial mediators such as LL-37 
(44) and LPS (45) have been shown to delay apoptosis, an effect 
which may help clear infection in healthy lungs but has the potential to 
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exacerbate lung disease in CF. To resolve inflammation properly, 
neutrophils must first apoptose and then be cleared to prevent the 
above effects. Many of the conditions of the CF lung confound this 
process. For example, pyocyanin, a metabolite produced by P. 
aeruginosa, has been shown to impair the engulfment of apoptotic 
neutrophils by macrophages, leading to a large increase in necrotic 
neutrophils in an in vivo mouse model (46). 
In a healthy lung, a balance exists between proteases and anti-
proteases, such as secretory leukoprotease inhibitor (SLPI), α1-
antitrypsin (A1AT), and elafin. This facilitates tight regulation of 
protease activities and is required to avoid the lung damage and 
immune dysfunction detailed above (42). Despite their potential for 
damage in CF, proteases have an important protective role in a 
healthy lung and this can be illustrated by the effects of their absence. 
S. aureus and C. albicans have both been shown to be markedly more 
virulent in mice lacking neutrophil-granule proteases (47). In another 
study, an NE-knockout mouse model was found to be more 
susceptible to Klebsiella pneumoniae and Escherichia coli (E. coli) 
infection than wildtype mice, confirming that NE is crucial for the 
antibacterial action of neutrophils (48).  
In CF the protease-antiprotease balance is dysregulated and 
proteases produced from the neutrophil-dominated epithelial 
inflammation can overwhelm the inhibitory defences (42). Unlike in 
many other lung diseases, the issue is not one of antiprotease 
deficiency but more of enzyme excess. High neutrophils numbers 
mean that large quantities of unopposed proteases are released into 
the ASL (41). This leads to lung matrix destruction and inflammation 
(49). There are several proteases from different sources, both host 
and bacterial, including serine, aspartyl, and metallo-proteases that 
are relevant to CF (32). 
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1.3 Proteases in cystic fibrosis  
Neutrophils are the source (although not exclusively) of many of the 
proteases associated with CF. The azurophilic (or primary) granules of 
neutrophils are the source of the serine proteases NE, cathepsin G 
(CG), and proteinase 3 (PR-3). These enzymes share significant 
sequence homology and play an important role in both infectious and 
non-infectious inflammation e.g. by digesting phagocytised 
microorganisms and other ingested material intra-cellularly (43, 50). In 
response to cytokines such as IL-8 and bacterial LPS, large quantities 
of proteases can be released extra-cellularly (49). Like all serine 
proteases they are characterised by the presence of serine in their 
catalytic centre, and all three belong to the chymotrypsin superfamily. 
However they differ in their substrate specificity, with NE and PR-3 
preferentially accommodating hydrophobic residues such as alanine 
and isoleucine and CG preferring phenylalanine and methionine and 
positively charged residues such as arginine (49).  
In normal protease notation, substrates are cleaved between amino 
acids termed P1 and P1’ (amino- and carboxy- terminal residues 
respectively). The adjacent residues on each side are named P2, P2’, 
P3, P3’ and so on (51). 
1.3.1 Neutrophil elastase 
NE is the most important protease in CF, with a number of proteolytic 
and immunomodulatory properties. Its name would suggest activity 
against elastin (the first substrate used to characterise its activity (49)) 
but NE can cleave a wide variety of matrix and plasma proteins 
ranging from collagen and fibronectin, to complement and protease 
inhibitors (41). It contributes to the killing of bacteria, both extra- and 
intra-cellularly, allowing the clearance of foreign material after 
phagocytosis by the neutrophils. It is also involved in the regulation of 
the innate immune response (39). NE itself can stimulate the release 
of other proteases such as cathepsin B and matrix metalloprotease-2 
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(MMP-2) and may stand at the peak of a hierarchy of protease 
regulation (52). The abundance of NE in CF is the source of much 
morbidity for patients, it is the primary source of haemoglobin 
degradation in CF BAL fluid, producing haem, which can then 
stimulate the production of IL-8 (32). It can also directly stimulate the 
release of IL-8 from bronchial epithelial cells, leading to enhanced 
neutrophil accumulation and a cycle of inflammation (53). The 
observation that the application of SLPI can remove 90% of the 
elastinolytic activity of CF sputum is indicative that NE represents the 
main source of protease activity in the CF lung (SLPI is an inhibitor for 
NE but not PR-3) (32, 54).  
1.3.2 Proteinase 3 and cathepsin G 
PR-3 is thought to account for approximately 7% of the remaining 
protease activity of the CF lung (32) although levels higher than NE 
have been reported in CF sputum in one study (55). This serine 
protease has an important role in the regulation of the precursor Host 
Defence Peptide (HDP) hCAP-18. PR-3 and hCAP-18 are both 
located in different compartments of neutrophils, but upon exocytosis 
the protease cleaves the HDP, releasing the active peptide LL-37. 
Both CG and NE also cleave hCAP-18 but at different sites and do not 
generate the active LL-37. The activation cleavage site on hCAP-18 is 
an Ala-Leu bond, a bond preferred by PR-3. The enzyme has a 
preference for cleaving between two small aliphatic amino acids, in 
contrast to NE which prefers to cleave at a valine (56). This illustrates 
that, despite the sequence homology between the three serine 
proteases and many shared substrates, they can still display different 
cleavage patterns to each other. For example, PR-3 is unable to 
cleave the NE substrate Suc-AAA-Nitroanilide. PR-3 is also 40 times 
less catalytic than NE against the substrate MeO-Suc-AAPV-
Nitroanilide, a common substrate for many NE-quantification assays 
(cleavage of the amide bond releasing a chromophore) (50) while CG 
does not cleave it at all (57). CG has a significant preference for 
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substrates with a phenylalanine at P1 (58). The differences extend to 
inhibitors, PR-3 is not inhibited by SLPI, but is inhibited by A1AT for 
example (50). 
CG is generally less active against most substrates than the other 
serine proteases, having a lower intrinsic catalytic activity (59) that has 
been estimated to be two orders of magnitude lower than NE (58). 
However, it has still been shown to cleave components of the extra-
cellular matrix (but not to the same extent as NE) (60). Like NE, it has 
also been shown to be crucial for killing of bacteria by neutrophils (47). 
However in one study the clearance of P. aeruginosa from mouse 
lungs was improved in CG-deficient mice, illustrating the potentially 
harmful effects of the unopposed protease on the lung immune 
response (61).  
1.3.3 Pseudomonas proteases 
The contribution of proteases from Pseudomonas in CF is often 
overlooked. The bacterium produces two metalloproteases relevant to 
CF, pseudomonas elastase (PE) and alkaline protease that have a 
number of important biological properties. Like NE and PR-3, both 
metalloproteases cleave haemoglobin, allowing the bacterium to use 
microbleeds in the CF lung as a potential iron source (32). They also 
degrade many components of the host immune system and enhance 
survival of the bacteria. For example, PE can cleave and inactivate LL-
37, reducing the bactericidal activity of the HDP in vitro, an effect 
abolished by the addition of metalloprotease inhibitors (62). Like NE, 
PE can degrade elastin and a number of other substrates, hydrolysing 
a number of tetrapeptide sequences such as tetra-alanine (63). 
Pseudomonas metalloproteases have also been shown to degrade the 
protease inhibitors SLPI, A1AT, and elafin. Purified PE was shown to 
reduce the NE-inhibitory effects of elafin, disturbing the lung’s anti-
elastase defences (64). While PE is a major virulence factor for 
Pseudomonas and can cause extensive damage to host tissue, it has 
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a biological function in the bacterium beyond virulence, acting as an 
important mediator in the production of alginate (65).  
1.3.4 Host metalloproteases 
MMPs are a large group of zinc metalloproteases that have a number 
of functions in the healthy lung. These include degradation of 
membrane components and their repair, cytokine release, and 
modulation of cell mobility. They are characterised by an active 
catalytic domain with a zinc-binding region. When they are 
dysregulated, their ability to degrade the membrane can lead to 
pathogenic destruction of the lung epithelium and the impairment of 
repair. Some have been the subject of much interest in CF, e.g. MMP-
9. Others, such as MMP-2, while known to contribute to the 
pathogenesis of diseases such as cancer, have been studied less in 
the context of CF (66). 
MMP-9 is one of the best characterised proteases and is released 
from the tertiary granules of neutrophils. Enzyme levels have been 
found elevated in the sputum of CF patients compared to healthy 
controls (with a mean of 1.21µg/ml). In the same study MMP-8, on the 
other hand, was found to be decreased in CF patients. While MMP-9 
is normally held as an inactive pro-form in healthy lungs, it is found 
constitutively active in CF. In addition, the high levels of NE in CF are 
able to both activate MMP-9 and inactivate its inhibitor (67). Substrate 
studies indicate that, because of the structure of its active site, MMP-9 
prefers to cleave near a large hydrophobic residue, showing marked 
preference for leucine over alanine. An arginine residue at P2’ and a 
proline at P3 have both been shown to highly favourable for 
proteolysis (68). 
MMP-7, the smallest known MMP, is thought to have a major role in 
repair of the epithelium and is found in the conducting airways of 
healthy patients. Its expression has been found to be upregulated in 
CF, especially at sites of epithelial damage. It is normally not found in 
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the lower bronchioles and alveoli but expression has been observed in 
CF alveolar cells (69). 
MMP-12 is secreted by macrophages and may play a role in the killing 
of Gram-negative and -positive bacteria (66). It is also detectable in 
the sputum samples of CF patients (67). In a CF mouse model, it has 
been demonstrated that upregulation of the genes expressing MMP-12 
is linked with worsening emphysema and that MMP-12 activity is 
increased on the surface of mouse and human macrophages in CF, 
but not found free in mouse BAL fluid. MMP inhibition and genetic 
deletion have both been shown to reduce airway disease in these 
mice (70). It shares a number of substrates with MMP-3, -7, -13, all 
characterised by the presence of proline (71). This seems to be a 
common requirement for MMP substrates, for example PLGLWAR is 
cleaved very efficiently by a number of MMPs at the Gly-Leu bond and 
forms part of a very sensitive reporter for MMP activity (72).  
1.3.5 Summary 
Both host and bacterial enzymes contribute to the cycle of infection 
and inflammation that characterises the lung disease of CF. Figure 1.1 
illustrates how P. aeruginosa can directly and indirectly cause tissue 
damage, with proteases being central to the perpetuation of the cycle.  
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Figure 1.1: The cycle of infection and inflammation in CF. 
Pseudomonas can directly damage host tissue but also induce the 
release of pro-inflammatory cytokines. These recruit neutrophils which 
can also damage host tissue by releasing proteases. The proteases 
degrade antimicrobial peptides as well as other components of host 
defence. This facilitates further infection, which continues the cycle. 
This continues with progressive tissue damage that eventually leads to 
fatal pulmonary disease. Taken from (11). 
 
1.4 Management of cystic fibrosis  
In addition to nutritional and digestive enzyme therapy, the main focus 
of CF treatment is the eradication of pulmonary infection with 
antibiotics. As stated previously, the primary source of morbidity and 
mortality in CF is persistent lower respiratory tract infection. The most 
common pathogens are S. aureus and H. influenzae in young children, 
and P. aeruginosa in older children and adults (10). Rigorous antibiotic 
therapy with drugs such as inhaled tobramycin is recommended; 
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improving lung function and reducing the number of pulmonary 
exacerbations. Other antibiotics used include inhaled colistin and 
ciprofloxacin (15). While systemic antibiotics also form an important 
part of the treatment strategy, inhaled antibiotics have several 
advantages, including allowing higher local drug concentrations while 
limiting systemic toxicity (as infection is restricted to the endobronchial 
space, systemic delivery is not an absolute requirement) (20). 
Antibiotics delivered systemically operate mainly in the alveolar sacs 
while those that are inhaled have their effects from the trachea to the 
bronchioles. A combination of both routes would theoretically provide 
maximum coverage, although the use of inhaled antibiotics alone has 
had considerable success (10).  
Other components of CF treatment include hypertonic saline, delivered 
at concentrations of 3-7% w/v, which improves lung function through a 
variety of means, including restoring the height of the ASL and 
increasing mucociliary clearance (73). Similarly, dornase alfa 
(recombinant human deoxyribonuclease) is used as a mucolytic. It is 
an enzyme that selectively cleaves eDNA and was the first drug 
developed specifically for CF (74). It non-specifically hydrolyses 
double stranded DNA into low molecular weight fragments, relying on 
Mg2+ for catalysis (75)
. 
Cleaving the high levels of eDNA can improve 
the access of antibiotics to bacteria and co-administration has been 
demonstrated to improve the ability of both endogenous and 
exogenous HDPs to kill P. aeruginosa; complexation of LL-37 to eDNA 
has been shown to be detrimental to activity (76, 77). Functionalisation 
of tobramycin/alginate/chitosan nanoparticles with dornase alfa has 
been shown to increase the ability of the antibiotic to penetrate CF 
sputum (78). NE is also bound to eDNA, and treatment of patients with 
dornase alfa has been demonstrated to increase the levels of free NE 
in sputum, releasing the enzyme from eDNA-complexation. However, 
this effect is transient and long-term therapy modestly reduces the 
protease burden in the CF lung (79).  
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Despite improvements in quality of life and longevity, CF and the 
treatments involved place a significant burden on patients. Daily 
exercises and treatments can take up to 2h each day (15, 20). The 
importance of this disease in an Irish context is clear from the high 
incidence rate relative to other countries, 1 in 1461 births compared to 
1 in ~2000 in Caucasians in general (80). The combined prevalence of 
∆F508 homozygous and heterozygous mutations is 90.18% and 
13.9% for the G511D mutation (the next most common). 65.4% of 
adult Irish CF patients are chronically infected with P. aeruginosa (81). 
1.4.1 CFTR modifier use in CF  
The identification of the mutations that cause CF has led to intensive 
efforts to discover small molecules that can directly correct 
dysfunctional CFTR activity. The resulting compounds have begun to 
reach clinics and may be divided into “correctors”, which promote the 
maturation of CFTR, and “potentiator”, which increase the open time of 
existing CFTR channels (82). Treating a CF patient with a modifier 
requires one to consider the consequences of the specific mutation (of 
which there are >1000) on the CFTR. The many mutations are divided 
into five classes. Class I comprises synthesis defects, Class II protein 
processing defects, Class III protein regulation defects, Class IV 
protein conductance defects, and Class V reduced functioning protein. 
Class I and II have the highest mortality rates (37). G551D is a class III 
defect and results in impaired gating of the channel, and ∆F508, while 
primarily a class II defect where the CFTR is degraded before 
reaching the membrane, encompasses both a trafficking and gating 
defect (3). 
Ivacaftor is a CFTR potentiator, which can restore CFTR function in 
patients with the G551D mutation and was the first approved treatment 
that addresses the underlying cause of CF. However, it has only been 
found to be effective in patients with the specific mutation, who 
represent less than 5% of all CF patients worldwide (83). There may 
also be some benefit in patients with similar defects to G551D but it is 
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estimated that in total this only represents 10% of the CF population at 
most (3). The increase in the chloride transport afforded by the drug is 
only effective if the CFTR receptor reaches the cell surface, which is 
not the case in ∆F508, and a clinical trial investigating the use of 
ivacaftor in ∆F508 found no benefit over placebo (84). 
The combination of trafficking and gating dysfunction in ∆F508 
requires the co-administration of both a corrector to allow delivery of 
the protein to the cell surface, and a potentiator to allow proper gating 
and ion flow. Corrector molecules have been developed, and one, 
lumacaftor was the subject of a clinical trial with homozygous ∆F508 
patients. In vitro data had previously demonstrated significant 
correction of the defect, but this was not replicated in vivo, where no 
improvements in lung function were observed. The implication is that 
more than one corrector is needed to overcome the defect in patients 
(3). The combination of ivacaftor and lumacaftor has also been 
investigated, hoping to combine the effects of both to overcome the 
dual defect in ∆F508. A phase II trial demonstrated that the 
combination could provide a significant improvement in lung function 
(85). Both studies were carried out over a relatively short time period, 
and the effects of long-term therapy are not yet fully understood. One 
in vitro study has demonstrated that chronic ivacaftor treatment may 
increase the turnover of lumacaftor-corrected CFTR channels, 
possibly reversing the effects long-term and requiring longer-term in 
vivo studies (82). However, on the basis of two 24-week phase III 
trials, TRANSPORT and TRAFFIC, a new drug application was 
submitted by the manufacturers for the use of the combination of 
lumacaftor and ivacaftor in ∆F508 CF patients (86). The results 
indicate an improvement in lung function compared to placebo, with an 
absolute improvement of forced expiration volume (FEV1) of 2.6 to 
4.0%, a reduction in lung exacerbations, and increased weight gain 
(possibly due to decreased energy expenditure) (87). The use of the 
combination (brand name Orkambi®) in ∆F508 patients over 12 years 
old was approved by the US Food and Drug Administration in July 
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2015 (88). However, it must be noted that the improvements were not 
as profound as with the treatment of G551D patients with ivacaftor, 
where an absolute FEV1 improvement of over 10% was observed, as 
was an even greater reduction in exacerbations. The authors of that 
study noted that ivacaftor compares well with FEV1 improvements 
seen with other treatments, e.g. 12%, 5.8%, and 3.2% for tobramycin, 
dornase alfa, and hypertonic saline respectively (89).  
The cost of therapy with these small molecules remains a major issue, 
with the initial estimated annual cost of ivacaftor treatment per patient 
being €243,804 in Ireland. The National Centre for 
Pharmacoeconomics advised against the reimbursement of the drug 
as a result (90). However, political pressure and renegotiation of the 
price with the manufacturer led the government of Ireland to approve 
its provision to patients (91). The financial burden of providing the 
ivacaftor, in conjunction with the reduced efficacy of the combination 
therapy in ∆F508 patients, may potentially prevent the use of these 
drugs in the wider CF population.  
 
1.5 Host defence peptides 
HDPs are short, cationic, amphipathic, peptides that play a crucial role 
in the innate immune system of all multi-cellular organisms (92). They 
are generally 12-50 amino acids in length with a net positive charge 
due to an excess of basic residues such as lysine and arginine. In 
addition, they contain over 30% hydrophobic residues (92, 93). Some 
HDPs with a net negative charge have also been described such as 
SAAP, but they are the exception (94, 95). Many of these highly-
conserved peptides possess substantial antimicrobial activity (96), 
which is initiated through electrostatic interactions with the anionic 
phospholipid head-groups of the bacterial cell envelope. This can lead 
to either membrane perturbations or translocation across the 
membrane and interaction with various intracellular targets (97-99).  
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Nowhere is the importance of HDPs to innate defence more apparent 
than in those animals that have no adaptive immunity, such as 
invertebrates. Insects, for example, are entirely reliant on the 
production of a number of highly-active HDPs, reaching µM 
concentrations in the insect haemolymph a few hours after initial 
infection. This is a process that is 100 times more energy efficient than 
immunoglobulin production, and over 100 times faster. The highly 
active peptides of insects have been the subject of much interest for 
exogenous application in humans but are not without their drawbacks: 
many are toxic to eukaryotic cells and, while they are relatively stable 
in insect haemolymph, are highly susceptible to mammalian proteases 
such as trypsin (100). They can, however, be modified to produce 
desirable characteristics while maintaining their activity. For example, 
the peptide Cecropin A from the silk moth larvae, Hyalophara 
cecropia, has been combined with the peptide Magainin 2 from the 
clawed frog, Xenopus laevis, to produce the hybrid peptide P18, which 
displays both high activity against bacterial cells and low haemolytic 
activity against mammalian erythrocytes (101). 
1.5.1 Classes of HDPs 
There are a wide range of HDPs described in the literature with 
diverse characteristics and, at times, little sequence homology, which 
complicates their classification. However, there are several structural 
characteristics, crucial for activity, shared between HDPs that go 
beyond the simple presence of hydrophobic and cationic residues that 
may be used to group them.  
Many HDPs share three-dimensional topology and this can be used to 
classify them. Alternative methods of classification are by source, 
precursor, or intramolecular bonds. The two largest structural groups 
are the α-helical and β-sheet peptides. This method of classification 
may be broad at times, with many of the former only becoming helical 
upon interaction with amphipathic membranes and the latter 
representing a highly diverse group in structure. Despite this, both 
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groups can be characterised by structurally distinct hydrophobic and 
hydrophilic regions which mediate membrane interaction and are 
crucial for the pore-formation and cell disruption (102). 
The main mammalian families of HDPs include the defensins, 
cathelicidins, and histatins. Defensins consists of parallel β-sheets 
linked by disulphide bonds (classed by structure). Cathelicidins consist 
of a highly conserved precursor domain (classed by precursor, but 
including among them α-helices or disulphide-bonded peptides) (103). 
The diversity of sequences is enormous, with one species potentially 
possessing dozens of different HDPs, and with no similar sequences 
found in related organisms. This may be due to rapid evolution of 
sequences, with modification occurring as each species faces very 
different microbial challenges (92). The result of this rapid evolution is 
a rich library of potential sequences, of varying characteristics and 
activities that may be harnessed for exogenous use against infection 
(104).  
1.5.2 Mechanisms of action of HDPs  
Several models exist for HDP membrane disruption and each depends 
on the characteristics of the HDP (Figure 1.2). However, all rely on the 
exploitation of the fundamental differences between mammalian and 
bacterial cell membranes, including composition, transmembrane 
potential, and structural features. A key feature for a HDP is the 
degree in which it can differentiate between membranes. While all 
biological membranes are essentially composed of amphipathic 
phospholipid bilayer, beyond this, prokaryotic and eukaryotic 
membranes differ greatly in composition. Human cell membranes are 
predominantly composed of the lipids phosphatidylethanolamine, 
phosphatidylcholine, and sphingomyeline, all of which are without net 
negative charge. This is an important characteristic for the initial 
electrostatic interaction with the cationic peptides. In contrast, bacterial 
membranes, composed predominantly of phosphatidylglycerol, 
cardiolipin, and phosphatidylserine, are generally negatively charged 
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(102). In cell membrane-mimicking liposomes, the increased net 
negative charge of lipid membranes has been shown to increase HDP 
adsorption and HDP-induced leaking of liposomal contents compared 
to zwitterionic membranes, demonstrating the higher affinity of the 
HDPs for anionic lipid components (105). Bacteria are completely 
lacking membrane sterols such as cholesterol or the ergosterol found 
in fungal membranes. Cholesterol condenses the lipid bilayer and 
renders the adsorption of bulky amino acids such as tryptophan, found 
commonly in HDPs, energetically unfavourable (105). Mammalian 
membranes also have a lower transmembrane potential than bacterial 
membranes, ∆Ψ of -90 to -100mV versus -130 to -150mV respectively. 
This difference may also act to concentrate the positively charged 
HDPs on the bacterial cell surface. In general, the membranolytic 
action of HDPs is non-stereospecific, a fact that is demonstrated by 
the comparable antimicrobial activity of both natural L-amino acid 
HDPs and their D-amino acid isoforms (102).  
There are many structural determinants of HDP activity, including 
conformation, net charge, amphipathicity, hydrophobicity, and polar 
angle. They confer specificity for bacterial membranes to HDPs in 
different ways. A high cationic net charge allows strong initial 
electrostatic interaction and is correlated with activity. However, 
mammalian cytotoxicity can ensue when the net charge is too high. 
Similarly, high amphipathicity and hydrophobicity is linked to high 
activity (linked to portioning the lipid bilayer) but increasing it beyond a 
certain threshold leads to the loss of antimicrobial specificity. The polar 
angle, i.e. the relative proportion of polar and non-polar facets in a 
peptide helix, must also be balanced: too acute and membrane pore 
formation rate is weakened, too obtuse and pore stability is 
compromised (102). 
1.5.3 Models for membrane disruption by HDPs 
Several models exist for membrane disruption. The barrel-stave model 
concerns the aggregation of HDPs in a barrel-like ring on the bacterial 
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membrane, forming an aqueous pore and the leaking of cytoplasmic 
components (106). The peptides initially bind to the membrane as 
monomers and self-aggregate after reaching a threshold 
concentration. The hydrophilic surfaces of the peptides then face 
inward, forming pores of differing diameters spanning the membrane. 
The threshold concentration for this model, and indeed all pore 
forming models, is dictated by not just the peptide’s propensity to self-
assemble (with distinct hydrophilic and hydrophobic domains being 
crucial) but also membrane phospholipid composition, fluidity, and 
transmembrane potential.  Relatively few peptides have been 
demonstrated to display this activity, and a requirement is that the 
peptide must be long enough to span the membrane (102).    
In the toroidal pore model another channel is formed, but lipids are 
intercalated with the adsorbed HDPs and a fold in the membrane is 
induced. This model is more common than the barrel-stave (106). The 
curvature strain that is induced by the lipid-peptide complex (relative 
ratio of 1:30 with Magainin for example) causes a transient pore to 
form. The eventual disintegration of the pore may also be the 
mechanism by which many peptides enter into the cytoplasm. 
Membrane-spanning length is not a requirement for peptides in this 
model (102). 
The carpet model involves a detergent-like effect induced by high 
concentrations of HDPs accumulated at the membrane surface. This is 
not, however, as indiscriminate a process as it sounds and is a 
common mechanism for many HDPs (106). The adsorption of the 
peptides causes the displacement of phospholipids, changes in 
membrane fluidity, and the reduction in barrier properties. When a high 
concentration is reached, rather than forming a pore as above, the 
peptides cause unfavourable membrane energetics, with the loss of 
membrane integrity ensuing. Cecropin is an example of a peptide that 
uses this mechanism (102). 
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Other mechanisms have been described and one possible target for 
HDPs are intra-cellular components, with the possibility existing for a 
peptide to kill bacteria without the involvement of membrane 
disruption. HDPs could, for example, bind to negatively-charged DNA 
fragments. Buforin II has been shown to kill bacteria by disrupting 
intra-cellular functions (102). 
Because HDPs have multiple modes of action, including membrane 
depolarisation, pore formation, induction of degradative enzymes and 
disruption of intracellular targets, bacteria may have a lower propensity 
for the development of resistance to HDPs compared to conventional 
antibiotics. This would potentially increase the lifetime of any 
exogenous HDP in clinical use (107) and provide another option for 
antimicrobial therapy. In addition, their ability to permeabilise bacterial 
membranes may facilitate the activity of conventional antibiotics (102, 
108). 
 
 
Figure 1.2: Three models of HDP disruption of bacterial membranes. 
Barrel-stave (A), Toroidal pore (B), and Carpet (C). Taken from (106). 
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1.5.4 Immunomodulation of HDPs  
In addition to antibacterial activity, many HDPs possess 
immunomodulatory effects, involving cellular recruitment and 
stimulation of components of innate immunity (93). This has been 
extensively investigated with human cathelicidin, LL-37, found in high 
concentrations at sites of inflammation. LL-37 has been shown to have 
a chemotactic effect on immune cells such as neutrophils and 
monocytes at high concentrations (109), attracting them to the site of 
infection and helping clear the inflammatory insult (110). LL-37 can 
modulate the release of pro-inflammatory cytokines such as IL-8 (and 
has been found to directly stimulate IL-8 release itself) in response to 
stimuli (111). It can also both reduce and increase cytokine levels in 
response to LPS in different cell types (112, 113). Although these 
differing effects may appear to be paradoxical, its role in vivo may 
involve maintaining a balance between pro- and anti-inflammatory 
responses (110). The mechanism of action is still not fully elucidated 
and while the “formyl peptide receptor-like” receptor (FPRL1) has been 
found to play a role (44, 109, 114), the action of LL-37 may not be 
entirely receptor-mediated. For example D-amino acid LL-37 can 
induce a greater IL-8 response than the natural L-amino acid 
sequence. This indicates that the response may be related to 
membrane effects and, like with antimicrobial activity, not 
stereospecific (115). LL-37 is not alone amongst HDPs in 
immunomodulation, e.g. Human β-defensin 2 has been shown to 
induce some neutrophil chemotaxis (116), and human defensin 5 
stimulates IL-8 release in epithelial cells (117). This is not surprising 
when one considers that defensins in general, with their β-sheets and 
disulphide bonds share many structural features with chemokines. 
Similarities between both are further demonstrated by the fact that 
many chemokines have direct antimicrobial activity themselves (103). 
Immunomodulatory HDPs have also been rationally-designed 
peptides. The peptide Innate Defence Regulator-1 (IDR-1), for 
example, has been shown to be protective against infection in vivo, 
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with an accompanying modulation of cytokines such as IL-6 and IL-10, 
but without direct in vitro antimicrobial activity (118).  
1.5.5 Shortcomings for HDP therapeutics and potential solutions  
Despite the wealth in number and characteristics, the development of 
HDPs as antimicrobial agents has been hampered so far by a series of 
shortcomings. The main issues include the cost of production, lability 
to proteases and potential for toxicity. Shorter peptide sequences can 
address some of the cost issues and the use of non-natural amino 
acids (such as D-amino acids) can prevent protease degradation (as 
the mechanism of action is not stereospecific, as stated above, it will 
not compromise activity). Toxicology can only be dealt with via careful 
selection of sequence and proper screening (104). 
1.5.6 Potential use of HDPs in CF  
The rationale exists for using HDPs as exogenous therapeutics for CF 
as the activity of endogenous HDPs can be compromised. In addition 
to other immune components, pulmonary proteases in CF cleave 
endogenous HDPs. This can take the form of the proteinase 3-
regulated activation of  LL-37 from hCAP-18 (39), but also degradation 
and inactivation by NE. The effect of the dysregulation of protease 
expression in CF has been demonstrated by comparing BAL fluids of 
healthy controls and CF patients. The former will process hCAP-18 to 
LL-37, while the latter will further degrade LL-37 (119). Similarly, the β-
defensins have been shown to be cleaved and inactivated by 
cathepsins B, L, and S. Again, these enzymes are present in CF BAL 
fluid (120). In addition to high protease activity, it has been suggested 
that CFTR dysfunction leads to high pulmonary salt levels, which can 
deactivate HDPs (121). However, whether the ionic composition of the 
ASL is abnormal in CF is a subject of debate (5, 122-124).  
Compounding the impaired host HDP function in CF, fears over 
bacterial resistance in CF provides further impetus for developing 
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HDPs as therapeutics. The growth of resistance has led to previously-
restricted therapeutics, such as the use of colistin, being re-examined 
and re-entering the clinic (125). Concern is growing in particular over 
the development of multi-drug resistant P. aeruginosa and the need for 
new drugs to treat it (10, 15, 20).  
However, the issues of protease degradation and salt-inactivation are 
not the only barriers to HDP use in CF. Significant research has been 
undertaken to develop HDPs as viable therapeutics for a host of other 
infectious diseases, but progress has been limited by a variety of 
factors. While a number of HDPs are the subject of clinical trials, none 
have yet received approval, and the majority of these trials focus on 
topical applications (107, 126); rapid metabolism and a lack of affinity 
for their target means that HDPs often have very narrow therapeutic 
indices (107, 127). An issue with rational design, as seen above, is 
that increased activity, e.g. due to increased hydrophobicity, is often at 
the expense of selectivity between eukaryotic and prokaryotic 
membranes and results in host toxicity (103). Even endogenous 
HDPs, such as LL-37, can be cytotoxic at high concentrations (128). 
Some of the most potent natural HDPs are the β-hairpin peptides, 
such as polyphemusin 1 derived from the horseshoe crab. It has a 
very low MIC against P. aeruginosa of 0.25µg/ml (129). Though highly 
active, it exhibits haemolytic activity at higher concentrations and a 
derivative, iseganan, failed at phase III trials against oral mucositis 
(104). This represents a major obstacle to the use of HDPs in CF; the 
primary aim of chronic P. aeruginosa infection therapy is the 
preservation of lung function (10, 15). Non-selective HDPs will bind to 
both bacterial and human cell membranes, and can form 
transmembrane pores, such as via the barrel-stave mechanism (130). 
Additionally, when internalised in eukaryotic cells, HDPs can interact 
with mitochondrial membranes, which, like bacterial membranes, are 
negatively charged, and induce their permeation, the release of 
cytochrome c, and induction of apoptotic pathways (130). The 
potential for mammalian cell toxicity has been exploited in the area of 
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cancer chemotherapy research. For example, when hydroxyalkanoic 
acid is coupled to P18 it increases its cancer specificity, killing the 
cancer cell primarily via induction of apoptosis (131). In addition, many 
α-helical HDPs kill cancer cells by damaging cell membranes and 
causing necrosis, with HDP classes including cathelicidins, cecropins, 
and magainins all displaying activity against human cancer cells (132).         
 
1.6 Host defence peptide prodrugs1  
Designing a peptide rationally with the correct combination of high 
antimicrobial activity, low cytotoxicity, and protease-resistance that is 
short in length and has favourable immunomodulatory effects for a 
specific disease model has not been achieved to date. Many peptides 
have been described that cover many, but not all of these 
requirements. As a result there are currently no HDPs in clinical use 
for internal infections like those in CF. An alternative approach is to 
convert favourable HDPs into prodrugs. Prodrugs are chemically-
modified inactive derivatives of active agents that are transformed in 
vivo to produce the active drug (133). This can allow the activity of the 
HDP to be targeted to a specific bacterium or biological system and 
reduce cytotoxicity distal from the site of activation (Figure 1.3). This 
approach has parallels in nature with activation of hCAP-18 to LL-37 
by PR-3. In this manner, the activity, and potential cytotoxicity, of the 
endogenous HDP can be limited until required to fight infection (56). 
Colistin, which is widely used as an antimicrobial agent against P. 
aeruginosa in CF, is delivered as a prodrug to the lung for reasons of 
toxicity (20, 134). 
 
 
                                            
1
 Please note that some of this section has been adapted from a 
review written on the topic by the author of the thesis (134). This 
review is available in the appendices. 
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Figure 1.3: Overview of the HDP prodrug model. The pro-moiety 
prevents the active HDP from interacting with cell membranes, both 
bacterial and mammalian, reducing both activity and cytotoxicity. The 
targeting mechanism, e.g. bacterial or host enzymes, releases the 
active HDP, restoring activity and limiting cytotoxic effects distal from 
the site of activation. Adapted from (135). 
1.6.1 Net charge reduction as a prodrug strategy  
There are a variety of ways in which peptides can be modified to 
convert them to prodrugs. Numerous approaches and accompanying 
pro-moieties have been investigated (135). One of the most effective 
methods is the reduction of net charge. As discussed above, the 
different electrostatic interactions between HDPs and membranes 
grant them a degree of selectivity (96) and allows them to disrupt 
bacterial cytoplasmic membranes, both Gram-positive and -negative 
(93). The importance of this interaction is underlined by the fact that 
nearly all HDPs have a net charge in the range of +2 to +9 (136). 
Peptides derive their net positive charge from their N-terminus amine 
and basic residues such as arginine and lysine. The prodrug of the 
peptide drug colistin is an example of net charge reduction. Its use 
was limited for many years over fears of nephrotoxicity but was 
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reconsidered with the emergence of bacterial resistance (125). 
Electrostatic interaction with LPS in the outer Gram-negative 
membrane is the basis of its activity and is not unlike that of HDPs 
(137). Currently it is delivered as its prodrug colistimethate via 
inhalation (20, 134). Colistimethate is inactive and less toxic due to the 
addition of sulfomethyl groups to the five primary amines of colistin 
(125). This changes the net charge from +5 to -5, reducing both 
antimicrobial activity and host toxicity (138). The sulfomethyl groups 
are hydrolysed in vivo, releasing active colistin and restoring the net 
positive charge (139). However, sulfomethyl is not an attractive pro-
moiety for HDPs. The release of the active colistin relies on 
spontaneous hydrolysis, an inefficient and non-selective process, 
releasing a mixture of partially sulfomethylated derivatives alongside 
free colistin, with the net charges of the derivatives ranging from -3 
(four attached sulfomethyl groups) to +3 (one attached group). In 
addition, factors such as pH and temperature have a major effect on 
release. For example, an in vitro study reported that only 31.2% of 
colistimethate was hydrolysed to colistin after 4h in aqueous solution 
at 37oC (125). Commercially-available preparations of colistimethate 
may also differ between suppliers, with spontaneous hydrolysis 
resulting in undefined mixtures of substituted compounds with different 
activities (140). 
The reduction of net charge has been used to reduce the uptake of 
cell-penetrating peptides (CPP) that, like HDPs, rely on high net 
positive charge as a mechanism of action. The addition of anionic 
glutamic or aspartic acid residues has been shown to inhibit their 
cellular uptake. In one study, the insertion of an MMP-targeted 
PLGLAG linker in between the CPP and anionic groups allowed MMP-
2 and -9-dependent increases in CPP uptake to occur, the enzyme 
cleaving the anionic group and restoring the net positive charge (141). 
It is of note that this linker is consistent with the characteristics of an 
ideal substrate discussed in section 1.3.4 for MMP-9 (68). 
Independently, a similar approach to that of the CPPs was 
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successfully employed by our group using the relatively facile addition 
of an oligoglutamic acid pro-moiety to reduce the net charge of P18 
from +8 to +3, reducing its antimicrobial activity against P. aeruginosa 
and S. aureus, and lowering it haemolytic activity. Included in the 
design was a tri-alanine linker designed for cleavage by NE, allowing 
NE-dependent restoration of antimicrobial activity. In order to prevent 
the cleavage of the active sequence by NE, P18 was synthesised from 
D-amino acids, leaving the linker and pro-moiety as enzyme-labile L-
amino acids. However, the peptide resulting from NE activation, AA-
P18, had inferior antibacterial activity compared to P18 (142). 
The combination of an anionic pro-moiety and an enzyme-targeted 
linker sequence has been applied to a series of disease models, with 
the potential to target both host and bacterial enzymes for cleavage 
and active HDP release. Some HDP prodrugs, for example, are being 
examined for anticancer applications. MMP-2 is overexpressed in 
cancer cells and has been targeted with a peptide linker consisting of 
the sequence GPLGIAGQ. The pro-moiety, based on a sequence from 
magainin, DAEAVGPEAADEEKDED, reduces the net charge of the 
HDP by 8 units and has been used with buforin, which has a net 
charge of +7. MMP-producing cancer cells were found to be 
susceptible in vitro to the pro-peptide. In cells without the enzyme, no 
toxicity was demonstrated (143). Similarly, the amoebapore lytic 
peptide H-3 has been modified with C-terminal γ-linked glutamic acids 
which prevent membrane interaction. The prodrug is targeted at the 
carboxypeptidase enzyme prostate-specific membrane antigen 
(PSMA), which can remove terminally-linked γ-glutamic acids and is 
found in malignant prostate tissue. Anticancer activity was 
demonstrated in cells overexpressing PSMA, with little lytic effects on 
PSMA-negative cell lines (144). In vivo studies using a mouse tumour 
xenograft model demonstrated reduced tumour size in treated mice 
compared to control and, in a separate experiment, no significant 
toxicity was observed in healthy mice after IV administration of a 
30mg/kg dose (145).  
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In targeting cancer, one of the issues associated with intravenous 
delivery is stability. A very recent paper (citing work carried out as part 
of this thesis) addresses this issue. The peptide Melittin is inactivated 
by the blocking segment PEPAPEPEAGADAEADPEA, reducing the 
charge from +3 to -5, and targets MMP-9 with the linker GPQGIAGQ, 
cleavage occurring at Gly-Ile bond. It reduced the cytotoxicity against 
human 2F2B cells (increasing IC50 from 2.4µM to >100µM). 
Incorporating the pro-HDP into perfluorocarbon nanoparticles 
increases its circulating half-life and slows cleavage. This minimises 
non-specific cleavage in the bloodstream but still allows cancer-
targeting. In a mouse model of cancer, treatment for 14 days with the 
pro-HDP nanoparticles reduced tumour size by 88% (146). 
The major advantage of the net charge reduction approach is that, 
even with the incorporation of an enzyme-targeted linker, the final 
peptide remains relatively short. This is important when the cost of 
production is taken into account but also in terms of the ease in which 
the sequence can be produced and modified in a research setting. 
Solid phase synthesis (see section 3.1.2) and RP-HPLC can be used 
to produce highly-pure well-characterised final products, allowing for 
the generation of in vitro data quickly. One can then return and 
optimise the pro-HDP based on the in vitro results. Industrial scale-up, 
and therefore economic viability and clinical approval, are also likely to 
be facilitated, as compared to a multi-component system.  
1.6.2 PEG as a pro-moiety  
Poly(Ethylene Glycol) (PEG) is one of the most widely used polymers 
for improving the pharmacokinetic and pharmacodynamic properties of 
low molecular weight drugs, peptides, proteins and oligonucleotides 
(Figure 1.4). It is synthesized via the nucleophilic attack of a hydroxide 
ion on the epoxide ring of ethylene oxide, leading to anionic 
polymerization. It can be covalently attached without crosslinking to 
drugs with a reactive functional group such as –COOH, -SH, -OH, or 
NH2 (147), making the attachment to a resin-bound, protected HDP 
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relatively straightforward. PEG is currently used as a conjugate for 
many protein drugs, conferring increased aqueous solubility, reduced 
immunogenicity, prolonged half-life and higher specificity than the 
active agent alone (148). PEG, when bound to water, has a 
hydrodynamic radius 5-10 times that of a globular protein of similar 
molecular mass. The water-associated PEG protects the attached 
active constituent from enzymatic degradation, protein interaction and 
fluctuations of temperature and pH. PEGylation can also prevent the 
attached drug from interacting with its target, but the resulting 
extensions in half-life can offset the effect of reduced activity (149). 
Many PEGylated anticancer agents, once localized in the tumour, are 
designed with a release mechanism that exploits lysosomal enzymes 
such as cathepsin B with a peptide linker of sequence GFLG (148, 
150, 151), or lower pH levels of tumour cells with a hydrazone linker 
(152). 
 
 
Figure 1.4: Poly(ethylene glycol) structure. 
PEG may be easily incorporated into resin-bound peptides, 
using supra-stoichiometric concentrations of the desired PEG in 
conjunction with a solid support that allows the diffusion of the polymer 
in its matrix. However, while widespread in anticancer therapies, PEG 
has not been used as extensively with HDPs. As with other molecules, 
PEGylation can decrease the binding of peptides to their biological 
targets i.e. cell membranes, and while this will reduce antimicrobial 
activity and potentially interaction with a targeted activating enzyme, it 
will also lower cytotoxicity and haemolysis (153).  
The reduction in both host- and bacterial-targeting effects has been 
exploited to improve the selectivity of HDPs, with mixed results. While 
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not incorporating a prodrug release mechanism, a conjugate of 
Magainin and 5kDa PEG had far lower cytotoxicity against CHO-K1 
cells but only a four-fold reduction in MIC against E. coli and 
Staphylococcus epidermidis (154). A conjugate of tachyplesin and 
5kDa PEG displayed similar reductions, again with no release 
mechanism incorporated into the design. However, while reducing the 
cytotoxicity of tachyplesin, PEG had a major deleterious effect on 
antimicrobial activity, increasing the MIC against E.coli from 0.5µg/ml 
to 32µg/ml (153). Reductions in haemolysis compared to control were 
noted in a PEGylated HDP, KYE28, and was inversely related to 
length of the attached PEG. Improved selectivity was demonstrated in 
a blood mixture supplemented with a bacterial inoculum, where 
PEGylation reduced haemolysis while maintaining antimicrobial effect. 
This ran in parallel with reductions seen in interaction with model lipid 
membranes (both anionic and zwitterionic) and antimicrobial effect 
with increasing PEG length. Also noted was a modest reduction in 
LPS binding with PEGylation, which was interesting from an 
immunomodulatory aspect. Furthermore, while the parent peptide 
reduced LPS-induced NF-κB activation of macrophages, the 
PEGylated peptide was moderately less effective, indicating that the 
pro-moiety was interfering with immunomodulatory effects (155).  
Using a short PEG, another group was able to demonstrate modest 
reductions in cytotoxicity with small decreases in antimicrobial activity. 
They proposed that PEGylation reduced the association with 
zwitterionic membranes, such as those in mammals, while leaving the 
interaction with anionic bacterial membranes relatively unaltered. They 
demonstrated that the PEGylated HDP, compared to the unaltered 
HDP, had an increased preference for binding with anionic model 
membranes than their zwitterionic counterparts. Interestingly they 
demonstrated that the PEG used was unable to prevent HDP 
degradation by rat lung proteases and that the PEGylated peptide was 
more labile than the free HDP. They proposed that in this case 
PEGylation may interfere with the HDP’s ability to self-associate and 
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reduce its stability (156). Conversely, the use of short PEGs has been 
shown to protect against degradation by chymotrypsin and serum 
proteases, which is important when one considers the impediment to 
HDP development that protease-lability represents. A comparison 
between an active HDP and its PEGylated derivative showed that, 
while the latter had reduced antimicrobial activity, it maintained this 
activity in serum, while serum had a major deleterious effect on the 
activity of the parent HDP. The authors of the study noted that the 
PEG length was below that which is usually required to extend peptide 
half-life (2kDa and higher) but that the short PEG may still shield the 
peptide core from degradation (157). The ability of PEG to protect from 
proteolytic degradation may depend on the enzyme in question and 
the length of PEG used. Relevant degradative enzymes would have to 
be taken into account when considering the length of PEG for use in a 
prodrug system. 
While PEGylation alone may be used to improve the selectivity of 
HDPs, the inclusion of targeted release mechanisms can take 
advantage of the reductions in cytotoxicity while circumventing the 
issue of reduced antimicrobial activity, creating a true prodrug. The 
covalent linkage of PEG or other polymers to the HDP can be 
designed for cleavage under certain physiological and enzymatic 
conditions to ensure controlled release of the active peptide and 
limitation of host toxic effects, producing a prodrug (152). Nollman et al 
produced a series of PEG-HDP conjugates targeted for release by 
trypsin-like proteases found in serum using a GARSG linker sequence. 
The active sequences had previously been optimised for stability 
against mouse serum proteases. This provides a controlled systemic 
release of active HDP. It was again found that PEGylation reduced 
antimicrobial activity, in one case with MIC increasing from 0.8µM to 
9.3µM. Addition of mouse serum (containing the target proteases) 
restored activity and reduced the MIC back to 0.6µM. Release kinetics 
varied between pro-HDPs and depended on PEG length and linker, 
e.g. a longer PEG was found to slow the release rate. This is 
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consistent with the PEG shielding the linker from enzymatic 
degradation (158).  
PEGylation has produced mixed results in HDP prodrugs models. 
Improved specificity has been reported in some cases while major 
deleterious effects on activity were found in others. Its ability to shield 
peptides from protease degradation is also mixed, and the use of too 
large a PEG may preclude efficient release of the active HDP in vivo.  
However, taken together, the results of previous studies indicate that it 
may have a useful role in future HDP prodrugs, warranting further 
study with a suitable enzyme-linker system and an optimised PEG and 
linker length. Like oligoglutamic acid, it can be produced using solid-
phase synthesis, allowing highly-pure products to be obtained, 
although, unlike oligoglutamic acid, a polymeric prodrug would likely 
be relatively large, requiring careful economic consideration.  
1.6.3 Antibodies as pro-moieties  
In certain clinical scenarios it may be highly desirable to target the 
activity of HDPs at a pathogenic bacterium with minimal effect on 
normal commensal flora, such as in the mouth or the colon. Using 
antibodies as conjugates has been attempted to achieve this. In one 
study, the HDP SMAP was linked to immunoglobulin G antibodies 
specific for the bacterium Porphyromonas gingivalis. Preferential killing 
against P. gingivalis was demonstrated in a simulated microbial 
community at 20µg/ml but specificity was lost at higher concentrations 
(159). Antibody conjugates, however, have a major drawback in that 
modest improvement in specificity comes with a greatly increased 
product size and cost of production. The final therapeutic would likely 
have a molecular mass in the region of 150kDa and cannot be 
synthesised by solid-phase chemistry (135). For example, the HDP 
dhvar5 was conjugated to an antibody against Streptococcus mutans 
with a linker sequence targeted at the endoproteinase factor Xa, a true 
prodrug. While it was demonstrated that the linker allowed factor Xa-
dependent restoration of antimicrobial activity, purification and testing 
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of the larger antibody conjugate was not possible due to low yield, 
product degradation, and poor bacterial vector growth (160). 
1.6.4 Antibiotics as pro-moieties  
Conjugating HDPs to conventional antibiotics can use characteristics 
of both components to overcome issues of toxicity and selectivity. For 
example, vancomycin has been combined with Magainin. Vancomycin 
targets Lipid II which is essential for peptidoglycan synthesis and has 
a much higher affinity for Gram-positive membranes compared to the 
non-selective electrostatic attraction of Magainin (and other HDPs). 
Like all HDPs, Magainin can take advantage of the lower propensity 
for resistance to develop in bacteria. The resulting conjugate had an 
MIC of 16µg/ml against vancomycin-resistant Enterococci compared 
to 128µg/ml for vancomycin alone (161). However, activity would 
potentially be limited to Lipid II-containing bacteria. 
Additional design characteristics can incorporate the antibiotic as a 
targeted pro-moiety. Conjugating antibiotics can provide a reduction in 
HDP net charge by masking the N-terminus amine and via the 
negative charge of antibiotic functional groups such as –COOH, 
inactivating the HDP in much the same way as oligoglutamic acid. A 
conjugate of the HDP Bac8c and the cephalothin was designed where 
the antibiotic acts solely as a pro-moiety as opposed to a co-drug. The 
net charge of the HDP is reduced from +4 to +2. The prodrug, targeted 
at the bacterial enzyme β-lactamase, has lower antimicrobial activity 
than both separate constituents in the absence of the target enzyme, 
with β-lactam resistant E. coli the target. The enzyme cleaves the β-
lactam bond of the antibiotic and releases the active HDP. Cleavage of 
the prodrug has been demonstrated with purified β-lactamase, but the 
prodrug showed reduced activity compared to Bac8c alone. However, 
the comparison of the activity of an uncleavable control confirms that a 
degree of enzyme-dependent activity was present but with the 
uncleaved prodrug still somewhat active (162). 
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1.6.5 Summary of HDP prodrugs  
The prodrug approach has the potential to greatly expand the number 
of HDPs suitable for anti-infective therapy. Highly-active HDPs that 
would otherwise be too cytotoxic under normal circumstances may be 
reconsidered for use as a prodrug that targets activity to a particular 
biological system such as the CF lung. Several options for pro-
moieties, with varying characteristics, have been investigated. Figure 
1.5 illustrates how these different conjugates may be used to decrease 
the absolute affinity of HDPs for cell membranes, reducing host 
cytotoxicity and, in many cases, antibacterial activity. While many of 
the modifications such as PEGylation will increase the selectivity of 
HDPs by increasing the relative affinity for bacterial cell membranes, 
the accompanying loss of absolute bactericidal activity necessitates 
the incorporation of a release mechanism for the active HDP i.e. the 
synthesis of HDP prodrugs. The various enzymatic targets used by the 
different prodrug models underlines how HDP activity can be tailored 
to a specific bacterium or region of the body, limiting cytotoxic effects 
of the already selective AMPs. 
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Figure 1.5: An overview of the effects of the different pro-moieties on 
the affinity of HDPs for mammalian and bacterial cell membranes, the 
size of the arrows representing the higher intrinsic affinity for HDPs 
towards bacterial cells. Lipid composition means that bacterial 
membranes are of net negative charge (-), while mammalian ones are 
neutral (+/-) with cholesterol as a major component (its hydroxyl group 
aligning with the phosphate heads of the outer surface of the 
membrane). These characteristics direct HDP affinity. The pro-
moieties also modulate this affinity to different degrees, with net 
charge reduction having the most impact. Adapted from (135). 
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Considering the complexity of the targeted biological systems, an 
important future milestone in the development of pro-HDPs would be 
an in-depth in vivo study of not just the antimicrobial activity of the pro-
HDP but also the activation by the target biological system, including 
analysis of the released active peptide in biological samples such as 
CF BAL fluid or serum. The reduction in toxic effects, if any, afforded 
by the modification must also be investigated. In addition, something 
that has not yet been studied in detail is the potential effects of the 
prodrug approach on the other effects of HDPs i.e. immunomodulatory 
activity, which may be a potential source of host toxicity with 
exogenous application. When one considers that membrane 
association and translocation may play a role in the 
immunomodulatory mechanism, it is possible that the addition of a pro-
moiety may reduce these effects. Furthermore, where the 
immunomodulatory effect is the result of binding to immunogenic 
molecules such as LPS, the possibility that the pro-moiety will reduce 
this effect must be investigated (155). Another important design 
consideration is whether the active sequence will be resistant to 
degradation by both target and off-target enzymes. HDP prodrug 
systems may rely on high concentrations of host or bacterial enzyme 
for activation, such as NE in CF, which could have the potential to 
degrade the active sequence. Strategies to avoid this must be 
incorporated into design, whether it be via PEGylation (157), D-amino 
acids (142), a protease-resistant sequence (158), or otherwise. These 
approaches, particularly D-amino acids, may also increase the future 
cost of production of pro-HDPs and alter immunomodulatory activity 
and must be carefully considered whether they are necessary.  
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Aims and summary of chapters 
 
This study aims to develop HDP prodrugs for use against bacterial 
infection in CF. HDPs form an important part of the innate immune 
system but their endogenous activity may be compromised in CF, 
contributing to chronic infection and lung disease. Developing HDPs 
for exogenous delivery is hampered by a series of factors including 
host toxicity. This project develops HDP prodrugs that will be active 
against CF lung infection but with reduced host toxicity. 
The overall aim was achieved through a series of related studies 
described in four chapters which are summarised as follows: 
• Chapter 1 describes the development of a new prodrug 
approach and its application with three candidate HDPs, P18, 
Bac8c and HB43. 
• Chapter 2 describes the approaches taken to achieve further 
improvements in activity and reduced cytotoxicity with CF 
conditions in mind. A more detailed in vitro evaluation of the 
previous series of pro-HDPs and further candidates is 
described and a final candidate peptide, pro-WMR was selected 
for further studies. 
• Chapter 3 describes the evaluation of pro-WMR in a 
nebulisation drug-delivery system. 
• Chapter 4 describes an in vivo CF mouse study of the toxicity 
and effectiveness of pro-WMR against P. aeruginosa lung 
infection. 
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2. Materials and methods 
 
2.1 Peptide synthesis and in vitro testing 
2.1.1 Strains and Clinical isolates  
The laboratory strain PAO1 (American Type Culture Collection, 
Rockville, MD, USA) was used as a reference. P. aeruginosa clinical 
isolates from CF patients were obtained from the Microbiological 
Diagnostic Laboratory of Beaumont Hospital, Dublin, Ireland. Isolate 
identity was confirmed by a combination of the BBLTM DrySlideTM 
oxidase test (P. aeruginosa is oxidase-positive) (BD, USA), the C-390 
DiatabTM disk test (where growing P. aeruginosa in the presence of the 
antibiotic disk produces no zone of inhibition) (Rosco Diagnostics, 
Germany), and Matrix Assisted Laser Desorption Ionisation – Time of 
Flight (MALDI-TOF) mass spectrometry (Bruker, Germany). 
2.1.2 CF BAL fluid collection  
Samples of CF BAL fluid were collected from consenting CF patients. 
Non-CF BAL was collected from patients with stage I or II sarcoidosis 
from a previous study. Both protocols for collection were approved by 
the Beaumont Hospital Ethics Research Committee (references 10/43 
and 99/94 respectively). Briefly, 30ml of sterile 0.9% NaCl was instilled 
into the right or left sub-segmental bronchus, collected immediately 
and stored at 4oC. After centrifugation at 500xg for 10min at 4°C, the 
supernatants were removed and stored in aliquots at -80oC until 
required. 
2.1.3 Blood collection  
Blood samples were collected from consenting healthy individuals. 
The protocol was approved by the RCSI Research Ethics Committee 
(reference REC951). For neutrophil isolation, blood was collected in 
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7.5ml tubes containing heparin lithium-coated beads (Sarstedt, 
Ireland). Blood collection tubes (2.7 ml) containing EDTA were used 
for erythrocyte collection (Sarstedt, Ireland). 
2.1.4 Peptide synthesis  
Five peptide amide sequences were investigated; D-Bac8c2, 5 Leu 
(rlwvlwrr), D-HB43 (fakllaklakkll), D-P188 Leu (kwklfkklpkflhlakkf), D-
WMR3, 6 Leu (wglrrllkygkrs), and D-WR12 (rwwrwwrrwwrr). The 
isoleucine residues normally found in Bac8c, P18, and WMR were 
replaced by leucine. This has previously been shown not to negatively 
impact on activity in Bac8c and P18 while decreasing the cost 
associated with D-isoleucine synthesis (131, 162). This modification 
has not previously been made to WMR and was investigated with 
comparison to L-WMR (WGIRRILKYGKRS) (see Results Chapter 
Two). Henceforth, the D-HDPs will be referred to as Bac8c, HB43, 
P18, WMR and WR12. 
The parent sequences were assembled by automated solid phase 
peptide synthesis on a 433A synthesiser (Applied Biosystems, UK) 
from 9-Fluorenylmethyloxycarbonyl (Fmoc)-protected D-amino acids 
(Merck Chemical, UK) according to the Fmoc-tBu strategy with 1-
[Bis(dimethylamino)methylene] 1H-1,2,3- triazolo [4,5-b]pyridinium 3-
oxid hexafluorophosphate (HATU)/N,N-Diisopropylethylamine (DIEA) 
coupling chemistry from a Rink Amide MBHA resin (Sigma, Ireland). 
Single coupling cycles using a 10-fold excess of Fmoc-amino acids 
were employed, except for the leucine at position 8 in P188 Leu, where 
double coupling was required. The excess ensures complete coupling 
during each synthetic step. Removal of Fmoc was carried out using 
20% v/v piperidine in N-Methyl-2-pyrrolidone  (NMP) and the reaction 
was monitored by the UV absorbance at 301nm of the Fmoc-
dibenzylfulyene adduct in the run-off. For the pro-HDPs, the addition of 
the AAAG linker, glutamic acids and N-terminal acetylation were 
carried out manually with L-amino acids in a syringe fitted with a Teflon 
frit. Coupling and deprotection, were monitored using the Kaiser test. 
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Addition of more than four glutamic acids was attempted using a 
combination of microwave-assisted synthesis and repeated couplings. 
The PEGylated pro-peptide was generated by first synthesising P18 
on PEGA resin (EMD Millipore, UK) using automated synthesis on a 
0.1mM scale, AAAG was then added manually with Kaiser test 
monitoring. PEGylation was carried out using 2 equivalents of 2000Da 
MeO-PEG-COOH (Iris Biotech, Germany) and HATU/DIEA coupling 
chemistry. 
Peptides were deprotected and cleaved from the synthesis resin using 
a mixture of 80% trifluoroacetic acid, 5% water, 5% triisopropylsilane, 
5% thioanisole and 5% 1, 2-ethanedithiol, at RT for either 2h (pro-
HB43 and pro-P18) or 4h (pro-Bac8c, pro-WMR, and pro-WR12), with 
the number of arginine residues present dictating the cleavage time. 
They were then precipitated by addition of diethyl ether, washed three 
times with 10 ml portions of diethyl ether, dried, dissolved in distilled 
water and lyophilised.  
Chromatographic analysis and purification were performed on a 
BioCAD SPRINT Perfusion Chromatography Workstation (PerSeptive 
Biosystems, UK) using Gemini columns (Phenomenex, 110Å, 5m, 
C18, 4.6mmd/250mmL or 100mmd/250mmL, for the analytical or 
semi-preparative columns, respectively). Buffers used were mobile 
phase A: 0.1% trifluoroacetic acid (TFA) in water; mobile phase B: 
0.1% TFA in acetonitrile with a gradient of 5 to 65% B in 18 column 
volume (analytical) or 5 column volume (semi-preparative) with a flow 
rate of 1ml/min (analytical) or 5ml/min (semi-preparative) and single 
wavelength detection at 214nm. A secondary wavelength at 280nm 
was used for Bac8c, P18, WMR, and WR12, and at 254nm for HB43. 
The PEGylated pro-peptide was purified as above but with a C5 
Jupiter column (Phenomenex, 300 Å). Purified peptides were finally 
characterised by MALDI-TOF MS using an α-cyano-4-hydroxy-
cinnamic acid matrix. 
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2.1.5 TFA removal of HDPs  
In order to exchange the TFA counter-ion with a Cl-, 20mg of HB43 
was dissolved in 15ml of deionised water. 100mg of Dowex® 1X8 
chloride form ion exchange resin (Sigma, Ireland) was added to the 
solution, which was then stirred at RT for 1h. The solution was filtered 
to remove the resin and lyophilised. The resulting peptide was 
analysed in D2O by 19F NMR and compared to unexchanged peptide 
to investigate TFA removal. The ion exchange procedure was 
repeated until the 19F peak was completed removed to ensure that 
TFA had been completely exchanged with Cl-. 
2.1.6 Enzymatic cleavage of pro-HDPs  
Each pro-HDP (250µg/ml) was incubated with 5µg/ml purified NE, 5 or 
10µg/ml PE (Elastin Products Company, USA) or 5µg/ml CG (Sigma, 
Ireland), at 37oC, in phosphate buffered saline (PBS), pH 7.4. At 
various time-points, samples were removed from the incubation 
mixture and analysed by HPLC and MALDI-TOF MS. To confirm the 
protease-resistance of the D-amino acid sequences, Bac8c. HB43 and 
P18 were incubated at 37oC with 100µg/ml NE for 24h and analysed 
by HPLC. 
2.1.7 Neutrophil elastase determination  
Neutrophil elastase activity of CF BAL fluids was estimated by 
measuring the cleavage of the NE substrate, N-methoxysuccinyl-Ala-
Ala-Pro-Val-p-Nitroanilide (AAPV-pNA) (Sigma, Ireland).  Briefly, 1mM 
AAPV-pNA was added to BAL fluids (diluted as appropriate) in buffer 
containing 0.05M sodium acetate and 0.1M sodium chloride, pH 7.5 in 
96 well plates. The rate of AAPV-pNA cleavage was measured as the 
increase in absorbance at 405 nm over 5 min at 37oC using a 2030 
Multilable Reader Victor X3 (Perkin Elmer, USA). Assays containing 
0.25 – 5µg/ml purified NE (Elastin Products, USA) were used to 
construct a standard curve on Graphpad Prism software. The standard 
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curve was used to calculate the NE concentration of the CF BAL 
fluids.  
2.1.8 Susceptibility testing  
Minimum inhibitory concentrations (MIC)  were determined using the 
broth microdilution method according to the guidelines of the Clinical 
and Laboratory Standards Institute (CLSI) (163), with modifications for 
cationic peptides as described by Wu & Hancock (164). Briefly, serial 
doubling dilutions of peptide were made in a sterile solution containing 
0.2% w/v bovine serum albumin (BSA) and 0.01% v/v acetic acid with 
a concentration range of 0.5 - 64µg/ml (units chosen for consistency 
with guidelines). These were added to a 96-well microtitre plate with a 
1.5 x 105 CFU/ml inoculum of P. aeruginosa reference strain PAO1 or 
clinical isolates in Mueller-Hinton broth (non-cation adjusted, Oxoid, 
UK).  The lowest peptide concentration showing no visible growth was 
recorded as the MIC. The result was confirmed by measuring 
absorbance at 620nm and determining the concentration at which it 
was reduced by 90% compared to control. 
2.1.9 Bactericidal killing activity  
P. aeruginosa strain PAO1 and clinical isolates were grown overnight 
at 37oC on Mueller-Hinton (MH) agar. Suspensions were prepared in 
0.9% w/v NaCl from isolated colonies to the density of a 1.0 
McFarland standard using a Densichek meter (Biomerieux, Ireland) 
and were further diluted 1/100 in potassium phosphate buffer, pH 7.4 
containing 0.2% BSA.  Assays were carried out in microcentrifuge 
tubes and contained 0.39 - 25µg/ml peptides, 10% v/v P. aeruginosa 
suspension (approximately 1.5 × 106 CFU/ml)  and 10mM potassium 
phosphate buffer, pH 7.4 containing 0.2% BSA. Assays were 
incubated at 37oC, 200rpm in a shaking incubator for 1h (Gallenkamp, 
UK) and then diluted 1/10 with 0.95% w/v NaCl.  After vortex mixing 
for 30s, a 100µl aliquot was spread onto MH agar and incubated 
overnight at 37oC. Killing activity (%) was calculated from viable 
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counts (CFU/ml) from assays containing peptides compared to control 
assays not containing peptides. The effects of the addition of purified 
NE (5-20µg/ml), CF BAL fluid (25% v/v) and NaCl (300-600mM) on 
killing activity were determined by the addition of these to the assays 
and the inclusion of appropriate controls.  
2.1.10 Static Biofilm studies  
The reference strain, PAO1 and P. aeruginosa clinical isolates with 
strong biofilm-forming ability based on the criteria of Stephanovic et al 
(2000) (165) were used. Overnight cultures of the isolates were diluted 
in 5ml of tryptic soy broth (TSB) (Oxoid, UK) supplemented with 0.5% 
w/v NaCl and incubated with shaking at 37oC to an optical density of 
0.8 at 600nm. The cultures were diluted 1:40 with fresh TSB/NaCl and 
150µl was added to each well of a 96 well microtitre plate (HDPs were 
present from seeding in some experiments). The plates were sealed 
with parafilm and incubated for 48h at 37oC. Treatment was with active 
HDPs in TSB for 24h or dH2O as a positive control. Biofilm staining 
was with crystal violet (CV). Briefly, after washing three times with 
dH2O, CV was applied to the biofilms for 15min and removed, biofilms 
were washed three times with dH2O and the remaining CV solubilised 
with 30% v/v acetic acid. The absorbance was measured at 595nm. In 
addition, metabolic activity in biofilms was investigated by incubating 
the biofilms with 440mM Resazurin sodium (Sigma, Ireland) in NaCl/Pi 
for 3h, and measuring fluorescence at 590nm after excitation at 
544nm. The activity of the peptides both in preventing biofilm 
formation and against pre-formed biofilms was tested. 
2.1.11 Flow Biofilm studies  
An overnight culture of P. aeruginosa PAO1 was diluted and grown to 
a concentration of 1 x 108 CFU/ml and seeded in the eight flow 
chambers of a Vena8 Fluoro+ biochip (Cellix, Ireland) and incubated 
at 37oC for 3h to allow the bacteria to adhere. The chambers were 
subjected to flow using a Kima pump (Cellix, Ireland) at a rate of 
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30µl/min using 25% v/v tryptic soy broth (TSB) for 48h. After 
incubation, the biofilms were treated statically with peptide in PBS for 
6h. Live/dead staining was then carried out by incubating with 
0.027mM SYTO®9 green and 0.16mM propidium iodide  (Molecular 
probes, USA) for 1h. Green and red fluorescence (live and dead) was 
detected on an inverted Zeiss LSM 510 META confocal microscope. 
At least three representative images were obtained per chamber per 
experiment. Image J 1 software was used to quantify fluorescence 
intensity. Each experiment was performed three times. 
2.1.12 Cell culture  
The human ∆F508 homozygous CFBE41o- bronchial and CFTE29o- 
tracheal epithelial cell lines were obtained as a gift from D. Gruenert 
(California Pacific Medical Centre Research Institute, San Francisco, 
CA) (166, 167). Cells were cultured in minimal essential medium 
(MEM) supplemented with 10% v/v foetal calf serum (FCS), 100U/ml 
penicillin, and 100µg/ml streptomycin, at 37oC in a humidified 
atmosphere with 5% CO2. Cells were used or detached with 
Trypsin/EDTA and re-seeded at lower cell densities when they 
reached 90% confluency in flasks pre-coated with fibronectin. 
2.1.13 Neutrophil isolation  
4ml of a 10% w/v solution of Mr 500000 Dextran (Sigma, Ireland) in 
purified water was added to 40ml of freshly-collected blood, gently 
mixed, and allowed to rest until settled. To 15ml of the resulting 
supernatant, 5ml of LymphoprepTM (Axis-shield, UK) was underlayed, 
and it was centrifuged at 800xg for 10min. Remaining erythrocytes 
were lysed from the resulting pellet by exposure to 25ml of purified 
water for 10s, with the isolated neutrophils recovered by the immediate 
addition of an equal volume of 1.8% w/v NaCl. After further 
centrifugation at 500xg, the remaining pelleted neutrophils were 
resuspended in 1ml PBS/0.09% w/v glucose. Neutrophils were then 
counted using Trypan Blue staining (VWR, Ireland) and a 
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haemocytometer under a microscope, and were routinely recovered at 
a purity of at least 95%. 
2.1.14 Cytotoxicity assays  
CFBE41o- and CFTE29o- cells were seeded on 96 well plates at a 
density of 3 x 105 cells/ml, and neutrophils were seeded at a density of 
5 x 106 cells/ml. The epithelial cells were incubated for 24h at 37oC. 
The cells were then treated in triplicate with a concentration range of 
0.2 – 300/600µM of the peptides and their prodrugs in serum-free 
media (units chosen for consistency with literature and for accurate 
comparison of pro- and active HDPs). MEM media was used for the 
epithelial cells and Roswell Park Memorial Institute (RPMI) 1640 was 
used for neutrophils. Incubation was for 24h for epithelial cells and 3h 
for neutrophils. After incubation, media was removed and the cells 
were incubated with 500µg/ml of thiazolyl blue tetrazolium bromide 
(MTT) (Sigma, Ireland) in serum-free media. Incubation time was 4h 
for epithelial cells and 2h for neutrophils. The MTT solution was 
removed and 100µl of dimethylsulphoxide (DMSO) was added to each 
well, mixed by shaking, and the absorbance at 560nm was recorded. 
The IC50 values, defined as the peptide concentration that resulted in 
50% cell death, were calculated using Graphpad Prism software from 
the resulting sigmoidal dose-response curve. 
2.1.15 Cytokine release assays 
CFBE41o- cells were seeded on 24 well plates at a density of 3 x 105 
cells/ml and incubated for 24h at 37oC. The cells were treated in 
triplicate with sub-IC50 concentrations of the peptides and their 
prodrugs in MEM media containing 1% FCS. The plates were 
centrifuged at 700xg for 5min and the cell supernatant was removed. 
The cytokine concentration of each supernatant was measured using 
a Human Pro-inflammatory Panel V-PLEX Plus Kit (MSD, Ireland) 
analysing levels of IL-1β, IL-6, IL-8, and TNF-α. Briefly, BAL samples 
were diluted and incubated on the plate for 2h at RT. Wells were 
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washed three times with PBS/0.05% TWEEN-20 and then incubated 
for 2h at RT with the secondary antibodies. Plates were washed again 
and then read by chemiluminescence on a MESO QuickPlex SQ 120 
(MSD, Ireland). LPS stimulation for 24h at a concentration of 50µg/ml 
was used as a positive control. 
2.1.16 Haemolysis assays  
Freshly-collected human blood was centrifuged at 100xg for 5min. The 
supernatant was removed and the erythrocyte-rich pellet resuspended 
in sterile PBS and centrifuged again. The blood was washed twice in 
this manner and resuspended to twice its original volume in PBS. In a 
96 well plate, 50µl of the erythrocyte suspension was mixed with 50µl 
of a peptide solution in PBS, to give a final assay concentration range 
of 0.195-500µM. The assay was performed in triplicate.  Positive 
controls containing 0.1% Triton-X and negative controls containing no 
peptide were also included. After 24h incubation at 37oC, the % 
haemolysis relative to control was calculated based on the absorbance 
at 450nm. 
2.1.17 Statistical analyses 
Statistical analyses of the data were carried out using Graphpad Prism 
software and the two-tailed unpaired t-test. P values are given 
throughout the results and in figures with * denoting P<0.05, ** 
P<0.01, and *** P<0.001. In most cases analyses were carried out in 
relation to controls. Where the relationship between other data groups 
are investigated, the significance of this relationship is provided 
graphically in the figures. This statistical analysis was used in all 
experiments where p values are given. 
 
 
 75 
 
2.2 Inhalation studies 
2.2.1 Light-scattering particle size analysis  
Laser diffractometry was carried out on a 1mg/ml aqueous peptide 
solution using a Spraytech Laser Light Scattering System (Malvern, 
UK). Briefly, 250µl of the 1mg/ml solution was nebulised into the 
apparatus using an Aeroneb® Solo vibrating mesh nebuliser 
(Aerogen, Ireland). An extraction flow of 15l/min was applied to 
prevent aerosol re-entry into the measurement zone. Particle sizing of 
the aerosol spray was carried out measuring the intensity of the light 
scattered from the laser beam as it passes through the spray. This 
allowed the calculation of the volume median diameter (VMD), where 
half the volume of the spray contains particles of larger and smaller 
diameter, and was carried out four separate times. 
2.2.2 Impaction particle size analysis  
A next generation impactor was also used to assess the droplet 
diameter of the nebulised spray. The nebuliser (Aeroneb® Solo) was 
attached to the apparatus via a plastic connector and metal inlet 
(throat). The intake was 15l/min and 1ml of the 1mg/ml solution in 
dH2O was nebulised. After nebulisation was complete, the apparatus 
was dismantled and the eight plates, connector, throat, nebuliser, and 
end filter (Respigard 303, Baxter, Ireland) were all thoroughly rinsed 
with dH2O to collect the impacted peptide. The washings of each stage 
were analysed by HPLC and compared to a standard line of peptide 
concentration versus peak area. The % deposition in each stage was 
used to calculate the mass median aerodynamic diameter (MMAD) of 
the spray and the mass balance of each stage. This was carried out 
three times for each peptide. Samples of low concentration were 
lyophilised and reconstituted in 1/10th the original volume to increase 
the HPLC signal and improve accuracy. 
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2.2.3 Breathing apparatus  
The Aeroneb® Solo was used to nebulise 1ml of a 1mg/ml solution in 
dH2O into a breathing apparatus. The conditions of a healthy human 
breathing pattern was simulated using a Salter valved facemask 
81070-0 (Salter, USA) and an ASL 5000 active servo lung (IngMar 
Medical, USA). The parameters were 15 breathes/min, 
inhalation:expiration ratio of 1:1, tidal volume of 500ml, and 2l of 
supplementary gas flow. The nebulised peptides were collected below 
the model on a Respigard 303 filter (Baxter, Ireland) which was 
washed afterwards with 10ml dH2O. The nebuliser was also washed. 
The washings were analysed by HPLC and the % of the original dose 
delivered to the filter was calculated, giving the % deliverable to the 
lung. This was carried out three times for each peptide. 
 
2.3 In vivo studies 
2.3.1 Transgenic mice 
All in vivo studies were granted ethical approval by the 
Regierungspräsidium (Regional Council) of Karlsruhe, Baden-
Württemberg, Germany (reference G-284/14) and were carried out in 
collaboration with the laboratory of Prof Dr. Marcus Mall, University of 
Heidelberg, Germany. The animal handling licence was obtained from 
Laboratory Animal Science and Training, Ireland. The mouse strains 
used were Scnn1b-Tg (β-ENaC), and Scnn1b-Tg NE-/- (β-ENaC NE-
knockout) on a C57BL/6 background. All mice used in infection studies 
were 8-10 weeks old. For toxicity studies wildtype and NE-/- C57BL/6 
mice aged 11-15 weeks were used. 
2.3.2 Bacterial challenge 
Mice were sedated using 3% v/v isoflurane in O2 at a flow rate of 
2l/min and then suspended vertically by their incisors on a wire 
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attached to an upright examination board. 50µl of a P. aeruginosa 
PAO1 inoculum (1 - 2.5 x 107 CFU/mouse) was pipetted into their 
throat and their nose was covered until the mice fully inhaled the 
bacterial suspension. After 6h the mice were then treated in a similar 
manner with either 50µl of PBS or a 1mg/ml peptide solution. Mice 
were sacrificed 24h after initial infection. 
2.3.3 Lung lavage 
Mice were euthanized by intraperitoneal injection of 120mg/kg 
ketamine and 16mg/kg xylazine and exsanguination. The midline 
anterior was incised and the trachea isolated, cannulated with a 22G 
needle, and tied. 0.035ml cold PBS/g (bodyweight) was used to lavage 
the lungs. Bacterial counts were carried out on each BAL fluid using 
the plate count method, after which the BAL fluids were centrifuged at 
600xg for 5min and the supernatant removed. Murine NE was 
quantified in each BAL supernatant using MeOSuc-AAPV-AMC, 
measuring the change in fluorescence at 460nm after excitation at 
380nm. Recombinant murine NE was used as a standard (R & D 
systems, Germany), this was pre-activated by incubating for 4h at 
37oC with murine cathepsin C (R & D systems, Germany). This step is 
required to cleave the activation dipeptide from the amino terminal of 
the proenzyme (168). Please note that this is a different protocol to 
that used above for the determination of human NE levels in CF BAL 
fluid. 
2.3.4 Toxicity studies 
Wildtype mice were sedated and suspended by their incisors as with 
the infection studies. The mice were treated intratracheally with 50µg 
of peptide in the morning and evening and sacrificed 24h after the first 
dose. Any mice that were found to have died were not processed 
further. In living mice, lung lavage was carried out on half lungs while 
the other half was stored in 4% formaldehyde solution overnight, 
 78 
 
washed three times in dH2O, and stored in 70% ethanol at -20oC for 
histological processing and analysis.  
2.3.5 BAL cell count, total and differential 
BAL fluids were centrifuged at 600xg at 4oC for 5min. The cell pellet 
was resuspended in 50µl of cold PBS. The BAL fluid cell count was 
carried out microscopically using Trypan blue staining and a 
haemocytometer. The cell suspension was then then spread onto a 
slide by centrifugation using a Cytospin (3 x 104 cells per slide). After 
air-drying overnight the slides were stained using May-Grünwald-
Giemsa staining to count the relative proportion of each cell type. 
Briefly, slides were placed in May-Grünwald solution for 3min, rinsed 
in dH2O, placed in Giemsa solution for 7min and rinsed in dH2O. After 
drying the slides were placed in xylene for 5s and then mounting 
media and a coverslip were added. The proportion of each cell type 
was quantified using oil-immersion microscopy at 100x magnification. 
2.3.6 BAL cytokine release assay  
BAL supernatants were analysed for cytokine levels using a V-PLEX 
Plus Proinflammatory Panel 1 (mouse) Kit (MSD, Ireland), analysing 
levels of interferon γ (IFN-γ), IL-10, IL-12p70, IL-1β, IL-2, IL-4, IL-5, IL-
6, keratinocyte chemoattractant (KC), and TNF-α. Briefly, BAL 
samples were diluted and incubated on the plate for 2h at RT. Wells 
were washed three times with PBS/0.05% TWEEN-20 and then 
incubated for 2h at RT with the secondary antibodies. Plates were 
washed again and then read by chemiluminescence on a MESO 
QuickPlex SQ 120 (MSD, Ireland). Analysis was carried out on BAL 
fluids from mice in the toxicity study and from mice infected with 2.5 x 
107 PAO1 and then treated with PBS/AAG-WMR/AAG-P18.  
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3. Results Chapter One: Developing Host Defence 
Peptide Prodrugs for Cystic Fibrosis 
 
3.1 Introduction 
3.1.1 Rationale  
The treatment of the most important pathogen in CF, P. aeruginosa, 
with a pro-HDP targeted at the most common enzyme, NE, forms the 
basis of the prodrug model. The large quantities of the enzyme found 
in the CF lung would predict that the active sequence must be 
synthesised from D-amino acids to ensure that it is not degraded. 
Maintaining an L-amino acid linker will ensure that it is cleaved upon 
application of the pro-HDP to the endobronchial space with the release 
of the active peptide. Based on our own review of the literature, 
oligoglutamic acid is the most promising pro-moiety (135). 
3.1.2 Peptide synthesis 
Synthesis of the peptides in this project was carried by standard Solid 
Phase Peptide Synthesis (SPPS), using the Fmoc/t-Bu protection 
scheme. It involves incrementally synthesising the peptide from the C- 
to the N-terminus, in a manner that minimises racemisation and is 
easily automated, allowing large peptides to be synthesised quite 
rapidly. All amino acids used in the synthesis are temporarily protected 
with Fmoc, a base-sensitive Nα-amino protecting group. The C-
terminal carboxylic acid is left free, while any side-chain functional 
groups of the amino acid are also semi-permanently protected, but 
with an acid-sensitive group instead of Fmoc. An example of the 
protection scheme is given in Figure 3.1, with Fmoc-D-Arg(Pbf)-OH. 
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Figure 3.1: Fmoc-D-Arg(Pbf)-OH. The amine is protected by the base-
labile Fmoc, while the side-chain is protected by the acid-labile Pbf 
group. The C-terminal carboxylic acid is left free. 
The process of coupling multiple amino acids together to form a 
peptide begins with the attachment of the first amino acid onto an 
insoluble resin, a technique pioneered by Bruce Merrifield (169). The 
resin, which is retained by a filter in the reaction chamber, allows the 
application of multiple phases of excess reagents relative to the 
immobilised peptide. The excesses of reagents at each stage of the 
synthesis allow a very high level of conversion to be maintained. This 
is crucial when one considers that even a level of 99% coupling 
efficiency will lead to an overall synthetic yield of 82% for a 20 amino 
acid peptide. The coupling agent used, HATU, is one of the most 
efficient available and allows fast coupling with little loss of chiral 
integrity. This is important for the pro-HDPs for the maintenance of 
distinct D- and L-amino acid motifs. The reaction mechanism is 
illustrated in Figure 3.2 where the first amino acid has already been 
coupled to the resin and a second is being added. First, HATU reacts 
with the -COOH group of the second Fmoc-protected amino acid 
(AA2) (which is deprotonated by the base DIEA) [1]. This releases a 
side product, -OAt, which reacts with the concomitantly-formed 
isouronium ester to form another active ester [2], eliminating a 
substituted urea at the same time [3]. Both intermediate esters can 
next form an amide bond with resin-bound amino acid 1 (AA1) whose 
amine is not protected [4]. The coupling efficiency of HATU is superior 
as at this point compared to other agents as -OAt forms an N-H 
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hydrogen bond with the reacting amide [5] in a phenomenon known as 
the “neighbouring effect” (170). As the amide bond is formed, -OAt is 
eliminated, leaving a dipeptide coupled to the resin, but with the amino 
group protected by Fmoc [6]. 
Figure 3.2: Reaction scheme for the addition of amino acid 2 (AA2) to 
resin-bound amino acid 1 (AA1), using HATU/DIEA coupling 
chemistry. 
As stated above, Fmoc is base-sensitive (171), and can be removed 
with the application of 20% v/v piperidine. This allows intermittent 
steps of deprotection and coupling to be carried out (Figure 3.3A). To 
cleave the finished peptide, of n amino acids in length, and remove 
side-chain protecting groups, acidic conditions are used (Figure 3.3B). 
The conditions required to remove both sets of protecting groups 
(temporary Fmoc of the Nα-amino and semi-permanent t-butyl-derived 
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of the side-chain functions) are mutually exclusive (described as 
orthogonal), which ensures that side-chain branches cannot form and 
that only the amine of the N-terminal amino acid is free to react.  
 
Figure 3.3: Summary of SPPS. The peptide synthesis cycle involves 
incremental steps of coupling with HATU/DIEA onto an insoluble resin 
support followed by deprotection with piperidine. R = amino acid side-
chain, PG = protecting group, and n = number of amino acids (A). The 
complete resin-bound peptide is cleaved from the resin in acidic 
conditions which also remove side-chain protecting groups (B). 
Electrophilic and reactive entities are released from the protecting 
groups during the acidolytic deprotection. To prevent them from 
recombining with the nucleophilic liberated side-chain functional 
groups, the addition of nucleophilic scavenging agents to the cleavage 
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mixture is required. Different protecting groups are required for each 
amino acid, and in the same way, different scavenging agents are 
required for each protecting group (Figure 3.4). 
 
Figure 3.4: Side-chain protecting groups for each amino acid (A) with 
their corresponding scavenging agents (B). In addition Pbf is the 
protecting group for arginine. 1, 2 ethane-dithiol is required for 
cleavage reactions containing tryptophan (to protect its indole ring), 
and methionine and cysteine (to protect their sulphur-containing side-
chains). 
Synthesis of the entire D-amino acid active sequence is generally 
possible using automated peptide synthesis. However, further 
elongation with L-amino acid linker group and oligoglutamic acid pro-
moiety requires careful monitoring of coupling and deprotection by 
manual synthesis due to the potential aggregation of relatively long 
and hydrophobic (protected) peptide chains with the polymer matrix of 
the synthetic resin. Monitoring in this case is carried out by the Kaiser 
test, which measures the presence of a free Nα-amino group. A 
positive result indicates deprotection, while a negative indicates 
coupling. With this monitoring it is possible to determine if repeated 
 84 
 
coupling steps are required to complete the addition of an amino acid 
i.e. a double- or triple-coupling step. As the oligoglutamic acid 
sequence is elongated, multiple coupling steps are often required for 
each additional residue, as aggregation of the peptide chain can be 
promoted by the tri-alanine motif. 
3.1.3 Choice of linker  
The linker motif, first used with HDPs in (142) was slightly modified to 
AAAG. Glycine was added between the heterochiral sequences (L-
amino acid pro-moiety and D-amino acid active HDP) as it is achiral 
and can therefore act as a short spacer; the goal being a cleavage 
product with comparable bactericidal activity. The choice of linker was 
determined by the balance between enzyme-specificity and the 
difficulty in synthesis. The sequence AAPV is commonly used as a 
specific substrate in NE assays and would seem the logical choice, 
however, valine favours the aggregation of peptide chains and proline 
is the least reactive of the amino acid residues (as amino partner in 
the coupling reaction). Both amino acids would therefore compound 
the difficulties in the addition of the subsequent glutamic acids. In 
addition, PR-3 cleaves this substrate, albeit at a much reduced rate 
compared to NE, removing a degree of specificity. Conversely, NE 
cleaves AAA, while PR-3 does not (50). Considering that PR-3 
constitutes approximately 7% of CF lung protease activity (32), this 
would mean that although other enzymes may cleave AAA, they would 
likely be at very low concentrations relative to NE. This linker also 
does not contain a proline or large hydrophobic groups which should 
render it unfavourable for MMP-cleavage (68). One enzyme of interest 
is PE, which has been shown to cleave AAAA sequences (63), and 
this was also investigated in this chapter. The lability of AAA to CG 
has not been determined and is investigated in Results Chapter Two. 
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3.1.4 Choice of active peptides  
Three peptides were chosen to generate the first prodrug candidates. 
This allows the choice of a range of different net charges and peptide 
lengths in order to determine the optimum peptide for the CF model. 
Bac8c, HB43, and P18 were modified to contain the linker motif and 
the anionic oligoglutamic acid pro-moiety.  
The three peptides were initially selected based on the requirement for 
relatively short HDPs, that can be readily synthesised, and that are 
active against P. aeruginosa. Bac8c is an eight amino acid peptide 
derived from Bactenecin, a product of bovine neutrophils (172). It has 
relatively high bactericidal activity against Gram-positive and Gram-
negative bacteria (173). Its mechanism of action is complex, targeting 
multiple membrane-associated and intra-cellular processes. Studies 
into moderate resistance of bacteria against Bac8c, have 
demonstrated that energy metabolism and membrane disruption may 
play crucial roles in its mechanism of action (174). Preliminary studies 
indicated that its activity is salt-sensitive (Figure 3.5) but, despite this, 
its short length and reported MIC against P. aeruginosa of 8µg/ml 
makes it an attractive candidate for modification (172). HB43 is a 
thirteen residue HDP. It was previously shown to maintain high activity 
against P. aeruginosa in conditions representative of the CF lung, e.g. 
high levels of mucins, eDNA and NaCl. Its relatively short length and 
MIC of 8µg/ml against PAO1 are desirable (121). As stated in the 
introduction, P18 is an eighteen residue, hybrid sequence derived from 
Cecropin A and Magainin 2 (175). It has demonstrated high activity 
against Gram-negative bacteria in the presence of high NaCl 
concentrations e.g. an MIC of 2µg/ml against P. aeruginosa in 200mM 
NaCl (176). These characteristics are highly desirable, despite the 
relatively long sequence of P18. 
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Figure 3.5: The effect of NaCl on the bactericidal activity of Bac8c and 
HB43 (12.5µg/ml) against P. aeruginosa PAO1. The ability of P18 to 
maintain activity in high salt concentrations (up to 200mM) has already 
been established in the literature (176). Values shown are the means 
± SEM for three independent assays carried out in duplicate. 
Statistical analyses were carried out using an unpaired two-tailed t-test 
* denotes p<0.05, ** p<0.01, and *** p<0.001 compared to the peptide 
in 0mM NaCl. 
3.1.5 Considerations for CF  
The pro-HDPs are being developed for local delivery to the CF lung, 
similarly to that described for tobramycin therapy (134). This will 
potentially limit cleavage of the pro-HDPs to the region of the 
bronchioles, where mucus and NE are localised (10). To simulate the 
physiological conditions of the ASL, with which the pro-HDPs will 
interact, CF BAL fluid was added to bactericidal assays. Incubation of 
the pro-HDPs with BAL fluid provides endogenous NE for pro-HDP 
cleavage. As components of BAL fluid have previously been shown to 
inhibit the activity of some HDPs (77, 119, 121, 177-179), it also acts 
as a robust test of the feasibility of local lung delivery. Failure of the 
pro-HDPs to be activated in BAL fluid would mean that their inhaled 
delivery to the lung would likely fail to treat infection. 
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The purpose of this chapter was to demonstrate that the reversible 
reduction of a peptide’s net charge may be used to reduce the 
epithelial cell cytotoxicity. It is also the goal to determine whether the 
inhibition of HDP activity in CF can be circumvented by the rational 
design of HDP prodrugs and whether an environment similar to that 
found in the CF lung may be effectively exploited in the targeted 
application of pro-HDPs. This chapter illustrates the potential of pro-
HDPs as a delivery strategy to the CF lung on the basis of reduced 
cytotoxicity and increased specificity. 
 
3.2 Results 
3.2.1 Pro-HDPs are cleaved by purified NE 
Cleavage of pro-HDPs by 5µg/ml NE was shown after 1h incubation. 
Cleavage mainly occurred between the 1st and 2nd alanine of the linker 
group and to a lesser extent, between the 2nd and 3rd alanine 
(numbered from the N-terminus). This cleavage pattern (i.e. 
generation of AAG-HDP and AG-HDP) was found for pro-Bac8c and 
pro-P18. Pro-HB43 yielded predominantly AG-HB43. These cleavage 
products were synthesised as controls and are called thereafter 
fragment peptides to differentiate them from the parent sequences. 
The former peptides differ therefore from the latter ones by the 
presence of 2 to 3 residual amino acids from the linker. The HPLC 
chromatograms for the pure cleaved peptides were consistent with the 
products produced by the original cleavage experiments (see 
appendices for further information). The AAAG linker was not labile to 
PE, as indicated by the detection of only pro-HDPs after incubation 
with this enzyme for 24h. Incubation of Bac8c, HB43, and P18 with 
100µg/ml NE for 24h resulted in no cleavage (data not shown). 
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3.2.2 Pro-HDPs have greater MIC values than parent and fragment 
HDPs 
The MIC values for both parent and fragment HDPs were comparable 
(Table 3.1). The additional glycine and alanine residues increased the 
MIC from 4 to 8µg/ml for the HB43 series and there was no increase 
for the Bac8c or P18 series. In all cases, the pro-HDPs had MIC 
values greater than or equal to the highest concentration tested 
(64µg/ml). The MICs for both pro- and active HDPs towards PAO1 
were comparable to those found for the four clinical isolates tested 
(Table 3.1). 
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Table 3.1: MIC values for parent HDPs, fragment HDPs, and pro-HDPs vs. P. aeruginosa PAO1 and clinical isolates 
Peptide 
 
Sequence* 
MIC vs. P. aeruginosa strains (µg/ml) 
PAO1 PABH01 PABH02 PABH03 PABH04 
Bac8c rlwvlwrr-NH2 4 NT NT NT NT 
AAG-Bac8c AAGrlwvlwrr-NH2 4 8 8 16 8 
Pro-Bac8c Ac-EEEEAAAGrlwvlwrr-NH2 >64 >64 >64 >64 >64 
P18 kwklfkklpkfhlhlakkf-NH2 2 NT NT NT NT 
AAG-P18 AAGkwklfkklpkfhlhlakkf-NH2 2 2 4 4 2 
Pro-P18 Ac-EEEEAAAGkwklfkklpkfhlhlakkf-NH2 >64 64 64 >64 64 
HB43 fakllaklakkll-NH2 4 4 8 8 4 
AG-HB43 AGfakllaklakkll-NH2 8 4 8 4 4 
Pro-HB43 Ac-EEEEAAAGfakllaklakkll-NH2 >64 >64 >64 >64 >64 
* Upper case = L-amino acids, lower case = D-amino acids. NT = Not Tested 
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3.2.3 Pro-HDPs are bactericidal towards PAO1 in the presence of NE  
The bactericidal activity of parent and cleaved active HDPs were comparable 
(Figure 3.6) over the concentration range tested. As 100% killing of PAO1 
was achieved at 6.25µg/ml for parent and fragment HDPs, this concentration 
was selected for bactericidal testing of pro-HDPs in the presence of NE. 
Bactericidal activity was negligible for pro-Bac8c and pro-HB43 in the 
absence of NE, whereas pro-P18 was bactericidal (66.8 ± 11.7% killing 
activity) under these conditions (Figure 3.7). Bactericidal activity increased in 
the presence of NE for all pro-HDPs. The bactericidal activity, with 5µg/ml 
NE, increased to 73.3 ± 0.2% for pro-Bac8c, and 90.1 ± 5.8% for pro-HB43 
(p<0.0001 for both). The activity also increased for pro-P18, to 93.5 ± 4.7%, 
but this was not statistically significant (p = 0.102). The level of bactericidal 
activity appeared to be independent of the NE-concentration tested. No 
bactericidal effect was observed for NE alone in phosphate buffer pH 7.4, at 
any of the concentrations investigated (data not shown). 
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Figure 3.6: Bactericidal activity of parent and fragment HDPs against P. 
aeruginosa PAO1. Data shown are the mean ± SEM for three independent 
assays carried out in duplicate. 
   
92 
 
0 5 10 20
0
20
40
60
80
100
120
Pro-Bac8c Pro-HB43 Pro-P18
**
**
***
***
***
***
NE concentration (µg/ml)
P.
 
ae
ru
gi
n
o
sa
 
ki
lli
n
g 
ac
tiv
ity
 
(%
)
 
Figure 3.7: Effect of 5-20µg/ml purified NE on the bactericidal activity of pro-
HDPs against P. aeruginosa PAO1. NE was added to assays containing 
6.25µg/ml pro-HDPs. Killing activities shown are the mean ± SEM from three 
independent assays carried out in duplicate. Where no killing activity was 
observed, no bar is shown. Statistical analyses were carried out using an 
unpaired two-tailed t-test, ** denotes p<0.01, and *** p<0.001 compared to 
the control of pro-HDP with 0µg/ml NE. 
3.2.4 In the presence of NaCl, pro-HDPs are activated by CF BAL fluids  
Six CF BAL fluids were used to investigate pro-HDP activation. The NE 
concentration in CF BAL fluids varied (range 0 - 193.3µg/ml, Table 3.2).  
With the exception of CF005, which had significant bactericidal activity (at 
25% v/v final assay concentration) against PAO1 (74.5%), the killing activity 
of the CF BAL fluids against PAO1 was <20%. 
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Table 3.2: Comparison of the neutrophil elastase concentration and bactericidal activity of different  
CF BAL fluid samples. Patient details are included 
CF 
BAL 
Age Gender Genotype NE Concentration 
(µg/ml) 
% killing* 
CF001 28 M ∆F508/E60X 35.7 0 
CF002 22 F ∆F508/∆F508 0 0 
CF003 25 F ∆F508/G542X 136 7.8 ± 6.8 
CF004 26 M ∆F508/∆F508 46.4 10.4 ± 10.6 
CF005 24 M ∆F508/Unknown 193.3 74.5 ± 4.6 
CF006 29 M ∆F508/∆F508 62.8 15.6 ± 3.3 
* Mean ± SEM for 3 separate determinations where 25% v/v BAL fluid was added to 
assays.  
 
The bactericidal activities of the pro-HDPs were not initially restored by any 
of the CF BAL fluids investigated. Pro-P18 retained bactericidal activity in the 
absence of CF BAL fluid. However, after accounting for activity due to BAL 
alone, the bactericidal activity of pro-P18 was reduced by the addition of CF 
BAL fluid (Figure 3.8C). 
 
   
94 
 
Co
ntr
ol
no
 
BA
L
CF
00
1
CF
00
2
CF
00
3
CF
00
4
CF
00
5
CF
00
6
0
20
40
60
80
100
120
 Pro-Bac8c
A
CF BAL Fluid
P.
 
ae
ru
gi
n
o
sa
 
ki
lli
n
g 
ac
tiv
ity
 
(%
)
 
Co
ntr
ol
no
 
BA
L
CF
00
1
CF
00
2
CF
00
3
CF
00
4
CF
00
5
CF
00
6
0
20
40
60
80
100
120
 Pro-HB43
B
CF BAL Fluid
P.
 
ae
ru
gi
no
sa
 
ki
lli
n
g 
ac
tiv
ity
 
(%
)
 
Co
ntr
ol
no
 
BA
L
CF
00
1
CF
00
2
CF
00
3
CF
00
4
CF
00
5
CF
00
6
0
20
40
60
80
100
120
 Pro-P18
C
CF BAL Fluid
P.
 
ae
ru
gi
n
o
sa
 
ki
lli
n
g 
ac
tiv
ity
 
(%
)
 
Figure 3.8: Effect of 25% v/v BAL fluid on the bactericidal activity of pro-
Bac8c (A), pro-HB43 (B), and pro-P18 (C) against P. aeruginosa PAO1. BAL 
fluid (CF001-006) was added to assays containing 6.25µg/ml pro-HDPs. 
Killing activities shown are the means ± SEM for three independent assays 
where activity due to CF BAL fluid alone was subtracted. Where no killing 
activity was observed, no bar is shown. Controls represent the corresponding 
cleaved HDP e.g. AAG-Bac8c at 6.25µg/ml for pro-Bac8c.  
A change in assay conditions, i.e. the addition of 300mM NaCl (which 
reduces non-specific electrostatic interaction of cationic entities such as 
HDPs with anionic components of CF BAL fluid) and an increase of pro-HDP 
concentration to 25µg/ml in the bactericidal assays, resulted in the 
restoration of bactericidal activity of pro-HB43 and pro-P18 but not pro-
Bac8c. This effect was shown for three selected CF BAL fluids with NE 
concentrations in the range of 46.4 - 136µg/ml (BAL fluids with significant 
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antimicrobial activity were excluded) (Figure 3.9). NaCl alone did not 
increase the bactericidal activity of CF BAL fluid (Figure 3.10). 
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Figure 3.9: Effect of 300mM NaCl and 25% v/v CF BAL fluids on the 
bactericidal activity of pro-HDPs (25µg/ml) against P. aeruginosa PAO1. 
Values shown are the means ± SEM for three independent assays where 
activity due to CF BAL fluid alone was subtracted. Where no killing activity 
was observed, no bar is shown. Statistical analyses were carried out using 
an unpaired two-tailed t-test, * denotes p<0.05, and ** p<0.01, compared to 
the control of pro-HDP with 300mM NaCl alone. 
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Figure 3.10: Effect of 300mM NaCl on the bactericidal activity of CF BAL 
fluid (25% v/v) against P. aeruginosa PAO1. Values shown are the means ± 
SEM for three independent assays. 
Further increasing the NaCl concentration (450mM and 600mM) did not 
increase the bactericidal activity of pro-HB43 (BAL fluid CF004, Figure 3.11). 
The killing activity of pro-HB43 was significantly increased with 300mM NaCl 
and CF004 BAL against the CF clinical isolates (Figure 3.12). In the case of 
the isolate PABH02, the activity increased from 0% (pro-HB43 with NaCl) to 
99.2 ± 0.7% (pro-HB43 with NaCl and CF BAL, p<0.0001). 
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Figure 3.11: Effect of 300-600mM NaCl and 25% v/v CF004 BAL fluid on the 
bactericidal activity of pro-HB43 (25µg/ml) against P. aeruginosa PAO1. 
Values shown are the means ± SEM for three independent assays where 
activity due to CF BAL fluid alone has been subtracted. Statistical analyses 
were carried out using an unpaired two-tailed t-test, * denotes p<0.05, and ** 
p<0.01, compared to the control of pro-HDP with 300mM NaCl alone. 
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Figure 3.12: Effect of 300mM NaCl and 25% v/v CF004 BAL fluid on the 
bactericidal activity of pro-HB43 (25µg/ml) against P. aeruginosa clinical 
isolates from CF patients. Values shown are the means ± SEM for three 
independent assays where activity due to CF BAL fluid alone has been 
subtracted. Where no killing activity was observed, no bar is shown. 
Statistical analyses were carried out using an unpaired two-tailed t-test, * 
denotes p<0.05, ** p<0.01, and *** p<0.01 compared to the control of pro-
HDP with 300mM NaCl alone. 
3.2.5 The pro-HDPs potentially inhibit biofilm formation 
The activity of the fragment HDPs against established 48h biofilms was 
investigated using three P. aeruginosa strains; PAO1 and the clinical isolates 
PABH02 and PABH03. The peptides were unable to disrupt the biofilms to a 
significant extent at concentrations ranging from 2-128µg/ml when analysed 
for biofilm metabolism, using rezasurin sodium, and mass (Figures 3.13 and 
3.14). At 256µg/ml both AG-HB43 and AAG-P18 had some activity against 
the biofilms of PABH03 and PAO1 (Figure 3.13). However this effect was 
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modest and only statistically significant in the case of PABH03 with AAG-P18 
(from 97.7 ± 4.7% for 2µg/ml to 57.5 ± 10% for 256µg/ml, p = 0.022). This did 
not correlate with a reduction in biofilm mass (Figure 3.14). AAG-Bac8c did 
not reduce biofilm metabolism or mass at 256µg/ml, the highest 
concentration investigated. 
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Figure 3.13: Antibiofilm activity (metabolism) of 2-256µg/ml fragment 
peptides against 48h established biofilms of three P. aeruginosa 
isolates/strains; PABH02, PABH03, PAO1. Biofilm metabolism, as 
represented by rezasurin sodium conversion, was expressed as % of the ‘no 
peptide’ control. Values shown are the means ± SEM for three independent 
assays. A positive control of dH2O was included. Statistical analyses were 
carried out using an unpaired two-tailed t-test, * denotes p<0.05, compared 
to 2µg/ml peptide. 
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Figure 3.14: Antibiofilm activity (mass) of 2-256µg/ml fragment peptides 
against 48h established biofilms of three P. aeruginosa isolates/strains; 
PABH02, PABH03, PAO1. Biofilm mass, as represented by crystal violet 
staining, was expressed as % of the ‘no peptide’ control. Values shown are 
the means ± SEM for three independent assays. A positive control of dH2O 
was included. 
The fragment peptides showed more activity in the prevention of biofilm 
formation (Figures 3.15 and 3.16). Metabolic studies demonstrated that AG-
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HB43 had the highest activity, e.g. 47.4 ± 15.8% and 59.9 ± 12.8%, against 
PABH03 and PAO1 respectively at 16µg/ml. This was also demonstrated 
with biofilm mass. 64µg/ml of AG-HB43 and AAG-P18 compared to 2µg/ml 
reduced the mass of PAO1 biofilms to 26.9 ± 9.9% compared to 84.7 ± 3.3% 
(p = 0.005) and 23.4 ± 14.5% compared to 96.1 ± 2.4% (p = 0.008) 
respectively (Figure 3.16). 
While effective against PABH02 and PABH03 at 64µg/ml, AAG-Bac8c 
demonstrated the lowest antibiofilm activity of the three peptides. At 32µg/ml 
against PAO1, biofilm metabolic activity was 103.2 ±13.9% (Figure 3.15). 
Similarly, the biofilm mass of PAO1 in the presence of 64µg/ml AAG-Bac8c 
was 68 ± 27.3%. 
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Figure 3.15: Biofilm inhibition (metabolism) of 2-64µg/ml fragment peptides 
against biofilms of three P. aeruginosa isolates/strains; PABH02, PABH03, 
PAO1 grown in the presence of the peptides. Biofilm metabolism, as 
represented by rezasurin sodium conversion, was expressed as % of the ‘no 
peptide’ control. Values shown are the means ± SEM for three independent 
assays. Statistical analyses were carried out using an unpaired two-tailed t-
test, * denotes p<0.05, ** p<0.01, and *** p<0.001 compared to 2µg/ml 
peptide. 
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Figure 3.16: Biofilm inhibition (mass) of 2-64µg/ml fragment peptides against 
biofilms of three P. aeruginosa isolates/strains; PABH02, PABH03, PAO1 
grown in the presence of the peptides. Biofilm mass, as represented by 
crystal violet staining, was expressed as % of the ‘no peptide’ control. Values 
shown are the means ± SEM for three independent assays. Statistical 
analyses were carried out using an unpaired two-tailed t-test, * denotes 
p<0.05, ** p<0.01, and *** p<0.001 compared to 2µg/ml peptide. 
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3.2.6 Pro-HDPs displayed lower cytotoxicity against CFBE41o- cells 
than fragment HDPs  
The 24h IC50 values were higher for the pro-HDPs compared to the fragment 
HDPs (Table 3.3). The addition of the pro-moiety increased the IC50 from 
38.3µM to >300µM for pro-Bac8c, from 3.6µM to 50.8µM for pro-HB43, and 
from 35.5µM to 77.3µM for pro-P18. Cytotoxicity was reduced in AAG-P18 
compared to P18 with IC50 values of 35.5µM and 8.1µM respectively. IC50 
values were similar for AG-HB43 and HB43, being 3.6µM and 2.8µM 
respectively.  
Table 3.3: Comparison of the IC50 values of pro- and fragment HDP against CFBE41o- cells 
Peptide Sequence IC50 (µM)* 
Pro-Bac8c Ac-EEEEAAAGrlwvlwrr-NH2 >300 
AAG-Bac8c AAGrlwvlwrr-NH2 38.3 
Pro-HB43 Ac-EEEEAAAGfakllaklakkll-NH2 50.8 
AG-HB43 AGfakllaklakkll-NH2 3.6 
HB43 fakllaklakkll 2.8 
Pro-P18 Ac-EEEEAAAGkwklfkklpkfhlhlakkf-NH2 77.3 
AAG-P18 AAGkwklfkklpkfhlhlakkf-NH2 35.5 
P18 kwklfkklpkfhlhlakkf 8.1 
* Mean values for 3 separate determinations 
 
3.3 Discussion 
Life expectancy in cystic fibrosis has been greatly increased by the use of 
antibiotics to treat lower airway disease and delay the progression from 
acute to chronic infection (10). However, significant challenges remain to be 
overcome. Once a patient becomes chronically infected by P. aeruginosa, 
the current guidelines recommend long-term antibiotic therapy. This has led 
to the development of antibiotic resistance due to selective pressure and 
sub-therapeutic local drug concentrations (17, 20, 134, 180, 181). In addition, 
the ability of P. aeruginosa to grow as a biofilm further reduces its 
susceptibility to certain antibiotics (17, 19, 20, 182). Currently-used 
antibiotics cannot eradicate P. aeruginosa chronic infection, and the 
continuing exaggerated inflammatory response leads to progressive loss of 
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lung function (15). There is a need for novel alternative therapeutic agents 
that are highly active against CF pathogens and less vulnerable to 
development of resistance. Delivery of such agents in high concentrations in 
the endobronchial space without the accompanying systemic effects and 
toxicity would be desirable. The requirement for high concentrations can be 
met by the use of inhaled drug delivery (20, 41, 134), while HDPs have the 
potential to meet the need for new agents. Without novel antimicrobials there 
is a risk that many of the gains made in CF may be lost with increasing 
antimicrobial resistance. 
Potential host toxicity is currently a limitation to the development of HDPs as 
antimicrobial agents. Here we demonstrate that prodrug modification can 
mask HDP bactericidal activity and may reduce host cytotoxic effects. 
Furthermore, the reversible conjugation of the pro-moiety can be targeted for 
cleavage by NE, in a manner similar to the enzymatic activation of LL-37 by 
PR-3 in vivo (127), allowing for targeted restoration of bactericidal activity 
and limitation of cytotoxic effects. NE cleavage produces HDPs that have 
similar antimicrobial activity to the parent HDPs and, in some cases, reduced 
cytotoxicity, e.g. P18 vs AAG-P18.  In addition, the reactivation of two of the 
pro-HDPs by NE has been shown under in vitro conditions that are 
representative of in vivo conditions in the CF lung, through the use of CF 
BAL fluid. The NE concentration required to cleave the pro-HDPs was within 
the range observed in CF BAL fluids. NE levels varied considerably in CF 
BAL fluids in this study and the wide variation is consistent with what has 
been reported by others. For example, Rees et al reported ranges from 0.47 
– 18.5µM (13.8 – 545.8µg/ml) in the sputum (54). In addition, NE 
concentrations have also been reported to vary over time within the same CF 
patients (41). While BAL fluid can be considered to be a dilute representation 
of ASL, the degree of dilution cannot be accurately stated. However, using 
urea as a marker, for example, it has been estimated to be as high as a 100-
fold dilution (183). Taking the dilution level to be 25 to 50-fold it has 
previously been estimated, that the NE concentrations at the respiratory 
surface (as opposed to CF BAL itself) may be in the range of 92 – 185µM 
(2.7 – 5.5 mg/ml) (40). These levels, in combination with the fact that the pro-
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HDPs were cleaved in 5µg/ml NE, demonstrate that the proteolytic needs will 
be met by CF. 
Although purified NE was shown to re-activate pro-HDPs in the present 
study, this effect was not initially apparent in CF BAL fluids containing NE, 
despite confirmation of NE concentrations that were high enough to catalyse 
the cleavage step. However, increased concentration of HDPs and the 
addition of NaCl restored the bactericidal activity of pro-HB43 and pro-P18 in 
CF BAL fluid, overcoming the antagonism of BAL components. It has been 
previously observed that the bactericidal activity of LL-37 was inhibited by 
proteolytic degradation by NE and cathepsin D in CF BAL fluid (119) and that 
cationic HDPs bind to anionic components of BAL and CF sputum, such as 
F-actin, eDNA (77, 177), mucins (178), and glycosaminoglycans (119, 184). 
In addition, both eDNA and mucins have been reported to increase the MIC 
values for synthetic HDPs such as HB43 (121). It was previously shown that 
300-450mM NaCl can, through the disruption of electrostatic interactions, 
liberate LL-37 from BAL fluid components and restore its bactericidal activity 
(119). The use of all D-amino acid active HDPs in the present study prevents 
their proteolytic degradation in vivo, as evidenced by their stability in 
100µg/ml NE for 24h. In addition, the stringent cleavage and reactivation 
conditions demonstrated here for activation in the lung environment, such as 
the addition of NaCl, may be met therapeutically by inhalation of hypertonic 
saline and by using higher concentrations of pro-HDPs. Hypertonic saline is 
currently used alone at 1.2 M for the improvement lung function in CF (119, 
185). The failure to achieve activation of pro-Bac8c in the presence of CF 
BAL and NaCl, in contrast to pro-HB43 and pro-P18, may be related to the 
ability of the latter two HDPs to maintain activity in high NaCl concentrations 
(Figure 3.5) (121, 176). 
As stated above, the susceptibility of P. aeruginosa to antibiotic treatment 
can be greatly decreased in its sessile biofilm form (4, 19, 186). The biofilm 
inhibition and disruption activity of the novel HDPs was therefore 
investigated. Biofilms have been found to be particularly resistant to HDPs, 
with many of their anionic components binding to the peptides and 
deactivating them (187). However, some HDPs have still been found to have 
   
108 
 
significant antibiofilm activity. Human cathelicidin, LL-37, has been shown to 
inhibit the formation of P. aeruginosa biofilms at concentrations 1/16th of its 
MIC (4µg/ml) and decreased the thickness of 24h biofilms pre-formed in flow 
cells (182). Similarly, shortened sequences of LL-37 have been shown to 
prevent biofilm formation and disrupt those already established, with 
improved cytotoxicity compared to LL-37 (188). A shortened variant of 
chicken cathelicidin, F2, 5, 12, has also been used to impair Staphylococcus 
epidermidis biofilms (189). 
The HDPs did not demonstrate significant activity against pre-formed biofilms 
but prevented biofilm formation. However, the concentration required for the 
latter was in excess of the MIC and the killing of planktonic bacteria may 
have likely contributed to this result. Other mechanisms of inhibition, such as 
disruption of quorum sensing (QS) pathways, which have been described for 
LL-37 biofilm inhibition (182) may also exist but were not investigated in this 
model. Given the nature of CF P. aeruginosa infections, the ideal pro-HDP 
candidate would have activity against established biofilms. However, it must 
be noted that the microtitre method of biofilm analysis used here provides at 
most, a crude estimation of the antibiofilm activity of antimicrobial agents as 
it does not accurately represent the conditions of the CF lung where P. 
aeruginosa biofilms form. The use of more sophisticated methods such as 
peg lids (186), the Calgary Biofilm Device (190), flow chamber assays, and 
confocal microscopy may provide a more accurate representation of the 
effects of pro-HDPs on biofilms. The latter would also allow more detailed 
analyses of the biofilms such as thickness measurement, live/dead staining, 
and 3D structural analysis (182, 188). Ideally, before any HDP can be 
considered for CF infections it would have to demonstrate some degree of 
activity against mature biofilms and if this cannot be shown, other parent 
sequences would need to be considered. 
The effectiveness of the NE-targeted approach for two pro-HDPs is 
demonstrated here, but there is further scope for the application of this 
approach to other HDPs. Highly-active HDPs, with varying length, charge, 
activity and cytotoxicity have been described (121, 172, 191-195). However, 
the appropriate selection of parent HDP requires consideration. In the 
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present study, since the number of glutamic acids added to the pro-HDPs 
was limited to four, the final pro-HDPs were of different net charges (-1, 0 
and +3, for pro-Bac8c, pro-HB43, and pro-P18 respectively). While in 
principle the number of glutamic acids in the pro-moiety can be adjusted to 
match the number of positive charges of the parent HDP, practically, this 
number is limited by synthetic constraints. Therefore, the bactericidal activity 
and cytotoxicity of P18, which still retained significant cationic net charge, 
was not masked as markedly as for the other candidates (Figure 3.8). These 
results demonstrate that a high starting net charge may be undesirable for 
the modification described here. The net charge reduction, while being 
sufficient for masking activity against S. aureus (142), may be insufficient 
against Gram-negative organisms such as P. aeruginosa.  Alternatively, 
other synthetic approaches may be used for parent HDPs with high net 
charge in order to extend the oligoglutamic acid moiety (142). 
The linker moiety of pro-HDPs may also be tailored to contain specific 
sequences cleavable by enzymes appropriate to the application or the 
disease.  In the present study, the AAAG linker was labile to human NE but 
not PE from P. aeruginosa, both of which are relevant to CF. It is possible 
that AAAG can be cleaved by other host/bacterial enzymes and this may 
need to be determined using sophisticated NE-knockout models. If other off-
target enzymes are identified that could potentially cleave a pro-HDP in a 
disease model, they would ideally be investigated. 
Suitable HDP candidates for pulmonary delivery as pro-HDPs against CF 
infections would ideally be short, highly active against P. aeruginosa, highly-
salt resistant, and of low to moderate net charge. The issue of net charge 
has been observed previously by our group for cephalothin-Bac8c 
conjugates, where activity was incompletely masked (162). The use of D-
amino acids may be necessary to avoid deactivation by the abundant 
proteases of the CF lung and any potential candidate would have to be 
compatible with local lung delivery such as is used with tobramycin and 
colistin in CF (20, 134, 196).  
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This prodrug approach potentially provides the means to deliver effective 
bactericidal HDPs to the CF lung in therapeutic concentrations, while limiting 
cytotoxicity distal to the site of activation and infection (i.e. the endobronchial 
space). HDP prodrugs may provide novel anti-infective agents against acute 
bacterial infection in CF and alternative therapeutics in the prevention of 
chronic pseudomonal infections.  
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4. Results Chapter Two: Optimising and Evaluating Host 
Defence Peptide Prodrugs in Cystic Fibrosis 
 
4.1 Introduction 
4.1.1 Rationale  
The prodrugs described in Results Chapter One illustrate how the simple 
addition of glutamic acid residues can increase the selectivity and reduce the 
cytotoxicity of HDPs in a CF environment. However host toxicity still 
remained an unresolved issue with these prodrugs, with both pro-HB43 and 
pro-P18 displaying cytotoxicity at concentrations close to the antibacterial 
range. In addition, the complex immune and bacterial environment of the CF 
lung necessitates that the pro-HDPs need to be evaluated in more complex 
in vitro models, taking immunogenicity, haemolysis, and cytotoxicity against 
a wider range of cell types, both immune and epithelial, into account. 
Therefore this chapter describes the refinement of the pro-HDP design by a 
variety of means and the further evaluation of the new pro-HDPs to select a 
candidate peptide with characteristics more suitable for development as a 
therapeutic for CF. 
4.1.2 Further elongation of oligoglutamic acid  
The addition of four glutamic acid residues, in conjunction with N-terminal 
acetylation, produced a reduction of net charge of 5; this is sufficient to 
reduce the net cationic charge of moderately charged HDPs, such as Bac8c 
and HB43, below or near 0. However, as seen previously, many active 
peptides have high net charges (+8 for P18) and therefore significant net 
charge remains after modification. Therefore it is possible that further gains 
in specificity can be achieved with additional pro-moiety modification. It was 
shown in Results Chapter One that the IC50 value of P18 against CFBE cells 
was only moderately improved (from 35.5µM to 77.3µM) when net charge 
was reduced to +3. One factor limiting the production of pro-HDPs with more 
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glutamic acids is that, as the pro-moiety is elongated, the increasing length 
and hydrophobicity of the protected peptide renders each additional coupling 
less efficient. Previously, multiple manual couplings were required for the 
final three glutamic acids in conjunction with careful reaction monitoring 
using the Kaiser test, underlining the difficulty. However, the high activity of 
P18 against P. aeruginosa (MIC against PAO1 of 2µg/ml), made it a very 
attractive candidate for further modification and the addition of five and six 
glutamic acids in total was undertaken. 
The unique conditions of the CF lung also raise challenges for the use of 
prodrugs bearing four glutamic acids. Numerous studies have demonstrated, 
in both human and animal models of CF, that the CFTR dysfunction can 
reduce the pH of the ASL. CFTR malfunction leads to dysregulation of HCO3- 
and increased ASL acidity, which can negatively impact the antimicrobial 
activity of some endogenous HDPs, such as LL-37, arising from changes in 
conformation (1). Many other defence components of the CF lung may be 
affected, including ciliary function and mucus viscosity (197). In a CF porcine 
model, ASL pH was decreased compared to wild-type (~pH 6.8 compared to 
7.2) with accompanying lower ASL antimicrobial activity. It was also found 
that when CF ASL pH was increased in vivo to the level found in the healthy 
lungs (using aerosolised NaHCO3) that the CF ASL antimicrobial activity 
increased. Conversely, decreasing pH levels in wild-type pigs to that of CF 
animals had the opposite effect (198). In a human study, breath condensate 
was collected in both healthy and CF subjects and analysed. It was found 
that pH was decreased in all CF patients compared to healthy individuals, 
with the largest difference noted between healthy controls and CF patients 
undergoing exacerbations (pH 6.15 vs. 5.32 respectively) (197). The 
importance of this pH change in a pro-HDP context is that the side-chain 
carboxylic acid of glutamic acid has a pKa of 4.1. This means that at 
physiological pH it will remain deprotonated, negatively charged, and thus 
able to reduce the net charge of the pro-HDPs and deactivate them (see 
Figure 4.1). However, as pH decreases, the γ-carboxyl becomes protonated 
and the net charge of the pro-HDPs increases; the possibility exists then that 
the charge effects of the pro-moiety may be reduced. Additional glutamic 
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acid residues might protect against this charge alteration. In addition to 
investigating longer glutamic acid pro-moieties, the effect of pH on the 
existing pro-HDPs was investigated. 
 
Figure 4.1: The different conjugate base and acid forms (γ-carboxyl group) 
of Glutamic acid at pH 7.4 and 4.1. 
4.1.3 PEG as a pro-moiety  
An alternative to using oligoglutamic acid as a pro-moiety is PEG (Figure 
4.2). As discussed in section 1.6.2, PEG is the most widely used polymer in 
anticancer therapy, with many PEG-prodrug systems displaying higher water 
solubility, lower degradative enzyme lability, and higher specificity than the 
active anticancer agent alone. Many cytotoxic drugs, such as methotrexate 
and cisplatin have been PEGylated, with site-specific delivery built-in, such 
as controlled degradation in the target cell or tissue (147).  
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Figure 4.2: PEG-AAAG-P18, in this pro-HDP the oligoglutamic acid pro-
moiety is replaced by a PEG of n subunit length (top left of molecule). 
PEGylation, while widespread in anticancer therapies, has not been used 
extensively with antimicrobial peptides. Studies that have been carried out 
have shown that PEGylation in general will reduce both cytotoxicity and 
antimicrobial activity (154, 155). However, a combination of correct linker and 
PEG size can produce PEGylated HDP prodrugs that are cleavable by target 
enzymes, for example serum-derived trypsin (158). PEGylation has the 
potential to reduce the cytotoxicity of P18 and for this reason PEG was 
investigated as an alternative pro-moiety to oligoglutamic acid.   
4.1.4 Replacement of TFA as a counter-ion  
The cleavage of the peptide from the insoluble resin requires the use of TFA. 
In addition, TFA is used to improve HPLC purification by sharpening peaks. 
Therefore all peptides produced by SPPS are TFA salts (see Figure 4.3). It is 
common practice to convert the peptides from TFA salts to another counter-
ion such as acetate before using peptides in in vivo studies due to concerns 
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about the cytotoxic effects of the salt. The number of TFA ions associated 
with each peptide depends on the number of basic residues it carries, in 
addition to the (free) N-terminus, and it is possible that the high cytotoxicity of 
HB43 may be in part due to the number of TFA counter-ions associated with 
it. Counter-ion replacement can be achieved by a variety of means, including 
the use of an acid, such as HCl, that is stronger than TFA and will replace it 
as counter-ion. However, this approach requires an excess of a strong acid 
solution which has the potential to damage the peptide. As a result, an 
alternative approach using ion exchange resins is often employed 
successfully to replace TFA (199). HB43 can be expected to have five 
associated TFA molecules. The effects of salt exchange of HB43 on both in 
vitro cytotoxicity and antimicrobial activity were investigated to determine 
whether additional improvements in specificity could be achieved with this 
simple procedure and whether some of the cytotoxic effects observed were 
due to the counter-ion. 
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Figure 4.3: HB43 with five TFA counter ions for the positively charged lysine 
residues and N-terminal NH3.  
4.1.5 Investigating alternative HDP sequences  
The ideal basis of any pro-HDP for CF has been described in the 
conclusions of Results Chapter One. A number of HDPs have been 
described in the literature that meet some or all of these criteria. There is a 
large library of short HDPs, many of which are very effective against P. 
aeruginosa, e.g. the 18 amino acid horseshoe crab peptide Polyphemusin 1 
has a MIC of 0.25µg/ml against PAO1 (129). However, when salt-resistance 
and a low net charge are required, the number of available sequences 
decreases. While a number of salt-resistant peptides have been developed, 
a large proportion of them are too long for the purposes of this study. 
Examples are the analogues of Human β-Defensins (hBD) 1 and 3 
developed by Scudiero et al, which combine domains of both defensins. 
These are active in high NaCl concentrations, unlike hBD-1 alone, and 
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demonstrate little cytotoxicity at active concentrations. However, their net 
charge and length are major disadvantages e.g. the most promising peptide 
3N1, is 38 residues long with a net charge of +11 (192, 200). 
Chu et al synthesised a series of short peptides modified with a bulky β-
napthylalanine (Nal) group at their termini. These showed greatly increased 
antimicrobial activity against P. aeruginosa in 300mM NaCl compared to the 
non-modified peptides e.g. MIC of 3.125µg/ml compared to >50µg/ml for the 
HDP S1. The modification also improved the serum-stability of the peptides. 
However, in addition to economic considerations associated with using a 
non-natural amino acid like Nal, this approach demonstrated several 
shortcomings, with the modified peptides displaying increased haemolytic 
activity at relatively low concentrations (40% haemolysis for S1-NalNalNal at 
12.5µg/ml) which would preclude their use in vivo (201). 
An alternative approach, given the requirement for activity in an environment 
of high salinity, is investigating marine sources of HDPs. In studies, a 
synthetic peptide derived from a precursor found in the haemocytes of the 
tunicate Ciona intestinalis Ci-MAM-A24, had an MIC against P. aeruginosa of 
0.8µM (2.2µg/ml), retained its activity in 150mM NaCl against E. coli, and 
showed little haemolysis at concentrations up to 10µM (202). A further study 
into its activity against P. aeruginosa found a Minimum Bactericidal 
Concentration range of 1.56-3.125µg/ml against 10 multiresistant clinical 
isolates (203). However, like the hBD analogues, its length (24 amino acids) 
and relatively high net charge of +7 do not make it ideal for the prodrug 
modification. The HDP myxinidin, derived from the hagfish Myxine glutinosa, 
has been shown to have significant antibacterial activity in 300mM NaCl and 
no haemolytic activity. Being one of the most primitive vertebrates, hagfish 
lack many components of adaptive immunity, relying instead on a robust 
innate immune response. Myxinidin is found in the epidermal mucus, acting 
as a barrier to aquatic infection (204). Further improvements to its activity 
were achieved in a subsequent study, where a structure-activity relationship 
produced the peptide WMR. They found an MIC of 2µM (3.3µg/ml) against P. 
aeruginosa with little haemolysis and cytotoxicity against Vero cells at 
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200µM. This, combined with its length of 13 residues and net charge of +5 
made it a promising candidate for pro-HDP modification (205, 206).  
Another potential source of short, salt-resistant HDPs are those rich in 
tryptophan and arginine. A number of studies have produced relatively-short 
Trp-Arg peptides that retain their activity in NaCl. As mentioned above, hBD-
3 is salt-resistant, with its C-terminal RRKK motif believed to contribute to 
this. Saravana et al attempted to incorporate this into the design of a 10 
residue synthetic analogue with increased hydrophobicity with tryptophan 
substitution and increased net charge with lysine and arginine substitution. 
They produced a series of peptides that had good activity against E. coli, S. 
aureus and P. aeruginosa with low haemolytic potential, but unfortunately the 
activity was lost against P. aeruginosa in 150mM NaCl (207). Another group 
produced a 13 residue peptide with an MIC of 3.125µg/ml against P. 
aeruginosa in 200mM NaCl. It was designed rationally with a tryptophan 
substitution at position 9 found to greatly increase activity in high salt 
concentrations. The authors conclude that this leads to an increase in 
hydrophobic surface available to insert into target membranes and is the 
basis of the increased activity in NaCl. This promising peptide was unsuitable 
for prodrug modification however as it had a net charge of +8 (208). 
Deslouches et al synthesised a series of Trp-Arg peptides ranging from 6 – 
18 residues in length. This was based on the observation that substituting 
tryptophan for valine in Trp-Val peptides resulted in increased broad-
spectrum antibacterial activity in challenging conditions such as in saline, 
serum, and whole blood. The most promising of the candidates was WR12. 
This peptide has net charge +6 and 12 residues in length, had a reported 
MIC of 11µg/ml against PAO1, retained activity in 150mM NaCl, and had 
limited haemolysis at active concentrations (209). Against a panel of 100 CF 
P. aeruginosa clinical isolates it demonstrated good activity (210). Its 
combinations of high activity and short sequence led to its selection as a 
possible pro-HDP candidate. 
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 4.2 Results 
4.2.1.pH does not decrease the MIC of the pro-HDPs   
The effects of reducing pH on the MIC of pro-Bac8c, pro-HB43, and pro-P18 
was investigated against PAO1. The antimicrobial activity of the pro-HDPs 
was unaltered when measured in Mueller-Hinton broth adjusted to pH 5 and 
6, with MIC values remaining the same (Table 4.1). This was compared to 
unadjusted MH broth (pH 7.3). In the case of pro-P18, MIC increased from 
64µg/ml to >64µg/ml in media adjusted to pH 5 and 6 compared to pH 7.3. 
 
Table 4.1: MIC values for pro-HDPs vs. P. aeruginosa PAO1 in different conditions of pH 
Peptide Sequence* 
MIC vs. P. aeruginosa PAO1 (µg/ml) 
pH 7.3 pH 6 pH 5 
Pro-Bac8c Ac-EEEEAAAGrlwvlwrr-NH2 >64 >64 >64 
Pro-HB43 Ac-EEEEAAAGfakllaklakkll-NH2 >64 >64 >64 
Pro-P18 Ac-EEEEAAAGkwklfkklpkfhlhlakkf-NH2 64 >64 >64 
* Upper case = L-amino acids, lower case = D-amino acids. 
4.2.2 Further elongation of oligoglutamic acid yielded no improvements 
 While a five glutamic acid pro-moiety was successfully added to P18 
(named 5E-P18), it was not possible to add six or more. Lability of 5E-P18 
with NE was confirmed by HPLC. As with the original pro-moiety, 5E-P18 
had a higher MIC than the AAG-P18 against P. aeruginosa (Table 4.2). 
When tested against PAO1, 20µg/ml NE increased the bactericidal activity of 
0.78µg/ml 5E-P18 from 13 ± 1.5% to 89.3 ± 3.3% (p<0.0001) (Figure 4.4). 
However, the difference in cytotoxicity compared to the original pro-P18 was 
negligible with IC50 values of 79.4µM and 77.3µM respectively (Table 2.3). 
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Table 4.2: MIC values for parent HDPs, fragment HDPs, and pro-HDPs vs. P. aeruginosa PAO1 and clinical isolates PABH01-04 
Peptide Sequence* 
MIC vs. P. aeruginosa strains (µg/ml) 
PAO1 PABH01 PABH02 PABH03 PABH04 
WMR wglrrllkygkrs-NH2 64 16 16 32 1 
L-WMR WGIRRILKYGKRS-NH2 64 32 64 32 2 
AAG-WMR AAGwglrrllkygkrs-NH2 32 8 16 32 16 
Pro-WMR Ac-EEEEAAAGwglrrllkygkrs-NH2 >64 >64 >64 >64 >64 
L-Pro-WMR Ac-EEEEAAAGWGLRRLLKYGKRS-NH2 >64 >64 >64 >64 >64 
AAG-WR12 AAGrwwrwwrrwwrr-NH2 32 8 32 16 32 
Pro-WR12 Ac-EEEEAAAGrwwrwwrrwwrr-NH2 >64 >64 >64 >64 >64 
PEG-P18 PEG-AAAGkwklfkklpkfhlhlakkf-NH2 >64 >64 >64 >64 >64 
5E-P18 Ac-EEEEEAAAGkwklfkklpkfhlhlakkf-NH2 >64 64 64 >64 32 
* Upper case = L-amino acids, lower case = D-amino acids.  
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Table 4.3: IC50 values for parent HDPs, cleaved HDPs, and pro-HDPs versus CF bronchial (CFBE) and tracheal 
(CFTE) epithelial cells lines, and healthy neutrophils 
Peptide Sequence* 
IC50 (µM) 
CFBE CFTE Neutrophils 
AAG-WMR AAGwglrrllkygkrs-NH2 >300 >600 >300 
Pro-WMR Ac-EEEEAAAGwglrrllkygkrs-NH2 >300 >300 ND 
L-Pro-WMR Ac-EEEEAAAGWGLRRLLKYGKRS-NH2 >300 ND ND 
AAG-P18 AAGkwklfkklpkfhlhlakkf-NH2 35.5† 4.7 9.2 
Pro-P18 Ac-EEEEAAAGkwklfkklpkfhlhlakkf-NH2 77.3† 55.9 ND 
5E-P18 Ac-EEEEEAAAGkwklfkklpkfhlhlakkf-NH2 79.4 ND ND 
PEG-P18 PEG-AAAGkwklfkklpkfhlhlakkf-NH2 38.7 ND ND 
Pro-moiety Ac-EEEEA-OH >300 ND ND 
* Upper case = L-amino acids, lower case = D-amino acids. †=From Results Chapter One. 
ND=Not determined. 
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Figure 4.4: Effect of 20µg/ml NE on the bactericidal activity of 5E-P18 and 
PEG-P18 against P. aeruginosa PAO1. Killing activities shown are the mean 
± SEM from three independent assays carried out in duplicate. Statistical 
analyses were carried out using an unpaired two-tailed t-test, * denotes 
p<0.05, ** p<0.01, and *** p<0.001 compared to the pro-HDP with 0µg/ml 
NE. 
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4.2.3 PEGylation produced an inferior pro-moiety to oligoglutamic acid  
A 2000 Da (polydisperse) PEG was successfully coupled to P18 with an 
AAAG linker using the same conditions as amino acid coupling, except for 
the use of 2 molar equivalents of MeO-PEG-OH and PEGA resin instead of 
Rink Amide MBHA resin. The PEGA resin, a poly(ethylene glycol-co-
acrylamide) support unlike the polystyrene-based Rink Amide MBHA resin, 
allows the diffusion of macromolecules of molecular masses up to 35kDa into 
the polymer matrix, affording PEGylation of peptides on their solid support. 
The final purified product (separated on HPLC using a C5 column as 
opposed to a C18 column for the other peptides) showed some 
polydispersity, as would be expected with the PEG reagent used (see PEG-
AAAG-P18 in appendix Figure A19). As with the original pro-P18, the MIC 
against P. aeruginosa was increased compared to the cleaved P18 (Table 
4.2). However, PEG-P18 did not show any cleavage after incubation with NE 
at 37oC (data not shown). This was also observed with PAO1, where the 
addition of purified NE did not increase the activity of PEG-P18 (Figure 4.4). 
Furthermore, PEG-P18 was more cytotoxic than pro-P18, with an IC50 
against CFBE cells of 38.7µM (Table 4.3). 
4.2.4 Replacing TFA as a counter-ion yielded no improvements in in 
vitro specificity  
To investigate whether replacing TFA as a counter-ion would improve the 
host toxicity profile of HB43, an ion exchange to Cl- was carried out. 19F NMR 
analysis was used to confirm the successful complete removal of TFA as a 
counter-ion while leaving the active peptide, HB43, unchanged (see 
appendix Figures A16 and A17). Comparison between the MIC values 
against PAO1 and the P. aeruginosa clinical isolates found no difference in 
activity. In addition, there was little change in cytotoxicity against CFBE cells 
with IC50 values of 2.8µM and 3.7µM for trifluoroacetate and chloride 
counter-ions respectively (Table 4.4). 
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Table 4.4: MIC values for HB43 chloride and TFA salts vs. P. aeruginosa PAO1 and 
clinical isolates PABH01-04. IC50 values against CFBE41o- cells 
Peptide 
MIC vs. P. aeruginosa strains (µg/ml) IC50 (µM) 
PAO1 PABH01 PABH02 PABH03 PABH04 
 
HB43 TFA 8 4 8 8 4 2.8 
HB43 Cl- 8 4 8 8 4 3.7 
 
4.2.5 New HDP sequences yielded improved specificity  
WMR and WR12 were selected for pro-HDP modification with the 
tetraglutamic acid pro-moiety and both were successfully synthesised. The 
synthesis of pro-WR12 was difficult and the yield was low due to a large 
number of deletion peptides formed i.e. peptide impurities where one or more 
amino acid has not been incorporated into the sequence. NE cleaved the 
peptides, leaving AAG-WMR and AAG-WR12 as cleavage products. As with 
the first generation of pro-HDPs, MIC values increased against P. 
aeruginosa from 8-32µg/ml for the fragment peptides to >64µg/ml for the pro-
HDPs. The activity of AAG-WMR compared to L- and D-WMR was not 
decreased except in the case of the isolate PABH04, indicating that the 
additional AAG residues and change to D-stereochemistry were generally not 
detrimental to activity (Table 4.2). 
The activity of both fragment peptides against PAO1 was maintained in NaCl 
concentrations ranging from 50 - 250µM (Figure 4.5) and the activity of the 
pro-HDPs was increased with the application of 20µg/ml NE, increasing from 
12.1 ± 3.8% to 93.8 ± 2.8% for 3.125µg/ml pro-WMR (p<0.0001) (Figure 
4.6). 
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Figure 4.5: The effect of NaCl on the bactericidal activity of WMR, AAG-
WMR, and AAG-WR12 (12.5µg/ml) against P. aeruginosa PAO1. Values 
shown are the means ± SEM for three independent assays carried out in 
duplicate. 
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Figure 4.6: Effect of 20µg/ml NE on the bactericidal activity of pro-WMR and 
pro-WR12 against P. aeruginosa PAO1. NE was added to assays containing 
3.125µg/ml pro-HDPs. Killing activities shown are the mean ± SEM from 
three independent assays carried out in duplicate. NE alone had no killing 
activity (data not shown). Statistical analyses were carried out using an 
unpaired two-tailed t-test, * denotes p<0.05, ** p<0.01, and *** p<0.001 
compared to the pro-HDP with 0µg/ml NE. ns = not significant. 
Because of the difficulties in synthesis and the poor synthetic yield, pro-
WR12 was not investigated further as a candidate. Studies with pro-WMR 
showed that activity in 300µM NaCl was greatly increased when 25% v/v CF 
BAL fluid was included in assays, e.g. from 8.4 ± 6.8% to 86.4 ± 0.9% with 
BAL fluid CF004 (p = 0.0004) (Figure 4.7). HPLC and MALDI-TOF MS 
analysis of pro-WMR incubated with 50% v/v CF004 (without NaCl) indicated 
that the cleavage product was the same as with purified NE, i.e. AAG-WMR. 
Cleavage was complete after 3h (see appendix Figure A27). Conversely the 
incubation of pro-WMR with two sarcoidosis non-CF BAL fluids (with no NE 
activity detected) resulted in no cleavage of the peptide after 3h incubation, 
similar to incubation with PBS (appendix Figures A34-36). After incubation all 
samples were filtered using a Centrisart centrifugal filter with a 10kDa cut-off 
(Sartorius, Ireland) to remove large proteins before analysis. Pro-WMR was 
   
126 
 
incubated with 5µg/ml purified CG, and was found to be unchanged after 1h 
incubation (appendix Figure A45). 
No BAL BAL003 BAL004 BAL006
0
20
40
60
80
100
*** *** ***
CF BAL FluidP
.
 
ae
ru
gi
n
o
sa
 
ki
lli
n
g 
ac
tiv
ity
 
(%
)
 
Figure 4.7: Effect of 25% (v/v) CF BAL fluids on the bactericidal activity of 
pro-WMR (25µg/ml) against P. aeruginosa PAO1 in the presence of 300mM 
NaCl. Values shown are the means ± SEM for three independent assays 
where activity due to CF BAL fluid alone was subtracted. Statistical analyses 
were carried out using an unpaired two-tailed t-test, *** denotes p<0.001 
compared to the pro-HDP in 300mM NaCl without BAL fluid. 
As expensive D-amino acids represent a potential economic barrier to the 
large-scale production of peptide therapeutics, an all-L-amino acid version of 
pro-WMR was synthesised. Although both D- and L- forms had comparable 
MICs (Table 4.1), when incubated with purified NE or CF BAL fluid, the 
active L-sequence as well as the pro-moiety, was cleaved. In addition, the 
bactericidal activity of L-pro-WMR against PAO1 was not increased with the 
addition of NE (Figures 4.6 and appendix Figures A30 and A31). To evaluate 
whether CF BAL fluid could cleave the pro-moiety after the linker, the peptide 
pro-GG-WMR (Ac-EEEEGGwglrrllkygkrs-NH2) was synthesised and also 
incubated with CF BAL fluid. After 3h the peptide remained intact (see 
appendix Figure A33). 
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4.2.6 Pro-HDPs do not stimulate IL-6/IL-8 release  
At sub-IC50 concentrations of pro-WMR and AAG-WMR (up to 100µM), 
negligible levels of the pro-inflammatory cytokines IL-6 and IL-8 were 
released from CFBE cells compared to the positive control (50µg/ml LPS). 
Similarly, no release was observed with the pro- and cleaved peptides of 
HB43 and P18 (Figure 4.8). 
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Figure 4.8: Cytokine release of IL-8 (A) and IL-6 (B) from CFBE cells in 
response to incubation with pro- and active peptides at sub-IC50 
concentration for 24h. Cytokines were measured using a Human Pro-
inflammatory Panel V-PLEX Plus Kit.  LPS concentration is 50µg/ml, control 
represents cells alone. Values shown are the means ± SEM for three 
independent experiments. TNF-α and IL-1β were also measured but the cells 
did not produce significant amounts in response to any stimulus. 
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4.2.7 Pro-WMR demonstrates low human cell cytotoxicity  
Both pro-WMR and the cleavage product, AAG-WMR, displayed low 
cytotoxicity against CFBE cells, with an IC50 over 300µM, but solubility issues 
precluded the extension of the concentration range beyond 300µM for pro-
WMR (Table 4.3). The released pro-moiety (synthesised from an Ala-Wang 
resin to maintain the C-terminus carboxyl) Ac-EEEEA-OH also demonstrated 
no cytotoxicity over the concentration range tested. Similarly the IC50 against 
CFTE cells was >600µM for AAG-WMR and >300µM for pro-WMR. This was 
higher than that for the previous lead pro-HDP, pro-P18, with IC50 values 
against CFTE cells of 55.9µM and 4.7µM for pro- and AAG-P18, 
respectively. 
The haemolytic activity of pro-WMR and its cleavage products was 
compared to pro-HB43, pro-P18, and their cleavage products. No 
haemolysis was seen up to 500µM (the maximum concentration 
investigated) for pro-WMR and AAG-WMR (Figure 4.9A), compared to 
significant concentration-dependent haemolysis with the other pro-HDPs 
(Figure 4.9B/C). Since the pro-HDPs are designed for cleavage by a 
neutrophil-derived enzyme, the toxic effects of the cleaved active peptides 
against purified neutrophils was also investigated. The 3h IC50 for AAG-P18 
was found to be 9.2µM and >300µM for AAG-WMR (Table 4.3). 
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Figure 4.9: Haemolytic activity in response to HDPs. Haemolysis is 
expressed as % Haemolysis relative to the 0.1% Triton-X control after 24h 
for pro-WMR and AAG-WMR (A), pro-HB43 and AG-HB43 (B), and pro-P18 
and AAG-P18 (C).  Values shown are the means ± SEM for three 
independent experiments. 
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4.2.8 AAG-WMR kills pre-formed biofilms  
Exposure of PAO1 biofilms, formed under flow for 48h, to concentrations of 
AAG-WMR above its MIC for 6h resulted in bacterial cell death which was 
concentration-dependent over the concentrations range investigated. Using 
confocal microscopy, the relative fluorescence of live cells to dead cells 
decreased with increasing peptide concentration. Percentage biofilm viability 
decreased from 87.6 ± 4.4% for media alone to 28 ± 1.6% for 256µg/ml 
AAG-WMR (p = 0.0002). Representative confocal images are provided of 
each biofilm chamber including the positive control of 50% ethanol in media 
(Figure 4.10). 
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Figure 4.10: Viability of a 48h PAO1 flow biofilm exposed statically to AAG-
WMR in PBS for 6h. % viability represents the fluorescence of SYTO ® 9 
green (live) relative to propidium iodide (dead) viewed under a 40x oil 
immersion lens. Biofilm images taken of each assay condition are 
representative (A). Values shown are the means ± SEM for three 
independent experiments (B). Statistical analyses were carried out using an 
unpaired two-tailed t-test, ** denotes p<0.01, and *** p<0.001 compared to 
the negative control (PBS alone). The positive control is 50% ethanol in PBS. 
ns = not significant. 
 
4.3 Discussion 
We previously demonstrated in Results Chapter One, using the pro-HDPs 
pro-HB43 and pro-P18, how an oligoglutamic acid modification could be 
used to target the activity of HDPs while limiting the cytotoxicity. These 
50μm 50μm 50μm 50μm 50μm 
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results have been published (211). However there were cytotoxicity concerns 
with these pro-HDPs and this required consideration. The focus of this 
chapter was on exploring additional methods of improving selectivity and 
evaluating the potential pro-HDP therapeutics more fully in terms of 
cytotoxicity, haemolytic potential, and immunogenicity. 
We have investigated here whether elongating the oligoglutamic acid 
sequence beyond four residues offers further advantages. Pro-P18 was 
chosen as the HDP for this purpose as it showed significant antimicrobial 
activity at 6.25µg/ml (Figure 3.7) and had a net charge of +3 which could be 
further reduced; for comparison purposes the net charge of active Bac8c is 
+4. The synthesis of these elongated peptides proved difficult with five 
glutamic acids requiring multiple couplings and the aid of microwave 
activation. Glutamic acid modification beyond five residues was not attained. 
While the five glutamic acid pro-P18 showed reduction of antimicrobial 
activity (restored by NE), and reduced cytotoxicity compared to AAG-P18, 
there was no discernible advantage over the tetraglutamic acid pro-P18. 
When these results are taken in conjunction with the difficulty in synthesis 
and the increased resource demands, the addition of further glutamic acids 
does not seem advantageous. The other rationale for additional reductions in 
net charge, that the slightly acidic conditions of the CF lung might protonate 
glutamic acid and compromise the net charge-reducing prodrug effects, was 
not supported by the results, with three pro-HDPs maintaining their high 
MICs in pH 5 and 6. This is likely to originate from the difference (greater 
than 1 pH unit) between the pKa of the side-chain carboxyl of glutamic acid 
and the lowest pH tested. In the CF lung the protective effects of the pro-
moiety would not be expected to be compromised by pH. For these effects to 
become significant the pH may need to decrease to pH 4 (the pKa of 
glutamic acid carboxyl being 4.1), which is not biologically relevant for CF 
(197, 198). 
PEGylation is a well-established method of prodrug delivery, particularly in 
the delivery of cytotoxic agents such as paclitaxel and larger biological 
agents such as erythropoietin (Mircera®); allowing a reduction in activity, 
reduction in cytotoxicity and controlled delivery (147). Unfortunately, 
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PEGylated P18 only demonstrated the first characteristic. While the 2000 Da 
PEG reduced the antibacterial activity of P18, this was not reversed by the 
addition of NE, with the enzyme unable to cleave the linker group. In 
addition, no benefit was demonstrated in terms of reduced cytotoxicity, with 
an IC50 against CFBE cells of 38.7µM compared to 35.5µM for AAG-P18. It 
may be that the PEG is not large enough to provide adequate reductions in 
cytotoxicity but still so large that it sterically hinders the cleavage of the linker 
by NE. Improvements in both cytotoxicity and enzymatic release of the active 
peptide might be achieved with the combination of a larger PEG and a longer 
linker; however, this would mean a much larger final product and therefore 
lower drug loading, which may be a disadvantage, especially considering 
these improvements can be made with the much simpler oligoglutamic acid 
pro-moiety. The already large size of the molecule before adding a long PEG 
is illustrated by Figure 4.2. Previously, the effect of PEG size on HDP release 
has been noted. Nollman et al produced a series of HDP-PEG conjugates 
with various linker groups. The release of the active HDP by the target 
enzyme (Trypsin) was far more efficient with the 750 Da PEG than the 5000 
Da PEG (for one peptide, 70% after 1h and 20% after 4h respectively). They 
also noted a reduction in antimicrobial activity, albeit one more modest than 
found here e.g. MIC values of 0.7µM vs. 2.8µM with and without Trypsin 
respectively for a 750 Da prodrug (158). Another study, comparing a 600 and 
2200 Da PEG found a correlation between increasing PEG length and a 
reduction in HDP antimicrobial activity and haemolysis. PEGylation was also 
found to potentially reduce cytotoxicity (155). Similarly, PEGylation of the 
HDP CaLL produced a modest reduction in MIC and cytotoxicity (156). 
Importantly, none of these studies fully quantified the IC50 against human 
cells, making the actual reduction in cytotoxicity hard to evaluate. The full 
determination of cytotoxicity used here may give a more accurate picture of 
the effect of 2000 Da PEG on a HDP such as P18. 
In a manner that has been noted previously by Pini et al (199), replacement 
of the TFA salt in HB43 had no effect on in vitro antimicrobial activity or 
cytotoxicity, with MIC and IC50 values near-identical for both the TFA and Cl- 
salts. This would indicate that for the purposes of in vitro evaluation of HDPs 
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there is no benefit to ion exchange and that the salt has negligible effect on 
the activity, even for a peptide like HB43 with high cytotoxicity and moderate 
net charge. The toxic effects of this peptide against host cells at low 
concentrations (Table 4.4) are a major barrier to its use in vivo and peptides 
with similar or better antimicrobial activity and lower cytotoxicity are 
available. Counter-ion replacement is still worthwhile for in vivo studies, as 
the removal of TFA does not seem to reduce antimicrobial activity and may 
reduce variability in response to the HDPs (199). 
The most success in improving the selectivity of the pro-HDPs was seen in 
the replacement of the active HDP itself. A search for new sequences from 
the large HDP library, based on desirable characteristics identified in Results 
Chapter One, produced two new candidates, WMR and WR12. As expected, 
they both demonstrated excellent salt-resistance. The two candidates were 
synthesised as pro-HDPs, and produced similar cleavage patterns in 
response to NE as seen with the first generation. The cleaved, active 
peptides had lower MICs against P. aeruginosa than the pro-HDPs but 
activity for both was less than previously reported in the literature, i.e. MIC 
values of 64µg/ml vs. 3.3µg/ml for L-WMR (205), and 32µg/ml for AAG-WR12 
vs. 11 ± 5µg/ml for WR12 against PAO1 (209). It is possible that the 
modifications to WR12 may adversely affect the MIC, although for WMR the 
additional alanine and glycine residues did not affect activity. The differences 
in MIC may be due to the use of different strains and assay conditions. 
Greater salt tolerance was observed for AAG-WR12 and AAG-WMR 
compared to the previous generation of cleaved HDPs. This is a favourable 
characteristic for a HDP as CFTR dysfunction has been linked to increasing 
salt concentrations in the ASL (121), although this remains the subject of 
debate (5, 122-124). In addition, high salt tolerance would facilitate the 
delivery of these HDPs with hypertonic saline, the inhalation of which 
improves lung function in CF (73, 119). 
The synthesis of pro-WR12 was challenging, requiring multiple coupling 
cycles for each amino acid after the active sequence i.e. Ac-EEEEAAAG and 
resulting in low yields. A number of contaminating deletion peptides, i.e. 
peptides where a coupling step has been missed and in which an amino acid 
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is absent, reduced the final yield of pure pro-WR12 to near 1mg (the 
theoretical yield being 145mg). This precluded cytotoxicity studies and 
allowed only limited antibacterial assays (Figure 4.11).  
 
Figure 4.11: 214nm RP-HPLC of crude pro-WR12. The number of peptide 
peaks from RT 21-23min indicates a series of deletion peptides arising from 
inefficient couplings. A crude product like this is exceedingly difficult to purify 
by HPLC and the majority of the crude product are peptides with an 
undesired sequence (A). Absorption spectrum of crude pro-WR12, high 
absorbance at 214nm and 280nm indicates the impurities are also peptides 
containing tryptophan (B). 
This was in contrast to the synthesis of pro-WMR, which was less complex 
and had a much higher yield. In 25% v/v CF BAL fluid pro-WMR performed 
better than both pro-HB43 and pro-P18, with near full bactericidal activity in 
BAL fluid but little activity in its absence, characteristics not seen with the 
others (Figure 3.9). This is significant because components of BAL such as 
proteases, mucins, and extracellular DNA may inactivate other HDPs (77, 
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119, 178). Complete cleavage of pro-WMR to the active HDP was observed 
using HPLC after 3h incubation with 50% v/v CF BAL fluid, but no conversion 
was observed in non-CF BAL fluid, devoid of NE activity. This demonstrates 
the enzyme-targeting afforded by the pro-moiety and linker. A prodrug of 
WMR with an uncleavable GG linker was unchanged after 3h incubation with 
CF BAL fluid, indicating that AAAG is the only point cleavable by the BAL 
fluid enzymes. The lack of cleavage observed with purified CG, purified PE in 
Results Chapter One, and the observed inability of PR-3 to cleave AAA in 
the literature strengthens the case for the specificity of the linker for NE (50).  
The cost of production of peptide drugs is greatly increased by the use of 
non-natural amino acids such as the D-amino acids; as a result their 
necessity in the design was investigated. The use of an all-L-pro-WMR, while 
providing low antimicrobial activity and cytotoxicity (Tables 4.1 and 4.2), 
resulted in cleavage of the active sequence by NE, both purified and in CF 
BAL fluid and therefore precluded its use in this disease model. The HPLC 
and MALDI-TOF MS analyses indicated multiple cleavage sites, ruling out 
the simple substitution of one or two amino acids with D-isomers, which 
would be an alternative approach to reducing costs and the issue of 
increased side effects with a prolonged peptide half-life (212). This 
degradation in CF samples has been seen previously with the HDP P-113, 
where 10% v/v CF sputum completely cleaved the peptide after 10min, 
removing all activity against P. aeruginosa. The addition of SLPI or A1AT 
had only a modest protective effect. The D-peptide, on the other hand, 
remained stable and retained activity in CF sputum even after one week’s 
incubation (76). For CF at least, it appears that an all-D-active sequence is 
essential to survive the challenging proteolytic conditions.  
Cytotoxicity is one of the major issues that have limited the progress of HDPs 
as therapeutics. Despite the improvements previously seen with HB43 and 
P18 after pro-HDP modification, some cytotoxic effects were evident based 
on their low IC50 values against CFBE cells (50.8µM and 77.3µM 
respectively). Their toxic effect on neutrophils, from which large amounts of 
the target enzyme are derived, was also unknown and to our knowledge, has 
not been investigated with HDPs before. Pro-WMR shows superiority to the 
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previous generation of pro-HDPs, exhibiting lower cytotoxicity against CFBE 
cells, CFTE cells and neutrophils, and lower haemolysis against 
erythrocytes. This is in agreement with the low cytotoxicity against Vero cells 
and haemolysis originally seen with L-WMR by others (205, 206).  
The cleaved peptide, AAG-WMR was not as active against P. aeruginosa as 
AG-HB43 or AAG-P18 (Table 3.1) but the improvements in toxicity 
compensate for this. For example, it was observed in this study that AAG-
P18 demonstrated high toxicity against neutrophils with an IC50 of 9.2µM. It is 
therefore likely that, upon delivery to the CF lung, neutrophils would be 
subjected to a high concentration of the active peptide and a large proportion 
would be killed. While CF is a neutrophil-dominated disease and the 
resultant high levels of NE contribute to morbidity (39, 40), it may be 
unfavourable to kill immune cells when a patient is suffering from a 
potentially severe infection. The necrosis of neutrophils in CF also leads to 
the release of extracellular DNA which increases mucous viscosity and 
facilitates bacterial attachment (19). In comparison, pro-WMR and AAG-
WMR had no measurable cytotoxicity in any cells tested. The lack of 
haemolysis is important as microbleeds in CF lead to the release of 
erythrocytes, the lysis of which can release haemoglobin, which is converted 
to haem by NE and acts as an inducer of IL-8 release and as an iron source 
for P. aeruginosa (32). 
The immunomodulatory properties of many endogenous HDPs such as LL-
37 are well-documented (110), however, the effects of exogenous peptides 
on immune function are less clear. The rationally-designed IDR HDPs, 
although devoid of antimicrobial activity, demonstrate anti-inflammatory 
effects and are protective against infection. The mechanism may involve 
interaction with intracellular targets or via direct receptor interaction (213). 
One might expect the D-HDPs, such as those used here, would be unable to 
interact with receptors and have immunomodulatory effects, but nonetheless 
it has been demonstrated that D-LL-37 can stimulate far higher IL-8 release 
from keratinocytes than L-LL-37, arguing against the necessity of structure-
specific binding to receptors for cytokine release (115). At concentrations 
below their IC50 values (up to 100µM for the WMR peptides) both pro- and 
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cleaved HDPs did not induce significant IL-6 or IL-8 release from CF 
bronchial epithelial cells. This is a desirable characteristic as IL-8 is a potent 
chemoattractant for neutrophils (13). The lack of pro-inflammatory cytokine 
response to the pro-HDPs is likely due to the lack of an immune response to 
the active HDP sequence. However, if an immunomodulatory HDP was 
modified to a prodrug, there is the possibility that the addition of the pro-
moiety could reduce the effects and this should be considered when 
investigating the consequences of pro-HDP modification. For example, it has 
been observed with one HDP that PEGylation can reduce its ability to inhibit 
LPS-induced NF-κB activation of macrophages (155). 
As discussed in Results Chapter One, when acute P. aeruginosa infections 
progress, adaptation can occur and the bacteria may form a biofilm as the 
infection becomes chronic. The biofilm matrix consists of 50-90% 
extracellular polymeric substances such as polysaccharides and nucleic 
acids that can resist mechanical forces and decrease the penetration of 
antibiotics (14). The reduced susceptibility of P. aeruginosa in a biofilm is 
well documented (17, 19, 20, 182) and the activity of HDPs is often greatly 
reduced against them. Despite this, a number of HDPs have been shown to 
have antibiofilm activity including LL-37 against 24h biofilms pre-formed in 
flow cells (182) and a shortened variant of chicken cathelicidin, F2, 5, 12, 
against Staphylococcus epidermidis biofilms (189). The short peptide 1037, 
despite having a very high MIC against P. aeruginosa, was shown to reduce 
biofilm formation at low concentrations (187). Short D-amino acid peptides 
have been developed that are able to disperse flow PAO1 biofilms at low 
concentrations (2.5µg/ml) and can protect both Caenorhabditis elegans and 
Galleria mellonella from biofilm infection from a variety of pathogens. These 
peptides’ antibiofilm activity is based on translocating into cells and 
disrupting biofilm signalling molecules, an effect which unlike membrane 
disruption, may be stereo-specific i.e. depending on amino acid conformation 
(108).  AAG-WMR was able to greatly reduce the viability of a 48h pre-
formed biofilm to near the level of the positive control after 6h of treatment, 
albeit at the high concentration of 256µg/ml, eight times its MIC against 
PAO1. While comparisons of the results between the flow biofilm used here 
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and the static biofilms of Results Chapter One are not easily made, AAG-
WMR would seem to be more effective than the previous generation of active 
HDPs. Despite the relatively high concentration required, the concentration-
dependent biofilm killing in conjunction with its low cytotoxicity would make 
pro-WMR a promising candidate for treating P. aeruginosa infection in an in 
vivo model. Further investigations with this pro-HDP will be required to fully 
evaluate its utility in CF and the advantage of the prodrug modification. This 
study demonstrates that simple modifications to HDPs can produce a 
potential therapeutic agent that may be suitable for use in difficult-to-treat 
conditions and that many of the shortcomings of HDPs such as protease-
lability and cytotoxicity are not insurmountable.
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5. Results Chapter Three: Evaluating the nebulisation of pro-
WMR 
 
5.1 Introduction 
5.1.1 Rationale 
Several antibiotics used to treat infection in CF are now delivered by the 
inhaled route, which has many advantages over systemic delivery. The 
combination of HDPs and nebulisation has been investigated in several 
studies as a means of delivery in in vivo models. However, the 
characterisation of the peptide spray has not been extensively studied and 
the compatibility of HDPs with this system has not been investigated. This 
chapter describes the evaluation of the delivery of pro-WMR using existing 
nebulisation technology to determine whether the characteristics of the 
aerosol spray are compatible with inhaled delivery of the peptide to the 
bronchioles and whether this delivery platform is feasible in CF.  
5.1.2 Inhaled delivery  
The delivery of peptides to their targeted site of action presents a series of 
challenges. Most peptide therapeutics are delivered by injection as issues 
with stability, half-life, and epithelial absorbance mean that they often display 
poor bioavailability by other routes. When the requirement is only for local 
action, however, the number of available routes of administration increases; 
the majority of non-injected peptides operate locally (214). Should a pro-HDP 
progress to more detailed clinical studies, it is envisaged that it would be 
delivered locally to the lung via inhalation, allowing high drug concentrations 
and minimal systemic exposure (134). Direct pulmonary delivery is extremely 
attractive for HDPs; for example sputum levels of tobramycin are over 1000 
times higher when delivered by inhalation versus the intravenous route (215). 
Inhalation also bypasses first pass metabolism and the requirement for 
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gastrointestinal absorption (which is poor with many peptide drugs) (216). If 
one considers insulin to be a peptide (with 51 residues, it is referred to as 
both a peptide and a protein depending on the definition) then the repeated 
attempts to deliver it systemically via the lung underlines the potential for 
inhaled delivery. While Pfizer’s insulin (Exubera®) was a commercial failure, 
other companies have continued research and Mannkind’s Afrezza® has 
demonstrated superiority in efficacy over subcutaneous injection in phase III 
clinical trials. Its particle diameter of 2µm allows systemic delivery with 
inhalation of a dry powder (214). In CF, the delivery of medicines such as 
antibiotics, corticosteroids, and bronchodilators is commonly via nebulisation. 
Dornase alfa, colistin, and tobramycin are all delivered this way (217). 
However, the large number of drug treatments required and extensive 
inhalation times mean that patients have a high treatment burden. The low 
adherence to treatment regimens that may follow can often contribute to the 
failure of antimicrobial therapies (15). Ideally, any new treatment should limit 
the increase in patient burden and therefore pro-WMR would ideally be 
combined with the fastest delivery method possible. The current standard of 
care for inhaled anti-pseudomonal antibiotics is tobramycin (300mg in 5ml), 
delivering high concentrations of drug to the endobronchial space and 
minimising systemic exposure. The typical delivery time is 12-15min by jet 
nebuliser, and this relatively lengthy time period can negatively affect 
compliance (218).  
The physicochemical properties of the inhaled drug, as well as the 
formulation, can affect its deposition in the lung. Particle size is crucial, a 
mass median aerodynamic diameter (MMAD) (the diameter at which 50% of 
the particles by mass are larger and 50% are smaller) of between 1 and 5µm 
is required for lower airway deposition. At size ranges lower than this, the 
particle is likely to be exhaled, and at higher size ranges it will physically 
impact the throat and only lower amounts will reach the lung (219). More 
specifically, particle diameter below 3µm is generally used to target the 
alveoli, the thinness of the epithelium there making it an attractive target for 
systemically-active peptides (220). However, this is not the target for pro-
HDPs. Newman et al investigated the delivery of carbenicillin with two 
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different nebulisers to treat P. aeruginosa and the results illustrate the 
important of particle size. One nebuliser produced droplets with a mean 
MMAD of 3.2µm and lower lung deposition of 0.81mg, compared to 7.3µm 
and 0.44mg with the other nebuliser. As would be expected, the 
oropharyngeal deposition of the latter aerosol was increased (on average 
four times higher) (221).  
Small peptides delivered to the lung are usually degraded by proteases. 
Those resistant to such proteolysis, such as D-amino acid peptides, could 
potentially be absorbed para-cellularly to the bloodstream. However, drugs 
such as tobramycin that are lipophilic with a net positive charge have been 
shown to preferentially bind to lung tissue. This effect might also be expected 
from the cleaved active peptide (222). 
There are several different means of delivering a medicine by inhalation: 
5.1.3 Metered dose inhalers  
The first Metred Dose Inhaler (MDI) was developed in 1956. Since then MDIs 
have become the most widely used treatment in several respiratory 
diseases, including asthma and COPD. The drug is formulated with a 
chemically-inert hydrofluoroalkane propellant and is released as a 
pressurised spray upon actuation (223). MDI inhalers were originally 
designed for the delivery of small, highly potent drugs such as salbutamol, 
the dose of which is 100µg per spray. The delivery efficiency of these 
inhalers is low at ~12%. This is not a major limitation with potent drugs, but 
renders MDIs unsuitable for delivery of antibiotics where the desired dose is 
greater than 1mg (216). With careful adjustment of the formulation it is 
possible to deliver peptide drugs with MDIs. One study reported 
bioavailability of 18.3% with MDI delivery of the nonapeptide hormone 
leuprolide. However, as with salbutamol, the dose was much lower than 
required for HDPs, at 500µg (224). 
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5.1.4 Nebulisation  
Conventional nebulisers consist of a compressor and a nebuliser chamber 
and include jet nebulisers which are commonly used with CF medication. 
Negative pressure draws the drug from a reservoir to the chamber where it is 
atomised by compressed air into a range of particle sizes. Only the smaller 
particles can exit the chamber, as large droplets are trapped by baffles in the 
chamber and recycled. The constant repetition of droplet formation and 
impaction can degrade large molecules and liposomes (causing their 
contents to leak) (225, 226). The high shear stress involved also leads to the 
denaturation of peptides and proteins (220). Conventional nebulisers are 
cheap to maintain and reliable, but are also noisy, slow, bulky, and wasteful 
of medication. As nebulisation continues, evaporation causes the drug 
solution to become more concentrated (219). Ultrasonic nebulisers use a 
vibrating piezoelectric crystal to cause droplets to form. They are faster and 
quieter than conventional systems but are unsuitable for many medications, 
including many of those commonly used in CF (217). The vibration of the 
crystal causes significant heat generation, which can be problematic for heat-
labile molecules such as peptides (225). 
Newer nebulisation technologies such as vibrating mesh nebulisers (VMN) 
have many advantages over conventional jet nebulisers, such as reduced 
treatment time and smaller particle size (217). As their name suggests, they 
generate an aerosol by the action of a vibrating mesh covered in microscopic 
holes, which control the droplet size of the produced spray (227). The 
droplets produced are optimally sized and the aerosol is low velocity, so this 
results in minimal throat impaction and increases delivery efficiency (228). 
Unlike bulky jet and ultrasonic nebulisers, VMNs have been miniaturised and 
can be carried with a portable power source (216). One example is the 
Aeroneb® Solo produced by Aerogen in Galway, Ireland (Figure 5.1), which 
is very compact and operates from a battery pack. VMNs represent a major 
improvement in convenience for patients. For example, comparing 
tobramycin solution delivered by jet nebuliser and VMN, a significant 
reduction in treatment burden is observed (218). Dornase alfa treatments 
times have also been reduced with a VMN. In addition, the lower residual 
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volume allows a larger proportion of the drug to be delivered (229). This can 
increase patient compliance and improve clinical outcomes. VMNs have 
demonstrated increased lung deposition in many cases compared to other 
nebulisation methods but this can be variable and depends on the system 
used. Based on the results of a number of studies, a Cochrane review 
concluded that VMNs held promise in optimising nebulisation therapy (217). 
 
 
Figure 5.1: Aerogen Aeroneb® Solo vibrating mesh nebuliser. 
5.1.5 Inhaled powder  
Dry powder inhalers (DPI) involve the inhalation of the drug in power form, as 
opposed to an aqueous solution. They are generally well-liked by patients 
because they are easy-to-use, fast, portable, and do not require any 
reconstitution. They have not typically been used for inhaled antibiotics as 
the amount deliverable is small and not suitable for high-dose treatments. 
DPIs have also traditionally been limited in terms of delivery efficiency and 
drug-loading. The particle size requirement of 1-5µm for inhalation meant in 
the past that drug powders had poor flow characteristics and aggregated 
readily. The high ratios of carrier particles, e.g. lactose, required to overcome 
this, coupled with poor delivery efficiency, meant that higher doses of drugs 
were not possible (216). However, the recent development of new 
formulation technologies has allowed the development of antibiotic DPIs with 
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high drug-loading and improved lung delivery efficiencies, using technologies 
such as spray-drying to produce favourable particle characteristics (230). 
While tobramycin is typically delivered as an inhaled solution, it has been 
formulated for dry powder inhalation. There are several advantages to this 
approach over solution including reduced delivery time (4-6min), portability 
and convenience of an inhaler, and no requirement for an external power 
source. The drug is manufactured as porous spheres with an MMAD below 
4µm, ensuring efficient lung deposition. Its use has been approved in the EU 
and US, demonstrating no inferiority to nebulised tobramycin and lower costs 
(215). Other antibiotics have been formulated as DPIs; including a DPI of 
colistimethate sodium approved for use in the EU. A ciprofloxacin DPI is also 
currently undergoing clinical trials (216). Mannitol, used as an osmotic agent 
to draw water into the airway and improve mucociliary clearance in CF, is 
delivered as a DPI (227). As mentioned previously, with smaller particle sizes 
of ~2µm it is possible to deliver peptides systemically via the inhaled route as 
a dry powder (214). An additional benefit of powder over solution is that the 
stability of the drug product is often greatly improved, for example it has been 
demonstrated that liposomal SLPI for aerosolisation is more stable under 
storage as a dry powder than as an aqueous solution (231) and parathyroid 
hormone has also been formulated in this manner for the same reason (232).  
5.1.6 Inhaled delivery of HDPs - options and challenges 
While delivering HDPs as a DPI may represent an attractive future 
proposition, their compatibility with the processes required to achieve high 
enough drug-loading would first need to be established and is beyond the 
scope of this project. Many chemically-labile compounds such as proteins 
and peptides are not amenable to the spray-drying process (223). The 
immediate availability of nebuliser technology makes it a more realistic route 
of inhaled administration; the relatively small size and fast delivery times of 
VMNs making them particularly attractive. The low residual volume 
compared to other delivery methods is an important advantage for peptides, 
considering their potential high costs of production (228). Establishing 
compatibility of pro-WMR with delivery by VMN would advance the case for 
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its use in CF as an anti-pseudomonal therapeutic agent. The requirements 
are that the peptide survives nebulisation, retains activity, and that the spray 
is of correct droplet size to ensure lower lung delivery (1-5µm).  Particle size 
distribution can be quantified by cascade impaction using a next generation 
impactor (Figure 5.2). This entraps aerosol droplets of different sizes in each 
stage of the impactor. The stages have a progressively smaller pore 
diameter, entrapping larger droplets and, with quantification of the proportion 
of the dose in each stage, allowing estimation of the spray’s MMAD. Droplet 
evaporation can sometimes lead to an underestimation of particle size with 
an impactor. To combat this, one can also measure droplet diameter using 
laser diffraction (225). Combining the two sizing methods allows broad 
determination of the particle size distribution of the spray (224). 
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Figure 5.2: Next generation impactor (in open configuration), consisting of 
eight different stages that entrap particles of different sizes. Each 
subsequent stage has a smaller pore diameter and will entrap particles of 
progressively smaller sizes e.g. stages 4 and 5 have cut-off diameters of 
3.3µm and 2.08µm respectively. The trapped droplets then settle on a 
removable cup. The final stage, the micro-orifice collector (MOC) collects 
particles of extremely small diameter (below 1µm). After nebulisation, the 
cups can be removed, washed, and analysed by HPLC. This allows accurate 
quantification of the droplet size distribution of the nebulised aerosol.  
 
5.2 Results 
5.2.1 Pro- and AAG-WMR are unchanged after nebulisation  
A 1mg/ml aqueous solution of pro-WMR and AAG-WMR were both nebulised 
using an Aeroneb® Solo. This was characterised before and after 
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nebulisation using electrospray mass spectrometry (ESI-MS) and HPLC. 
Neither peptide was changed by the nebulisation process as evidenced by 
the comparable retention times (20.89min vs. 20.857min for AAG-WMR) and 
mass spectra (Figures 5.3 and 5.4). A comparison of the MICs of both 
peptides before and after nebulisation was also made. Against P. aeruginosa 
PAO1 and three CF clinical isolates, no difference in MIC was observed 
(Table 5.1). 
Table 5.1: MIC values for pre- and post-nebulisation HDPs vs. P. aeruginosa PAO1 
and clinical isolates 
Peptide 
MIC vs. P. aeruginosa strains (µg/ml) 
PAO1 PABH01 PABH02 PABH03 
AAG-WMR 32 8 16 32 
AAG-WMR (nebulised) 32 8 16 32 
Pro-WMR >64 >64 >64 >64 
Pro-WMR (nebulised) >64 >64 >64 >64 
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Figure 5.3: HPLC and ESI-MS of AAG-WMR before (A) and after (B) nebulisation. Retention times 20.890min and 20.857min. The 
signals at m/z = 611.1, 458.6, and 367.1 are the (M+1)/3, (M+1)/4, and (M+1)/5 respectively for AAG-WMR. 
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Figure 5.4: HPLC and ESI-MS of pro-WMR before (A) and after (B) nebulisation. Retention times 22.527min and 22.450min. The 
signals at m/z = 820.8, 616, and 493 are the (M+1)/3, (M+1)/4, and (M+1)/5 respectively for pro-WMR.
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5.2.2 The particle size distribution of the peptides is favourable for lung 
delivery  
Analysis of the particle size of a 1mg/ml aqueous solution by laser diffraction 
gave the volume mean diameter (VMD) of both peptides: 3.79 ± 0.1µm and 
3.8 ± 0.1µm for pro- and AAG-WMR respectively, with accompanying 
geometric standard deviations (GSD) of 1.76 and 1.74. The % of particles 
with a diameter below 5µm, i.e. the fine-particle fraction (FPF) was above 
65% for both peptides (Table 5.2). 
 
Table 5.2: VMD, MMAD, GSD and %FPF values for pro- and AAG-WMR, determined using 
both laser diffraction and cascade impaction 
Peptide Laser Diffraction  Cascade Impaction 
VMD (µm) GSD %FPF<5µm MMAD (µm) GSD 
Pro-WMR 3.79 ± 0.1 1.76 67.1 3.59 ± 0.23 1.67 
AAG-WMR 3.8 ± 0.07 1.74 66.6 3.14 ± 0.25 1.93 
 
The results of the cascade impaction were in general agreement with the 
laser diffraction. The MMADs were 3.59 ± 0.23µm and 3.14 ± 0.25µm for pro- 
and AAG-WMR respectively (Table 5.2). The difference was not statistically 
significant (p = 0.0835). The mass balance of the different stages of the 
impactor indicated that the majority of both peptides settled in stages 4 and 
5, which had a cut-off diameter of 3.3µm and 2.08µm respectively. Negligible 
amounts of peptide remained in the nebuliser after the run was finished 
(Figures 5.5 and 5.6). 
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Figure 5.5: Mass balance of each stage of the next generation impactor for 
pro-WMR. Included are stages 1 to 7, the MOC, the connector, throat, and 
filter stages, as well as the remaining peptide in the nebuliser. Each stage of 
the impactor has a smaller cut-off diameter, with a large proportion of the 
peptide in stages 4 and 5 indicating a particle size below 3.3μm and 2.08μm 
respectively.   After nebulisation of 1ml, each stage was washed with dH2O 
and the washings analysed by HPLC to determine drug deposition. 
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Figure 5.6: Mass balance of each stage of the next generation impactor for 
AAG-WMR. Included are stages 1 to 7, the MOC, the connector, throat, and 
filter stages, as well as the remaining peptide in the nebuliser. Each stage of 
the impactor has a smaller cut-off diameter, with a large proportion of the 
peptide in stages 4 and 5 indicating a particle size below 3.3μm and 2.08μm 
respectively.   After nebulisation of 1ml, each stage was washed with dH2O 
and the washings analysed by HPLC to determine drug deposition. 
5.2.3 The peptides are deliverable to a model lung  
Using the parameters for a healthy adult lung, both peptides were nebulised 
into a breathing apparatus. The quantity of peptide collected in the terminal 
filter (representing the beginning of the lung) was compared to the initial 
dose. This allowed the percentage delivery to be calculated. For pro-WMR % 
delivery was 42 ± 3.1%, and for AAG-WMR 47.6 ± 7.8%. The difference 
between both peptides was not statistically significant (p>0.05). An image of 
the breathing apparatus is provided in Figure 5.7. The nebulisation time for 
the 1ml solution was less than 3min for both peptides (170 ± 3s for AAG-
WMR and 171 ± 2.3s for pro-WMR). 
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Figure 5.7: Image of the breathing apparatus used to determine the 
deliverable dose of both peptides to the lung. The parameters chosen were 
those of a healthy adult. An aqueous solution of peptide was nebulised by 
the VMN and inhaled by the apparatus through the mask. After passing 
through, it was collected in a gas permeable filter, representing the lung. The 
proportion of peptide collected in the filter was determined by HPLC. 
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5.3 Discussion 
Both pro- and active peptide were intact and unchanged after nebulisation, 
maintaining their antimicrobial activity and demonstrating no degradation. 
This has previously been an issue when biological agents have been 
delivered with nebuliser systems, e.g. with rhDNAse and insulin in an 
ultrasonic nebuliser, where activity has been shown to be altered (233). The 
protein lactate dehydrogenase is labile to both heat and shear stress, which 
are generated in the nebulisation process. Its degradation has been 
demonstrated with a series of jet and ultrasonic nebulisers, with an 
accompanying loss of activity (to around 20% in some cases) (234). 
Nebulisers have been shown to degrade other biopharmaceuticals, e.g. 
naked siRNA has been shown to be degraded by jet nebulisation (an effect 
avoided by formulating it as a nanoparticle) (235). On the other hand, other 
therapeutics can be unscathed by nebulisation and retain activity, e.g. 
colistin is not degraded and has been shown to maintain its MIC after both jet 
and ultrasonic nebulisation (233) and using a similar VMN to that used here 
(Aeroneb® Pro) siRNA nanocomplexes were found to maintain their ability to 
knockdown luciferase (236).  
The use of VMNs should reduce the degradation of biologicals agents such 
as peptides and proteins, with most of the instability of nebulisation observed 
with jet and ultrasonic nebulisers. However, this is not guaranteed and must 
be evaluated with every peptide-nebuliser combination. VMNs have a 
stability advantage because, unlike jet and ultrasonic nebulisers, they do not 
recirculate droplets. Furthermore, the generation of shear, heat, and air-liquid 
interface (where shear effects are most damaging) are reduced in VMNs. 
However, these effects are not completely absent or insignificant in VMNs. 
Reservoir temperatures of 40oC have been demonstrated with the Aeroneb® 
Go and VMNs generate (less obvious) air-liquid interfaces where new 
droplets are created, creating the potential for destabilising stress (237). 
Identical mass spectrums and chromatograms of the peptides pre- and post-
nebulisation are demonstrated here with pro- and AAG-WMR. However, 
HPLC alone cannot determine if a peptide remains active after nebulisation, 
and analysis must also include biological testing. It has been shown with the 
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PARI® eFlow VMN that a post-nebulisation protein may appear intact under 
HPLC but still be inactivated, the protein SM101 losing 50% of its potency 
(237). The thermal stress generated in VMNs can be reduced by pre-cooling 
solutions or actively-cooling the reservoir. This has been shown to reduce 
the aggregation and loss of activity of SM101 and lactate dehydrogenase. 
Cooling the reservoir solution also has the added benefit of increasing the 
fraction of droplets between 1 and 5µm. However, even with cooling, 
interfacial stress from VMNs can still degrade proteins including the previous 
two and even heat-stable molecules such as IgG1 (238). 
The facile nebulisation of both simple aqueous peptide solutions is 
advantageous when one considers that other peptides, for reasons of host 
toxicity and instability, often require reformulation to deliver them to the lung. 
A common approach in nebulisation, and one that deserves special 
consideration, is to deliver drugs as liposomes. While formulating inhaled 
peptides and proteins in this way has many advantages, especially in terms 
of improving drug stability (226), activity (239) and limiting host toxicity (240), 
there are several complications associated with it. Potential difficulties one 
can encounter included the issue of degradation and leakage of contents 
which can be induced by nebulisation or after a period of storage. The high 
HDP concentration required for effective treatment requires a parallel high 
lipid content which can increase solution viscosity and hinder nebulisation. 
Conversely, liposomes that produce less viscous suspensions can be less 
stable and leak their HDP contents (240). Optimisation of the lipid content 
can overcome many of the leakage issues, with the behaviour of different 
liposomes varying considerably. With the HDP CM3, one study observed 
encapsulation after nebulisation which varied from 20% to 90% depending 
on the formulation as peptide-leakage often occurred after processing. 
However, the stability under nebulisation does not necessarily correlate with 
the nebulisation efficiency of the drug, i.e. the amount of peptide the 
nebuliser will emit. A liposome that is resistant to leakage under nebulisation 
can still be inefficiently delivered, even though all formulations might have 
MMAD values between 1 and 5µm. With nebulisation both leakage and 
delivery must be considered with each liposome formulation (241).  
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While liposomes can protect from protease degradation, if peptide release is 
too slow it can exacerbate total proteolysis, the slow released of low 
concentrations of active peptide may facilitate enzymatic degradation 
whereas this is less likely with a high bolus dose. This was observed with the 
32 residue peptide calcitonin (242). Liposome leakage has been observed 
with SLPI delivered by jet nebulisation. The protein was encapsulated in 
liposomes to reduce its proteolytic inactivation, an issue which limits its 
clinical application. It was observed after nebulisation that its resistance to 
cathepsin L degradation was reduced by over 50%, a result of drug leakage 
from the liposomes induced by the nebuliser. However, this issue may be 
limited to jet nebulisers and the high encapsulation efficiency observed with 
SLPI, a result of the ionic interaction between the cationic protein and an 
anionic lipid, illustrates the potential for this technique to be used with active 
cationic HDPs (but perhaps not the low net charge pro-HDPs) (226). The low 
cytotoxicity of pro-WMR and the need for enzymatic cleavage makes the use 
of liposomes redundant, but while this approach is not suitable here, with the 
correct formulation it may serve as an alternative to the pro-HDP model. It 
has been applied to polymyxin B, aimed at improving the toxicity and 
residency time of the peptide in the lung. The importance of the liposome 
content is underlined by the fact that against the same P. aeruginosa strain 
(ATCC 27853), one study demonstrated improved activity compared to free 
drug (239) while another formulation reduced its activity (antimicrobial activity 
being further reduced by nebulisation) (243). Interestingly, reformulating 
SLPI as a dry powder for DPI delivery resulted in liposomes that were better 
at protecting the protein from enzyme inactivation after delivery, had better 
stability under storage, and had an MMAD of 2.44 ± 0.12µm (231). 
Another consideration is the effect of liposome size on the drug distribution in 
the lungs. Smaller liposomes might be expected to have a negligible effect 
on the droplet size of the aerosol but as liposome size approaches that of the 
droplets, e.g. 1-5µm, it is possible that their distribution among the various 
droplet sizes will be affected. In other words, would the liposome distribution 
among the different droplet sizes of a normal aerosol be homogenous or 
would larger liposomes be more likely to reside in larger droplets, and as a 
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result would liposomes deposited in the peripheral lung differ from those in 
central airways? This question was investigated with liposomal amikacin, 
again aerosolised to treat pulmonary P. aeruginosa. However, the liposome 
size in each stage of the impactor was below 0.4µm and mostly homogenous 
(244). Despite the demonstration of homogeneity with amikacin, this effect 
should be considered with every new liposomal formulation and remains a 
complication of their use. An alternative to liposomal or prodrug delivery is to 
formulate HDPs as nanoparticles, an approach that has been used in a study 
with tobramycin (which is also cationic) to provide a degree of controlled 
release and increase the residence time of the antibiotic. This also allows the 
coadministration of drugs such as dornase alfa, which as stated previous, 
has been functionalised onto these nanoparticles. The particle size achieved 
(~0.5µm) would ideally not interfere with homogenous nebulisation (78). 
The MMAD values for the combination of the Aeroneb® Solo and pro- and 
AAG-WMR (3.59 ± 0.23µm and 3.14 ± 0.25µm respectively) are within the 
desired range of 1-5µm for local lung delivery and compare favourably to the 
droplet diameter of other inhaled medicines for CF. Dornase alfa has a 
particle diameter of 4.2µm when delivered by jet nebuliser and 4.3µm with 
Omron’s MicroAir VMN (229). The particle size of the peptides is also above 
3µm and so would not be in the range for reaching the alveoli (which is not 
the target). Peptides that are delivered beyond the endobronchial space to 
the alveoli would be expected to be absorbed into the blood stream 
(depending on their characteristics), be degraded by proteases, or be 
removed by alveolar macrophages (220).  
MMAD is not just a function of the characteristics of the drug solution, as the 
nebuliser and its settings can also have a profound effect on particle size. In 
one study with the same tobramycin solution, for example, a range of 
MMADs were produced with different nebulisers, many of which were well 
outside the ideal range and not respirable (245). Achieving a suitable particle 
size with a simple aqueous solution is advantageous when one considers 
that additives are often required to render a drug respirable. Using a similar 
VMN to our own, the aerosol of a mannitol solution had a MMAD of 11.27µm. 
This droplet size is too large for lung delivery and co-formulation with 1% w/v 
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NaCl was required to lower it to a more feasible range for treatment 
(5.75µm). NaCl also greatly decreased the nebulisation time for 2.5ml from 
477s to 298s (228). For comparison, the treatment time of pro-WMR was 
171s/ml compared to 190.8s/ml for mannitol alone. While the combination of 
hypertonic saline and pro-WMR may be of potential benefit to CF patients 
(73), it is advantageous that the inclusion of any other excipients to the 
peptide solution would be for reasons of therapy and not formulation. The 
treatment time also compares well to tobramycin delivery, where delivery 
with a Pari® eFlow VMN was on average 156s/ml (678s/ml with a jet 
nebuliser) (246). 
The breathing apparatus results demonstrate that a large proportion of the 
peptide solution can be expected to reach the lung and compares well to 
established therapeutics. While a larger percentage of the active peptide 
reached the model lung, the difference between pro- and AAG-WMR was not 
statistically significant. In any case it is demonstrated that the additional 
residues and the modification of net charge are not detrimental to the 
pulmonary delivery. The settings for our apparatus were those of a healthy 
patient, with a tidal volume of 500ml, inhalation:exhalation ratio of 1:1, 15 
breaths/min, and 2l/min of supplementary gas flow. Under similar conditions 
(but with 12 breaths/min and no supplementary gas) the delivered dose of 
dornase alfa was 52% with a VMN (229). The parameters for a CF patient 
are different and may produce a different % delivery. Lange et al investigated 
the delivery of a liposomal HDP to a model adult CF lung, using a tidal 
volume of 620ml, inhalation:exhalation ratio of 1:1.3, and 18 breaths/min. 
Final delivery of the peptide dose with a jet nebuliser was 28%, while its 
MMAD was 2.84 ± 0.1µm (240). These parameters may form the basis of a 
future delivery analysis. For comparison with current in vivo efficiencies, in a 
group of male CF patients receiving 150mg of tobramycin from a Pari® 
eFlow VMN, 28.3% was deposited in the lung (246). 
The successful production of a respirable aerosol with pro-WMR represents 
another step towards the clinical use of pro-HDPs. We demonstrate here that 
the prodrug modification is not detrimental to delivery and that both peptides 
may be given therapeutically in a way which should not significantly increase 
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the treatment burden on CF patients. There are scarce reports of nebulised 
antimicrobial peptides in the literature, and while much work has been 
carried out on proteins and peptide hormones such as insulin, this study 
represents one of the few studies into the aerosol delivery of a HDP. It is also 
the first, to the author’s knowledge, to investigate a HDP with a prodrug 
modification. There are several reports of liposomes being used to delivery 
cytotoxic and unstable therapeutics to the lung. For HDPs, at least, the 
oligoglutamic acid prodrug modification may represent a more facile delivery 
method, D-amino acids negating the concerns over stability in vivo and the 
net charge reduction tackling potential toxicity. As an alternative approach it 
would bypass issues of leakage and formulation, requiring only a simple 
aqueous solution and being feasible with existing technology to treat CF 
infections. 
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6. Results Chapter Four: An in vivo study into the anti-
infective and toxic effects of pro-WMR 
 
6.1 Introduction 
6.1.1 Rationale  
The combination of favourable in vitro antimicrobial activity, low host toxicity, 
and its compatibility with nebulisation makes pro-WMR an attractive 
candidate to bring forward to in vivo studies. While the activation of the 
peptide in the presence of purified NE and CF BAL fluid has been 
demonstrated in vitro, in order for it and other pro-HDPs to progress in 
development it will need to be confirmed in vivo. This chapter deals with the 
design and implementation of suitable animal experiments to evaluate both 
the antimicrobial activity and cytotoxicity of pro-WMR in a model that closely 
resembles CF in a human context. 
6.1.2 In vivo studies with HDPs  
Many HDPs have been evaluated using in vivo lung infection models, with 
significant bacterial reductions being demonstrated. For example, 
intranasally-delivered LL-37 has been shown to induce an early neutrophil 
response to PAO1 infection in the lungs of mice, accelerating clearance of 
the bacterium (247). It has also been shown to ameliorate the pneumonia 
induced by MRSA when delivered in advance intratracheally (248). Beyond 
LL-37, in vivo activity has been demonstrated with exogenous HDPs. A 
series of peptides related to HB43 delivered in high doses were shown to 
greatly reduce the bacterial burden of a P. aeruginosa lung infection in rats 
after nebulisation over three days (121). Similarly, intraperitoneal 
administration of the peptide HPA3P2 was able to greatly improve mouse 
survival in a sepsis model of multidrug-resistant P. aeruginosa infection 
(249). The expectation for the reduction in bacterial load may be compared 
to a clinical setting. During chronic P. aeruginosa infection, bacterial numbers 
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can reach 107 to 108 CFU/g BAL fluid and a two log reduction after antibiotic 
therapy is considered a major effect (15). For this reason, and because is it a 
common measurement of treatment effect in animal experiments, CFU/ml 
BAL is used to quantify the effectiveness of the HDPs in the present study. 
 
6.1.3 CF mouse model  
The cause of cystic fibrosis may be simply explained by a number of 
mutations in the gene for CFTR leading to ion channel dysfunction. As 
detailed previously, this leads to depletion of ASL volume, impaired mucus 
clearance, and bacterial infection. Our understanding of the disease would 
predict that the simple deletion of CFTR would produce similar effects in 
mice, but this is not the case. Unlike in humans, the removal of CFTR activity 
does not lead to spontaneous lung disease, even in older mice raised 
outside the sterile environments commonly used in animal facilities. This is 
found consistently in CFTR-/- models and may be due to the fact that CFTR is 
not expressed in the lower airways of mice. Consequently, its removal will 
not have major pathological effects on the peripheral lung. In contrast, CFTR 
is common in the murine gastrointestinal tract and the CFTR-/- model has 
been found to closely mimic the intestinal pathophysiology of human patients 
(7).  
Defective Cl- secretion is not the only ionic characteristic of CF. The lung 
epithelium (and indeed other organ systems) is characterised by increased 
Na+ absorption which, in combination with chloride dysregulation, leads to 
depletion of water on the airway surface (250). To this end, an alternative 
mouse model has been developed that is characterised by Na+ 
hyperabsorption as opposed to reduced Cl- secretion. It is based on the “low-
volume” hypothesis i.e. that CFTR also regulates the epithelial sodium 
channel (ENaC), with dysfunction of the former leading to reduced NaCl 
concentrations in the ASL and a resulting reduction in osmotic force for water 
transport to the lumen. This is in contrast to the alternative “high-salt” 
hypothesis where the absence of CFTR is theorised to lead to increased 
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NaCl concentrations in the ASL and the inhibition of HDP activity, 
exacerbating bacterial infection. While evidence exists to support both 
hypotheses, the fact that ASL volume has been demonstrated to be lower in 
CF supports the “low-volume” hypothesis. Figure 6.1 demonstrates how 
defective Cl- and Na+ transport reduce the height of the ASL and impair 
mucociliary clearance. If the “high-salt” hypothesis was correct, the increased 
NaCl concentrations would induce an accompanying movement of water 
across the lumen and increase ASL depth. This increase in ASL depth, as 
seen in the disease pseudohypoaldosteronism, would increase mucociliary 
clearance, in contrast to the situation in CF, and one would expect it would 
act as an increased barrier to bacterial adherence rather than facilitate it 
(251). The “low-volume” hypothesis also predicts that increasing the salt 
concentration of the ASL would induce water entry into the lumen, increase 
the ASL depth, and improve clearance. Supporting this is the fact that 
hypertonic saline has been repeatedly shown to improve mucociliary 
clearance and lung function in CF (73).  
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Figure 6.1: A demonstration of the effects of CFTR and ENaC on 
mucociliary clearance (MCC) based on the “low-volume” hypothesis. Under 
normal conditions the balance of secretory and absorptive processes 
ensures that the ASL is an appropriate height (~7µm), compatible with 
effective MCC. In CF, defective Cl- clearance and inappropriate Na+ 
absorption leads to a dehydrated, compressed ASL (~3-4µm) that collapses 
the cilia, prevents MCC, and promotes bacterial adherence. Taken from 
(251). 
Mice have been generated that overexpress the β-ENaC subunit (encoded 
by the Scnn1b gene) which results in increased Na+ absorption, reduced 
airway surface volume, mucus obstruction of the lungs, neutrophilic 
inflammation, and, crucially, reduced clearance of a bacterial challenge 
compared to wild-type mice. The pulmonary disease phenotype of these 
mice is similar to the human disease (252). These have also been crossed 
with a murine NE (mNE)-/- mouse line (48) to examine the effects of mNE in a 
CF phenotype. The genetic deletion of mNE has been demonstrated in one 
study to reduce neutrophil recruitment. In addition, large quantities of mNE 
were found to be bound to the membranes of β-ENaC neutrophils, although 
free mNE was not detected in BAL fluid, potentially due to inhibition by a 
robust anti-protease defence. The results suggest that membrane-bound NE 
plays a large role in tissue degeneration in the mouse model (253). A similar 
observation has been made with MMP-12 levels in these mice (70). The lack 
of free enzyme has the potential to pose an issue for testing NE-activated 
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pro-HDPs, but in mice from the same background it has been shown in some 
studies active NE is expressed in BAL fluid after nasal instillation of P. 
aeruginosa or LPS (254). Overall, there are mixed reports on whether P. 
aeruginosa infection in these mice can induce substantial free NE activity 
(255, 256). 
Other CF in vivo models have been developed, using different species 
whose lung pathology more closely resembles human CF in many respects. 
CF is the first human disease to have two non-rodent knock-out models, pigs 
and ferrets. Unlike in CFTR-/- mice, the lungs of both CFTR-/- and 
CFTR∆F508/∆F508 pigs are characterised by lung infection, inflammation, and 
remodelling in the first months of life (257). The similar lung pathology allows 
important observations to be made that are precluded in CF patients, e.g. 
whether inflammation precedes infection, with the pig model demonstrating 
no significant inflammation a few hours after birth. A barrier to using this 
model however, beyond the obvious increased costs with raising enough 
pigs for statistically significant data, is that 100% of CFTR-/- pigs require early 
intestinal surgery for meconium ileus, i.e. intestinal blockage, comparable to 
the surgery to clear intestinal blockages that is sometimes required in CF 
patients (258).  
Ferret CF models have also been developed. They are an attractive species 
for modelling lung disease because they reproduce relatively quickly and 
share many features of lung biology with humans, such as a similar 
distribution of submucosal glands. It has been shown that CFTR-/- ferrets are 
extremely susceptible to lung infection early in life. This model, however, is 
also complicated by the fact that ferrets are obligate carnivores (unlike mice 
and pigs) which requires special considerations for their nutritional needs. 
Intestinal pathology is again an issue, with 75% having meconium ileus. This 
pathology of the ferret model is severe, resembling human CF in many 
respects (259). But while their susceptibility to infection and gastrointestinal 
pathology makes them attractive for establishing the link between CFTR and 
disease, it also means many CF ferrets die before reaching maturity (260). In 
addition, the necessity of antibiotic treatment from birth complicates 
experiments that investigate new therapeutic agents.  
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Considering all the options, the β-ENaC mouse model was the most 
attractive in terms of breeding speed, precedents set with other HDP 
treatments, parallels with human pathology, and economic considerations for 
the study.  
As the activity of pro-WMR is enzyme-dependent, an important consideration 
for the study was the potential differences between human NE and mNE, 
which could preclude the use of a mouse CF model. A study examining 
some of the differences in substrate affinity demonstrated that mNE had a 
higher Kcat/Km, i.e. catalytic efficiency, for the substrate Suc-AAA-pNa, nearly 
twice that of the human enzyme. From this, one would expect the AAAG 
linker of pro-WMR to be at least as labile to the mouse enzyme as to the 
human (168). Human NE and mNE share 69% sequence homology, in 
comparison to the 50% similarity between human NE and PR-3. However, 
there are subtle differences between the binding sites of both NE enzymes, 
such as the ability of mNE to bind acidic residues at P2’ (261). To ensure 
that any antibacterial activity was due to the active peptide and not the intact 
pro-HDP, the lability to purified mNE would need to be quantified. 
While generation of a respirable aerosol of pro-WMR was demonstrated in 
Results Chapter Three, the differences in breathing parameters between 
mice and humans means that delivery to the mouse lung via nebuliser is not 
used here. Discounting the differences in lung morphology which are a 
caveat when using in vivo models (262), the difference in breathing 
frequency is an order of magnitude greater. Previously, 18 breaths/min has 
been used as a parameter of human CF in model lungs (240) while the 
measured frequency of β-ENaC mice, though reduced from wildtype, is 172 
breaths/min (263). Most rodents are primarily nose-breathers and, in 
comparison to humans, lung deposition is lower (dogs and primates have 
closer deposition) (264). These differences could potentially compromise the 
delivery of HDPs via nebulisation and, as a result, intratracheal instillation 
was used as an alternative delivery method. This method is commonly used 
for delivering HDPs to rodent lungs (248, 265). 
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6.2 Results 
6.2.1 Murine NE cleaves pro-WMR but is less active than the human 
enzyme 
Using HPLC it was determined that pro-WMR was cleaved by mNE. Figure 
6.2 details how the peak for pro-WMR at 11.12min is not present on the 
chromatogram after overnight incubation with 5µg/ml of mNE, instead being 
replaced by a peak at 10.55min, close to the retention time for AAG-WMR of 
10.46min and within the variability for the HPLC machine. This indicated that 
the product of pro-WMR cleavage was the same as with human NE. Using 
this method, the velocity of the cleavage of the pro-peptide by both enzymes 
was compared (see Figure 6.3) by monitoring the change in the relative area 
of the peaks of pro-WMR and AAG-WMR. It was seen that 5µg/ml of human 
NE more efficiently converted the peptide, with 50% of pro-WMR cleaved 
after 31.51min, compared to 98.17min for 5µg/ml of mNE. 
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Figure 6.2: A comparison of the retention times of pro-WMR (A), AAG-WMR 
(B), and pro-WMR after overnight incubation with 5µg/ml of mNE (C). The 
retention time of 10.55min of pro-WMR after incubation with mNE indicates 
cleavage to AAG-WMR. The pink line represents the absorbance at 214nm, 
the blue 280nm. 
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Figure 6.3: A comparison of the % cleavage of 500µg/ml pro-WMR by 
5µg/ml of human and murine NE. The proportion of pro-WMR that was 
cleaved at each time-point was determined using RP-HPLC. 
Using the fluorescent substrate MeOSuc-AAPV-AMC, the ability of both 
enzymes to cleave the NE-specific linker AAPV was compared. The 
cleavage of the substrate at different enzyme concentrations was analysed. 
The slope of each cleavage over 10min was then plotted against enzyme 
concentration, giving a linear relationship. The slopes of the resulting lines 
for human and murine NE were then compared, demonstrating that human 
NE was the more potent enzyme for the with a slope of 11345 compared to 
4213 for mNE (arbitrary units) (Figure 6.4). 
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Figure 6.4: A comparison of the cleavage of the substrate MeOSuc-AAPV-
AMC by different concentrations of mouse and human NE. The change in 
fluorescence of the substrate over 10min incubation with enzyme was 
analysed and plotted. The slope of each cleavage was then plotted against 
enzyme concentration, demonstrating a linear relationship. The resulting 
slopes of the lines for mouse and human NE were then compared, a larger 
slope indicating a more active enzyme.   
6.2.2 Murine NE is produced in response to P. aeruginosa infection but 
it is insufficient for cleavage 
In most of the BAL fluids collected from mice infected with P. aeruginosa, low 
levels of mNE activity were detected (maximum 0.393µg/ml). The 
comparison between BAL mNE levels and CFU levels is shown in Figure 
6.5A. A linear relationship was not evident between both but with increasing 
levels of P. aeruginosa the levels of mNE tended to increase. When the BAL 
fluids were split into two groups, those with CFU/ml levels below and above 1 
x 105, the increase in mNE levels was statistically significant, from 0.08 ± 
0.02 µg/ml to 0.18 ± 0.03 µg/ml (p = 0.0341) (Figure 6.5B). The levels found 
were still relatively low compared to NE levels of human BAL as described in 
Results Chapter One. 
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Figure 6.5: The relationship between CFU/ml and mNE levels in mouse BAL 
fluid. The presence of mNE in all characterised BAL fluids versus the 
log(CFU/ml) of P. aeruginosa (n = 35) (A) and the comparison of the mNE 
levels of BAL fluids containing 0 to 1 x 105 CFU/ml (n = 14) and 1 x 105 to 1 x 
107 (n = 21) CFU/ml P. aeruginosa (B). * denotes P<0.05. 
Consistent with the low levels of mNE measured in BAL, when the pro-HDPs 
were incubated with β-ENaC BAL after P. aeruginosa infection, no cleavage 
was observed by HPLC after 48h incubation (Appendix figures A38 for pro-
WMR and A39 for pro-P18). This was in contrast with the incubation of both 
pro-HDPs with sputum from a CF patient undergoing an exacerbation, where 
cleavage was observed after 3h. When incubated with healthy human 
sputum, used as a control, neither pro-HDP was cleaved (Appendix figure 
A40). When incubated with four fresh β-ENaC BAL fluids after P. aeruginosa 
infection, as opposed to the BAL supernatant used above, pro-WMR was not 
cleaved after 3h (Appendix figure A41). These four BAL fluids contained P. 
aeruginosa ranging from 5 x 103 to 1 x 107 CFU/ml and 0.07 - 0.17 µg/ml 
mNE. 
6.2.3 Pro-WMR does not reduce the bacterial load of acute P. 
aeruginosa lung infection 
To evaluate the antimicrobial activity of the pro-HDPs against P. aeruginosa, 
an acute model of lung infection was employed. Mice were intratracheally 
instilled with an inoculum of 2.5 x 107 CFU/ml of PAO1, then treated with 
peptide after 6h intratracheally, sacrificed 24h after infection, and their BAL 
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fluids analysed for mNE activity and CFU/ml PAO1. It was noted that 
neutrophils made up 80-90% of the cells recovered from BAL after infection 
and that weight loss for all groups was 5-10% (data not shown). There was a 
trend for β-ENaC mice to have higher CFU counts than wildtype littermates, 
but the differences were not statistically significant (4 x 105 vs. 3 x 106, 
p=0.087). Consistent with the lack of cleavage seen in the BAL fluids, in 
wildtype and β-ENaC mice, pro-WMR did not reduce the bacterial load in the 
lungs compared to the PBS control. AAG-P18, which had the lowest MIC 
against PAO1 of all the active peptides described in Results Chapter One, 
also did not reduce the bacterial load, but instead increased it compared to 
PBS, from 4 x 105 to 6.6 x 106 CFU/ml (p = 0.0009) for wildtype mice (Figure 
6.6). 
Figure 6.6: The CFU/ml of P. aeruginosa PAO1 recovered from BAL fluids 
after treatment with pro- and active HDPs. Statistical analyses were carried 
out using an unpaired two-tailed t-test, * denotes p<0.05, and *** p<0.001 
compared to PBS alone. Lines show where comparisons have been made 
between treatment groups. The n number of each treatment is displayed 
beneath each bar. Wt denotes wildtype mice and Tg denotes β-ENaC mice. 
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In contrast to pro-WMR, AAG-WMR-treated mice demonstrated a reduced 
bacterial load, from 3 x 106 to 2.8 x 104 for β-ENaC mice. However, this 
reduction was not statistically significant (p = 0.1135). Despite the higher MIC 
against PAO1 for AAG-WMR (Table 4.2), the reduction in CFU/ml compared 
to AAG-P18 treatment for both mouse groups was statistically significant: 2.8 
x 104 compared to 6.6 x 106 CFU/ml in β-ENaC (p = 0.0187) and 1.1 x 104 
compared to 6.6 x 106 CFU/ml in wildtype (p = 0.0329). It must be noted 
however that the treatment groups were smaller for AAG-P18: n = 3 for β-
ENaC and n = 2 for wildtype. 
6.2.4 Prodrug modification reduces the toxicity of active peptides 
To compare the toxicity of pro- and active peptides, wildtype mice were 
treated twice intratracheally with 50µg of peptide and sacrificed the next 
morning. Of the four mice treated with AAG-P18, three died (Table 6.1). All 
mice treated with pro-P18 survived but displayed significant weight loss 
compared to the PBS control (5.0% compared to 0.4%, p = 0.018) and raised 
BAL cell numbers (7.8 x 105 compared to 4.8 x 104, p = 0.008). Both groups 
of mice treated with AAG-WMR and pro-WMR survived, with BAL cell counts 
comparable to the PBS control. However, mice treated with AAG-WMR 
displayed significant weight loss compared to pro-WMR (8.0% compared to 
0.4%, p = 0.0037) (Figure 6.7). Against NE-knockout mice, two out of three 
AAG-P18 mice died, while all pro-P18 mice survived (Table 6.1). 
Table 6.1: Mouse survival after two intratracheal treatments with 50µg of peptide 
Peptide 
Number of mice which survived (deaths) 
Wildtype Neutrophil elastase knockout 
PBS 4 (0) ND 
AAG-WMR 4 (0) ND 
Pro-WMR 4 (0) ND 
AAG-P18 1 (3) 1 (2) 
Pro-P18 4 (0) 2 (0) 
ND = not determined 
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Figure 6.7: The % weight loss of wildtype mice treated twice intratracheally 
with 50µg/ml of peptide (A) and the total BAL human cell counts after 
treatment (B). n = 4. Statistical analyses were carried out using an unpaired 
two-tailed t-test * denotes p<0.05, and ** p<0.01 compared to the PBS 
control. Lines show where comparisons have been made between treatment 
groups. AAG-P18 was not included as 3 of 4 mice died before lung lavage. 
6.2.5 Prodrug modification reduces the immunogenicity of AAG-WMR 
Cytokine analysis was carried out on the BAL fluids of the mice receiving a 
morning and evening dose of peptides with no infection. The release profile 
was variable, but statistically significant increases in cytokines were 
observed that correlate with the weight loss results. IL-5 and TNF-α were 
both increased with AAG-WMR compared to control (respectively to 12 ± 
3.4pg/ml p = 0.04 and 23.2 ± 5.4pg/ml p = 0.01). Additionally, the trend was 
for IL-6 and KC to be elevated but this was not statistically significant 
(respectively to 85 ± 32.2pg/ml p = 0.055 and 28.2 ± 6.5pg/ml p = 0.1). In 
response to pro-P18, the trend was also for increased cytokine release, 
particularly for IL-6, but this was also not statistically significant (to 3350 ± 
1752 pg/ml, p = 0.11). 
No increase in cytokine release compared to control was apparent with pro-
WMR. In comparison with AAG-WMR, the release of both KC and TNF-α 
was reduced with pro-WMR (3.1 ± 1.8pg/ml vs. 23.2 ±5.4pg/ml, p = 0.01 for 
the latter). Additionally, the trend was for lower levels of IL-5 and IL-6 but 
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again these were not statistically significant (p = 0.0765 and p = 0.0782 
respectively) (Figure 6.8). 
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Figure 6.8: Wildtype mouse BAL fluid levels of IL-5 (A), IL-6 (B), KC/GRO 
(C), and TNF-α (D) measured after 24 h in response to 2 doses (morning and 
evening) of 50µl PBS control or 50µg HDPs. n = 4. Statistical analyses were 
carried out using an unpaired two-tailed t-test, * denotes p<0.05 compared to 
the PBS control. Lines show where comparisons have been made between 
treatment groups. ns = not significant (with p values given above in some 
cases). AAG-P18 is not included as 3 of 4 mice died before lung lavage. 
The levels of IFN-γ, IL-1β, IL-2, IL-4, IL-10, and IL-12p70 were all also 
analysed but were not found to be elevated significantly in any of the 
treatment groups (Appendix figure A42). 
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6.2.6 Cytokine release is induced by PAO1 but not aggravated further 
by active peptides   
Cytokine analysis was also carried out on β-ENaC mice in response to PAO1 
infection and subsequent treatment with peptides. It was observed in both 
treatment groups (AAG-WMR and AAG-P18) and the PBS control, that high 
levels of KC (2800-6700pg/ml) and moderate levels of IL-5 were produced. 
No significant difference was observed between each group (Figure 6.9). 
This was also seen for the cytokines IFN-γ, IL-1β, IL-2, IL-4, IL-10, and IL-
12p70 (Appendix figure A43). 
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Figure 6.9: β-ENaC mouse BAL fluid levels of KC/GRO (A) and IL-5 (B) 
measured after 24 h in response to 2.5 x 107 CFU/ml PAO1 and 50µl PBS 
control or 50µg HDP 6h later. n = 4 (n = 3 for AAG-P18). Statistical analyses 
were carried out using an unpaired two-tailed t-test, ns = not statistically 
significant compared to the PBS control. 
 
6.3 Discussion 
As revealed by the experiments described in this chapter, in vivo evaluation 
of a pro-HDP targeted at a human enzyme requires special considerations. 
The activity differences between human and murine NE pose a potential 
roadblock in the testing of the pro-peptide activation. This issue is not 
unprecedented in cystic fibrosis therapeutics: in the development of the 
potentiator ivacaftor, the difference between mouse and human CFTR meant 
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that G551D and ∆F508 mice were unsuitable for testing (266). As a result, 
drug evaluation went directly from in vitro efficacy assays to testing in human 
subjects (89, 267). In the present study, the different substrate affinities of 
human and murine NE were taken into account in the design of the animal 
study, with the literature reporting a similar ability of both enzymes to cleave 
the AAA linker (168). We observed that 5µg/ml of both enzyme cleaved 
500µg/ml pro-WMR but the rate of cleavage was slower with the murine 
enzyme, taking 6h to entirely convert the pro-HDP to its active form and 
taking over three times as long to convert 50% of the prodrug as compared 
to human NE.  
Compounding the lower cleavage rate with the murine enzyme, the levels of 
active NE found in mouse BAL fluid were far lower than those previously 
observed in humans. While it was observed that sputum from a CF 
exacerbation could cleave both pro-WMR and pro-P18 after 3h, incubating 
these peptides with various mouse BAL fluids, sometimes for up to 48h, 
produced no cleavage. There was no observable activity in uninfected BAL 
fluids, which is consistent with previous reports of mouse NE activity. For 
example, β-ENaC mice have been found to have no soluble NE activity in 
BAL fluid due to a high endogenous anti-protease load (253). Free NE was 
detected in the BAL fluid after infection with PAO1 and when all treatment 
groups were compared there appeared to be some correlation between BAL 
CFU counts and NE levels. However, the levels were still much lower than 
that of human CF BAL fluids, the highest being 0.393µg/ml, which is very low 
when one considers the length of time required for 5µg/ml to cleave pro-
WMR. For comparison, the human NE levels observed in Results Chapter 
One neared 200µg/ml. The expression of free murine NE after stimulus is 
again consistent with the literature. Elastase activity has been induced in the 
same mouse background by stimulation with LPS (268), LPS and the 
neutrophil chemoattractant N-Formyl methionyl-leucyl-phenylalanine (254), 
and agarose-encased P. aeruginosa (256). The latter appeared to induce a 
significant (but variable) increase in mNE after 5 days. This was a chronic 
model of infection in contrast to our acute model. Unfortunately the authors 
did not quantify the mNE level in terms of µg/ml for comparison. Similar 
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studies to our own, using a PAO1 suspension in PBS failed to produce active 
mNE in BAL fluid, a fact that the authors again suggested was due to 
increasing antiprotease activity in response to lung infection (255). Future 
studies into pro-HDP design may benefit from adopting a more chronic 
model of P. aeruginosa infection which may have the potential to produce the 
high levels of NE required to cleave the pro-peptide. C57BL/6 mice have 
previously shown to have a more muted neutrophil response to stimuli such 
as LPS compared to BALB/c mice (254); another option may be to 
investigate an alternative genetic background for the β-ENaC model.  
The lack of CFU reduction with the application of pro-WMR is consistent with 
the low levels of mNE found in mouse lungs. The peptide would be expected 
to be inactive when uncleaved. The trend in wildtype mice was for the CFU 
count to increase with pro-WMR, which is unexpected but perhaps due to an 
inflammatory response to the treatment. What is more surprising is the 240 
times lower CFU count in response to AAG-WMR than with AAG-P18, 
considering the latter has a lower MIC against PAO1 (2µg/ml vs. 32µg/ml). 
While an expanded AAG-P18 treatment group is required to fully elucidate 
the difference, the superiority of AAG-WMR was profound. However, there 
was significant toxicity with two doses of AAG-P18 (killing over 70% of the 
mice tested) which may contribute to the large difference. The peptide 
perhaps exacerbates lung infection by causing lung damage in its own right. 
Another possible explanation is the high neutrophil toxicity observed with 
AAG-P18 in Results Chapter Two, which could affect the host’s immune 
response. 
The 100% survival of pro-P18-treated mice (both wildtype and NE-knockout) 
is evidence of the benefits of the pro-HDP model and is consistent with the 
reduced cytotoxicity previously noted in vitro (211). Consistent again with the 
in vitro cytotoxicity outlined in Table 4.3, there was less lung disease in both 
pro- and AAG-WMR compared to pro-P18, with lower BAL fluid host cell 
counts. The absence of weight loss with pro-WMR also illustrates the 
benefits of the prodrug model, even though the outward toxicity of AAG-
WMR is low. CF patients undergoing an acute pulmonary exacerbation 
frequently experience acute weight loss. In mice infected with P. aeruginosa 
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this phenomenon has been demonstrated to be the result of increased 
energy expenditure as opposed to reduced food consumption. This is 
potentially related to increased pulmonary inflammation and BAL levels of 
the cytokines KC, TNF-α, and mip-2 have all been shown to correlate to 
weight loss in mice (269). The observed increase in cytokines in response to 
the peptides supports this, especially when one considers there was no 
observed significant cytokine increase with pro-WMR (which also induced no 
weight loss). An increase in cytokine release was not observed with AAG-
WMR compared to its prodrug in CFBE cells in Results Chapter Two. The 
increase in KC and TNF-α may not necessarily be the result of direct 
immuno-stimulation but could alternatively be the indirect result of epithelial 
damage that the pro-HDP modification protects the lungs from. These 
cytokines have the potential to exacerbate inflammation in CF. TNF-α 
increases neutrophil chemotaxis, adhesion, and production (270), while KC 
is also a neutrophil chemoattractant (252). There is no structural analogue of 
IL-8, a potent human neutrophil chemoattractant, in mice; therefore it could 
not be analysed here (271). Analysis of β-ENaC BAL fluid after PAO1 
infection indicated that high concentrations of cytokines were present but that 
no increase in inflammation was observed after treatment with AAG-WMR or 
AAG-P18. The pro-inflammatory effects of the peptide treatment may have 
not been apparent when combined with the large pseudomonas-induced 
inflammation. The high levels of cytokines found are consistent with those 
seen elsewhere. For example, 2800-6700pg/ml KC here compared to 
~9000pg/ml KC in mice 24h after infection with agarose-embedded P. 
aeruginosa (269). The infection model produced comparable weight loss and 
neutrophil recruitment to that observed by others; another study with P. 
aeruginosa in agarose beads noted % neutrophils of 81 ± 2% and weight 
loss of ~11% 48h after inoculation (269). The trend for β-ENaC mice to have 
higher CFU counts compared to wildtype is also consistent with results seen 
elsewhere with PAO1 (252). 
While not statistically significant compared to control, the trend was for AAG-
WMR to reduce the mean bacterial burden, by 99% in β-ENaC mice and by 
97% in wildtype mice. The expansion of the treatment groups may bring the 
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CFU reduction with AAG-WMR to statistical significance and if so it would 
compare favourably to the treatment of P. aeruginosa with other peptides. 
Zhang et al described a series of antimicrobial peptides for treating the 
bacterium in CF, achieving a CFU reduction of 74% and 91% after three 
day’s treatment with 100µg of two peptides in their chronic rat lung infection 
model (121). In a similar rat infection model, treatment with 500µg of the 
polycationic antibiotic peptide polymyxin B was able to reduce the bacterial 
burden by 87% and this was even more profound when encapsulated in 
liposomes, where the reduction was 99.5% (239).  In an acute P. aeruginosa 
mouse infection model similar to ours, 10µg of LL-37 was administered 
immediately after infection and was able to enhance the clearance of 
infection, despite the low direct antimicrobial activity of the peptide. 24h after 
infection, the enhanced inflammatory response reduced the CFU count of the 
mouse lung homogenates to ~1/100th of that of the PBS control (247). In a 
similar manner, LL-37 and IDR-1 delivered at the same time as MRSA were 
able to ameliorate the lung disease induced by the bacteria. At higher doses 
(50-66µg/mouse) the protective effects of both peptides were lost. Survival 
time of the mice was also reduced compared to the MRSA-infected control, 
indicating a degree of host toxicity (248). Another peptide A3-APO was able 
to prevent K. pneumoniae lung infection from progressing to the bloodstream 
when 125µg was delivered intranasally, with some of its activity potentially 
due to the inhibition of inflammation. Dose-limiting toxicity was observed at 
625µg/mouse (272).  
The in vivo studies, although limited in evaluating the activity of pro-WMR 
due to the relatively low-NE levels of the specific infection model, 
demonstrate the superiority of AAG-WMR over AAG-P18 as an active 
peptide in CF, consistent with the results seen previously. The toxicity study 
also illustrates the benefit of delivering HDPs as a prodrug with the 
prevention of mortality with the P18 series, and the prevention of weight loss 
and cytokine release with the less toxic WMR series. Expansion of treatment 
groups and further detailed analysis will grant new insights into the 
pulmonary effects of the peptides; awaiting completion are the lung histology 
and differential cell counts. However, the work carried out so far makes a 
   
181 
 
strong case for the further development of the pro-HDP model and for pro-
WMR as an anti-pseudomonal therapeutic. 
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7. Conclusion and Future Plans 
 
7.1 Conclusion 
The aim of this project was to develop pro-HDPs for CF with two main goals: 
the first was to demonstrate the utility of the NE-targeted oligoglutamic acid 
model for HDPs in CF, the second was to bring one of these pro-HDP 
therapeutics closer to the clinic by evaluating its use in vitro and in vivo. The 
sum of the four results chapter has achieved these goals.  
Modification of five HDPs: Bac8c, HB43, P18, WMR, and WR12 has 
produced pro-HDPs with NE-dependent activity. In addition, reduction in 
cytotoxicity has been shown in four of these. The application of CF BAL fluid 
underlines the potential of the pro-HDPs to work in the CF lung and 
reinforces the potential for targeting prodrugs to NE. Some of the other 
enzymes relevant to CF such as PE and CG have been tested against the 
AAAG linker but the lack of proteolysis coupled with the concentrations 
several times lower than NE (which represents approximately 90% of the 
protease load) would render them inferior targets, should an alternative linker 
be used. The fact that the low levels of mNE found in the mouse BAL fluids 
were insufficient for cleavage emphasises this; the highest concentration 
found (0.393µg/ml) might be considered a high for another enzyme. While 
the pro-HDP model is versatile, and could be applied to other disease 
models such as cancer with a suitable linker, the requirement for an 
extracellular protease of sufficiently high concentration must be carefully 
considered. An appropriate combination of infectious disease/cellular 
dysfunction and co-localised high levels of protease would be an attractive 
target for HDPs. With this combination also comes the consideration of what 
the fate of the active sequence in the same conditions will be: it is shown that 
for CF, D-amino acids can provide stability in hostile proteolytic conditions 
where L-amino acid peptides would be quickly degraded and that this is more 
than likely an absolute requirement. 
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The development of pro-WMR not only represents a proof-of-concept for pro-
HDPs, it has the potential to be used as an antibacterial therapeutic in its 
own right. CF provides the required high levels of protease but also an 
uncomplicated means of delivering the peptide. It is demonstrated here that 
the nebulised delivery of pro-WMR is facile and that the additional glutamic 
acid residues are not antagonist to the generation of a respirable aerosol. 
The % deliverable to a model human lung compares well to other CF 
therapeutics. In other disease models this delivery may not be as 
straightforward. For example, injection of pro-HDPs for cancer introduces the 
complications of circulatory proteases and the exposure of off-target sites to 
the HDPs. In addition, the local drug concentrations with intravenous delivery 
are not as high as with inhalation. 
The results of the in vivo tests complement the in vitro data and demonstrate 
the reduction of host toxicity afforded by the pro-HDP modification. This was 
evident in the significant differential in outcome between AAG-P18 and the 
pro-HDP and also in the reduction in weight loss and cytokine release 
afforded by pro-WMR compared to AAG-WMR treatment. The trend is also 
for the less-cytotoxic AAG-WMR to reduce infection with P. aeruginosa in 
contrast to AAG-P18, which may facilitate bacterial infection by inducing lung 
damage, despite the fact that it has a lower MIC against the bacterium. This 
illustrates how the evaluation of in vitro antimicrobial activity and cytotoxicity 
may be used to predict which HDPs will perform better in vivo.  
In many respects, while pro-HDPs show great promise in treating CF 
infections, CF itself is ideally suited for pro-HDPs. The predominance of one 
particular pathogen, P. aeruginosa, a high concentration of co-localised 
enzyme, NE, and availability for local delivery simplifies the design and 
delivery of the peptides. We demonstrate with pro-WMR the potential for 
therapy of CF, killing the pathogen and targeting the enzyme. In other 
biological systems the difficulties in delivery and enzyme-targeting may be 
compounded, but the progress made with these peptides in CF should 
advise design. More-labile linkers can be developed for enzymes that appear 
in lower concentrations and modern drug-delivery systems such as 
liposomes or nanoparticles may be used to further localise delivery. For CF, 
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these considerations are thankfully not necessary and the present work 
validates that pro-HDPs should form part a potential strategy for developing 
new therapeutics for this disease. 
 
7.2 Future Plans 
The most important set of experiments that must be carried out to advance 
the results of this project is the expansion of the animal study. While many 
interesting conclusions could be drawn, more work beyond analysis of the 
current data should be ideally undertaken. Some of the treatment groups 
(especially AAG-P18) were too small for complete observations to be made. 
For example, the trend was for AAG-WMR to produce a 2 log reduction in 
CFU/ml, a figure which is consistent with some of the more active in vivo 
HDPs, but more subjects are required to bring the result to statistical 
significance. In addition, while it seems that the mouse model may not be 
suitable for testing a NE-dependent prodrug, they must first be tested in a 
chronic infection model before this can be fully ruled out. The literature is 
conflicting on whether enough free mNE can be induced, but the most 
optimistic model we could adopt is to infect mice with bacteria embedded in 
agarose beads and treat with pro-HDP several days later (256).  
There are several other interesting directions that may be taken to evaluate 
pro-HDPs for CF: 
7.2.1 Expanded clinical isolate groups 
The study has focused on reference strains and four clinical isolates of P. 
aeruginosa. The bacterium is usually initially acquired from the environment 
but may sometimes be transferred from patient-to-patient, leading to 
genotypically-indistinguishable and potentially-resistant strains passing 
between individuals. Infection with one strain for example, Liverpool 
Epidemic Strain, can lead to rapid loss of lung function and increased 
mortality while another strain resistant to colistin has been reported in a 
paediatric CF clinic (273). Classical phenotypic methods usually applied to 
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other bacteria such as serotyping are less discriminatory for P. aeruginosa, 
with the correlation with genotype being less clear (274). While clonal and 
epidemic strains are typically more resistant, they often do not show 
distinctive antibiograms which, along with other phenotypes, such as being 
mucoid, have been seen to vary over time (275). Despite the availability of 
fast and cost-effective PCR-based genotyping methods, the more laborious 
pulsed-field gel electrophoresis (PFGE) remains the gold standard for typing 
P. aeruginosa. This is useful for examining local populations but less so for 
cross-sectional studies (276). The demonstration of pro-HDP efficacy against 
well-characterised and representative P. aeruginosa clones that are 
circulating in the Irish CF population would be important. Nearly 30 CF 
isolates have so far been collected and characterised from patients in 
Beaumont Hospital. After collection and genotyping of the CF P. aeruginosa 
isolates a comprehensive review of the susceptibility to the HDPs could be 
carried out using MIC assays. Recently, an analysis of the activity of WR12 
against 100 CF P. aeruginosa strains was carried out, demonstrating the lack 
of intrinsic bacterial resistance to the peptide in the wider population (210). 
7.2.2 Quorum sensing effects 
Another interesting direction would be the effects of these HDP prodrugs on 
P. aeruginosa virulence factors at sub-inhibitory concentrations, specifically 
factors associated with Quorum Sensing (QS). QS describes the ability of 
populations of bacteria to coordinate gene expression in response to their 
surroundings, relying on the transmission of small diffusible signal molecules 
(277). Virulence factors such as rhamnolipids, elastases, and pyocyanin 
have been used before as indicators of QS activity and could be the subject 
of investigation in this study (277-282). QS is associated with much of the 
pathogenicity of P. aeruginosa infections and so any reduction would be 
beneficial (282). It has previously been shown that structurally-unrelated 
compounds such as azithromycin, ceftazidime, ciprofloxacin, and certain 
sesquiterpene lactones have the ability to reduce QS activity, and it has been 
suggested that the diversity of the compounds may indicate that membrane 
disruption is the source of the anti-QS activity. On the other hand, other 
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antibiotics do not have anti-QS activity, including tobramycin (277, 280). The 
effect of HDPs, which are known to disrupt membranes, on these virulence 
factors has not been extensively studied. The factors for investigation, 
elastase (LasB protease), rhamnolipid, and pyocyanin production, are 
associated with increased QS activity. As many reference strains can lose 
QS characteristics over time, clinical isolates would be used for comparison 
(281). The measurement of many of these factors is relatively 
straightforward. Elastase can be measured by incubating filtered culture 
supernatants in elastin congo red and measuring absorbance at 495nm, 
correcting for pigments already produced by P. aeruginosa (278, 281). 
Rhamnolipids can be measured by culture on M8 salt-based agar and the 
measurement of the blue rhamnolipid halo produced by the cultures (282). 
Pyocyanin can be measured at 520nm after extracting it from broths with 
chloroform and 0.2N HCl (279). The expression of specific QS genes after 
exposure to the HDPs may also be investigated using reverse transcriptase 
PCR (277). 
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Figure A1: HPLC chromatogram and MALDI-TOF mass spectrum of 
Bac8c
2,5 Leu 
Retention time 19.09 min. The signal at m/z = 1183.7135 
corresponds to the molecular ion. 
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Figure A2: HPLC chromatogram and MALDI-TOF mass spectrum of 
AAG-Bac8c2,5 Leu. Retention time 19.37 min. The signal at m/z = 
1382.8251 corresponds to the molecular ion. 
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Figure A3: HPLC chromatogram and MALDI-TOF mass spectrum of 
pro-Bac8c
2,5 Leu 
. Retention time 20.45min. The signal at m/z = 
2011.7845 corresponds to the molecular ion. 
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Figure A4: HPLC chromatogram and MALDI-TOF mass spectrum of 
HB43. Retention time 21.6min. The signal at m/z = 1456.0015 
corresponds to the molecular ion and the signal at m/z = 1477.9773 
corresponds to [M+Na]+. 
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Figure A5: HPLC chromatogram and MALDI-TOF mass spectrum of 
AG-HB43. Retention time 24.28min. The signal at m/z = 1584.0674 
corresponds to the molecular ion and the signal at m/z = 1606.0494 
corresponds to [M+Na]+.  
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Figure A6: HPLC chromatogram and MALDI-TOF mass spectrum of 
pro-HB43. Retention time 25.29min. The signal at m/z = 2285.3325 
corresponds to the molecular ion; the signal at m/z = 2307.3230 
corresponds to [M+Na]+,and the signal at m/z = 1570.6774 corresponds 
to the calibration standard. 
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Figure A7: HPLC chromatogram and MALDI-TOF mass spectrum of 
P18
8 Leu
. Retention time 19.33min. The signal at m/z = 2300.4690 
corresponds to the molecular ion; the signal at m/z = 1571.6694 
corresponds to the calibration standard. 
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Figure A8: HPLC chromatogram and MALDI-TOF mass spectrum of 
AAG-P188 Leu. Retention time 19.48min. The signal at m/z = 2499.7 
corresponds to the molecular ion; the signal at m/z = 2520.6653 
corresponds to [M+Na]+, and the signal at m/z = 2537 corresponds to 
[M+K]+. 
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Figure A9: HPLC chromatogram and MALDI-TOF mass spectrum of 
pro-P18
8 Leu
. Retention time 19.73min. The signal at m/z = 3128.8047 
corresponds to the molecular ion; the signal at m/z = 3151.8130 
corresponds to [M+Na]+, and the signal at m/z = 1564.8899 
corresponds to the calibration standard. 
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Figure A10: HPLC chromatogram and MALDI-TOF mass spectrum of 
pro-Bac8c
2,5 Leu
 and 5µg/ml neutrophil elastase after 1h incubation. 
Retention times 19.07, 19.24 (AAG-Bac8c2,5 Leu), and 20.39 min 
(Bac8c2,5 Leu). The signal at m/z = 1382.8209 corresponds to the 
molecular ion of AAG-Bac8c2,5 Leu; m/z = 1311.7871 of AG-Bac8c2,5 Leu, 
and m/z = 2013.0475 of Bac8c2,5 Leu . The signal at m/z = 1570.6674 
corresponds to the calibration standard, and m/z = 1404.8041 to 
[M+Na]+ of AAG-Bac8c2,5 Leu. 
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Figure A11: HPLC chromatogram and MALDI-TOF mass spectrum of 
pro-Bac8c
2,5 Leu
 and 10µg/ml pseudolysin after 1h incubation. Retention 
time 20.16 min (pro-Bac8c2,5 Leu). The signal at m/z = 2013.0105 
corresponds to the molecular ion of pro-Bac8c
2,5 Leu
. The signal at m/z = 
2033.9878 corresponds to [M+Na]+ of pro-Bac8c2,5. 
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Figure A12: HPLC chromatogram and MALDI-TOF mass spectrum of 
pro-HB43 and 5µg/ml neutrophil elastase after 1h incubation. Retention 
times 24.04 (AG-HB43) and 25.16 min (pro-HB43). The signal at m/z = 
1584.066 corresponds to the molecular ion of AG-HB43; m/z = 
1657.1227 of AAG-HB43, and m/z = 2285.3325 of pro-HB43. The signal 
at m/z = 1606.052 corresponds to [M+Na]+ for AG-HB43. 
   
230 
 
 
 
 
 
  
Figure A13: HPLC chromatogram and MALDI-TOF mass spectrum of 
pro-HB43 and 10µg/ml pseudolysin after 1h incubation. Retention time 
25.08min (pro-HB43). The signal at m/z = 2285.3264 corresponds to 
the molecular ion of pro-HB43. The signal at m/z = 2307.3152 
corresponds to [M+Na]+, and m/z = 1570.6774 corresponds to the 
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Figure A14: HPLC chromatogram and MALDI-TOF mass spectrum of 
pro-P18
8 Leu 
and 5µg/ml neutrophil elastase after 1h incubation. 
Retention times 19.04 (AAG-P188 Leu), 19.45, and 19.91min (pro-P188 
Leu). The signal at m/z = 2499.5676 corresponds to the molecular ion of 
AAG-P188 Leu; m/z = 2428.5322 of AG-P188 Leu, and m/z = 3128.8054 of 
pro-P18
8 Leu
. The signal at m/z = 1564.899 corresponds to the 
calibration standard, and m/z = 2521.5566 corresponds to [M+Na]+ for 
AAG-P188 Leu. 
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Figure A15: HPLC chromatogram and MALDI-TOF mass spectrum of 
pro-P18 and 10µg/ml pseudolysin after 1h incubation. Retention time 
19.72 min (pro-P188 Leu). The signal at m/z = 3128.755 corresponds to 
the molecular ion of pro-P18
8 Leu
. The signal at m/z = 1564.8798 
corresponds to the calibration standard. 
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Figure A16: HPLC chromatogram and 19F NMR of HB43 before TFA 
removal. Retention time 21.6 min. The chemical shift at -75.52 
represents TFA. 
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Figure A17: HPLC chromatogram and 19F NMR of HB43 after TFA 
removal. Retention time 21.68 min.  
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Figure A18: HPLC chromatogram and MALDI-TOF mass spectrum of 
5E-P18
8 Leu
. Retention time 20.08min. The signal at m/z = 3256.8176 
corresponds to the molecular ion. 
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Figure A19: HPLC chromatogram and MALDI-TOF mass spectrum of 
PEG-P188 Leu. Retention time 21.23min. The signals between m/z = 
4006.2717 and m/z = 4974.8047 corresponds to the molecular ions of 
the polydisperse PEG conjugates. 
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Figure A20: HPLC chromatogram and MALDI-TOF mass spectrum of 
WMR
3, 6 Leu
. Retention time 19.05min. The signal at m/z = 1631.8450 
corresponds to the molecular ion. 
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Figure A21: HPLC chromatogram and MALDI-TOF mass spectrum of 
AAG-WMR3, 6 Leu. Retention time 20.89min. The signal at m/z = 
1831.0861 corresponds to the molecular ion. 
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Figure A22: HPLC chromatogram and MALDI-TOF mass spectrum of 
pro-WMR
3, 6 Leu
. Retention time 20.19min. The signal at m/z = 
2460.2066 corresponds to the molecular ion. 
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Figure A23: HPLC chromatogram and MALDI-TOF mass spectrum of 
AAG-WR12. Retention time 21.85min. The signal at m/z = 2270.1965 
corresponds to the molecular ion. 
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Figure A24: HPLC chromatogram and MALDI-TOF mass spectrum of 
pro-WR12. Retention time 21.16min. The signal at m/z = 2899.3940 
corresponds to the molecular ion. 
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Figure A25: HPLC chromatogram and MALDI-TOF mass spectrum of 
pro-WMR and 20µg/ml neutrophil elastase after 3h incubation. Retention 
times 20.77min (AAG-WMR), and 21.53min (pro-WMR). The signal at 
m/z = 1759.9899 corresponds to the molecular ion of AG-WMR; m/z = 
1831.0222 of AAG-WMR, and m/z = 2460.2058 of pro-WMR.  
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Figure A26: HPLC chromatogram and MALDI-TOF mass spectrum of pro-
WR12 and 5µg/ml neutrophil elastase after 1h incubation. Retention times 
19.39min (AAG-WR12) and 20.33min (pro-WR12). The signal at m/z = 
2270.0989 corresponds to the molecular ion of AAG-WR12 and m/z = 
2899.2732 of pro-WR12. 
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Figure A27: HPLC chromatogram and MALDI-TOF mass spectrum of pro-
WMR and 50% CF BAL CF004 after 3h incubation. Retention times 
13.357min, 13.523min, 14.223min, 16.063min (BAL components, see figure 
A27), and 20.570min (AAG-WMR). The signal at m/z = 1761.1 corresponds 
to the molecular ion of AG-WMR and m/z = 1832.2 of AAG-WMR. 
 
 
Figure A28: HPLC chromatogram of 50% CF BAL CF004 alone after 3h 
incubation. Retention times 14.097min, 15.917min (BAL components).  
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Figure A29: HPLC chromatogram and MALDI-TOF mass spectrum of L-pro-
WMR. Retention time 24.3min (L-pro-WMR). The signal at m/z = 2460.4211 
corresponds to the molecular ion of L-pro-WMR. 
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Figure A30: HPLC chromatogram and MALDI-TOF mass spectrum of L-pro-
WMR and 20µg/ml neutrophil elastase after 1h incubation. Retention times 
21.050min (AAG-WMR), 23.690min and 26.283 (degradation fragments). 
The signal at m/z = 1760.1161 corresponds to the molecular ion of AG-WMR; 
m/z = 1831.1890 of AAG-WMR, and m/z between 970 and 1700 to different 
degradation fragments of L-pro-WMR. 
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Figure A31: HPLC chromatogram and MALDI-TOF mass spectrum of L-pro-
WMR and CF BAL CF004 after 3h incubation. Retention times 13.883min, 
16.007min (BAL components), 18.600min, 20.527min, 23.380min, and 
26.273min (degradation fragments). The signals at m/z between 900 and 
1900 correspond to the molecular ion of L-pro-WMR degradation products. 
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Figure A32: HPLC chromatogram and MALDI-TOF mass spectrum of pro-
GG-WMR. Retention time 21.765min (pro-GG-WMR). The signal at m/z = 
2305.222 corresponds to the molecular ion of pro-GG-WMR. 
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Figure A33: HPLC chromatogram and MALDI-TOF mass spectrum of pro-
GG-WMR and 50% CF BAL CF004 after 3h incubation. Retention times 
14.250min, 16.073min (BAL components), and 21.740min (pro-GG-WMR). 
The signal at m/z = 2305.3 correspond to the molecular ion of pro-GG-WMR. 
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Figure A34: HPLC chromatogram of pro-WMR and 50% non-CF BAL 50 after 
3h incubation. Retention time 22.987min (pro-WMR). 
 
 
Figure A35: HPLC chromatogram of pro-WMR and 50% non-CF BAL 53 after 
3h incubation. Retention time 22.737min (pro-WMR). 
 
 
Figure A36: HPLC chromatogram of pro-WMR and PBS after 3h incubation. 
Retention time 22.340min (pro-WMR). 
 
 
 
 
 
   
251 
 
 
 
 
 
 
 
Figure A37: HPLC chromatogram and negative ESI mass spectrum of Ac-
EEEEA-OH. Retention time 16.987min. The signal at 645.9 corresponds to 
the negative molecular ion of Ac-EEEEA-OH. Please note that the molecule 
was too small for accurate MALDI-TOF MS analysis and a different HPLC 
method was used, using an elution gradient from 2% acetonitrile to 65% in 
50 minutes. 
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Figure A38: HPLC chromatogram of pro-WMR after 48h incubation with CF 
BAL fluid from a β-ENaC mouse infected with 2.5 x 107 CFU of P. 
aeruginosa. Retention time 11.10min (pro-WMR), 13-20min (BAL 
components). The pink line represents the absorbance at 214nm, the blue 
280nm. 
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Figure A39: HPLC chromatogram of pro-P18 after 48h incubation with CF 
BAL fluid from a β-ENaC mouse infected with 2.5 x 107 CFU of P. 
aeruginosa. Retention time 11.74min (pro-P18), 13-20min (BAL 
components). The pink line represents the absorbance at 214nm, the blue 
280nm. 
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Figure A40: HPLC chromatograms of pro-WMR (A, B) and pro-P18 (C, D) 
after 3h incubation with human CF (A, C) and healthy sputum (B, D). 
Retention times 10.38min (AAG-WMR), 11min (pro-WMR), with other sputum 
peaks (A). Retention time 11.05min (pro-WMR), with other sputum peaks (B). 
Retention times 11.43min (AAG-P18), 11.70min (pro-P18), with other sputum 
peaks (C). Retention times 11.73min (pro-P18), with other sputum peaks (D). 
The pink line represents the absorbance at 214nm, the blue 280nm. 
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Figure A41: HPLC chromatogram of pro-WMR after 3h incubation with fresh 
CF BAL fluids from β-ENaC mice infected with 2.5 x 107 CFU of P. 
aeruginosa (A-D). Retention times 10.86-10.97min (pro-WMR), with other 
BAL fluid peaks. The chromatograms are edited, to remove regions after 15 
minutes, due to the occurrence of interfering air bubbles. The pink line 
represents the absorbance at 214nm, the blue 280nm. 
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Figure A42: 24h wildtype mouse BAL fluid levels of cytokines in response to 
a morning and evening dose of 50µl PBS control or 50µg HDPs. AAG-P18 is 
not included as 3 of 4 mice died before lung lavage. n = 4. 
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Figure A43: 24h β-ENaC mouse BAL fluid levels of cytokines in response to 
2.5 x 107 CFU/ml PAO1 and 50µl PBS control or 50µg HDP 6h later. n = 4 (n 
= 3 for AAG-P18). 
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Figure A44: HPLC chromatogram of pro-WMR and 5µg/ml cathepsin G after 
1h incubation. Retention time 21.683min (pro-WMR). 
 
